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Abstract 
 
 The Royal Canadian Mounted Police (RCMP) Forensic Laboratory Services 
(FLS) needed a method to confirm positive lysergic acid diethylamide (LSD) 
immunoassay screening results.  As a result, an ultra performance liquid 
chromatography tandem mass spectrometry (UPLC™/MS/MS) method was validated 
for the confirmation and quantitation of LSD, iso-LSD, N-demethyl-LSD (nor-LSD), 
and 2-oxo-3-hydroxy-LSD (O-H-LSD).  The method was validated in urine and whole 
blood, where linearity, accuracy, precision, sensitivity, stability, selectivity, recovery, 
matrix effects, and reproducibility were evaluated. 
 The method involved a liquid-liquid extraction (LLE) of the analytes and the 
deuterated internal standard from 1 mL of urine or whole blood with 
dichloromethane:isopropyl alcohol after being basified.  The average recovery for all 
analytes was ≥ 62%, and the matrix effect was found to be insignificant.  MS/MS 
analysis was conducted with a triple quadrupole mass spectrometer by positive 
electrospray ionization (ESI+) in multiple reaction monitoring (MRM) mode.  The 
lowest limit of quantitation (LLOQ) was 20 pg/mL for LSD and iso-LSD, and 50 pg/mL 
for nor-LSD and O-H-LSD.  The method was linear, accurate, precise, selective, and 
reproducible from 20 to 2000 pg/mL for LSD and iso-LSD, and from 50 to 2000 pg/mL 
for nor-LSD and O-H-LSD with an r2 ≥ 0.99. 
The refrigerated and frozen long term stability was investigated for 90 days.  
LSD was stable at all temperatures for 90 days.  Iso-LSD in blood was also stable at all 
temperatures for 90 days, but iso-LSD in urine showed an initial decrease followed by a 
gradual increase back to day 0 concentrations.  Nor-LSD was stable at all temperatures 
up to day 14, with >43% decrease by day 30, with no additional decrease for the next 60 
days.  O-H-LSD in urine was stable at all temperatures for 90 days, but by day 90 O-H-
LSD in whole blood stored refrigerated decreased in concentration by >37%.  
Additionally, a case sample that was stored at -50°C for ten years was found to still 
contain measurable amounts of each compound.   
The method was applied to blind samples and a case that screened positive with 
immunoassay.  Retention time, relative retention time, and ion ratios were used as 
identification parameters and found to correctly identify the analytes 100% of the time 
with no false positives.  The case sample showed that the concentration of O-H-LSD 
was 4 times greater than LSD in urine.  Furthermore, both the detection of O-H-LSD in 
a blood case sample, and LSD in a vitreous humor case sample were the first to be 
documented. 
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Chapter 1 
Introduction to Lysergic Acid Diethylamide (LSD) and its Forensic Significance 
1.1 Introduction 
 
 
Figure 1.1:  Structure of LSD, MW = 323.43 g/mol 
 
LSD is considered the most potent hallucinogen (Figure 1.1).  In 1938, Albert 
Hoffman of the Sandoz Laboratories in Basal, Switzerland began experimenting with 
lysergic acid derivatives hoping to find a new medicine (McKim 2003).  In 1943, Albert 
Hoffman ingested 250 μg of LSD to test its effects, and felt pleasantly sleepy, and then 
experienced fantastic, vivid images (O’Shea and Fagan 2001).  LSD’s popularity was 
the highest during the 1960s and 1970s.  Its use started to decline in the 1980s; however 
its popularity began to increase again in the 1990s (Ellenhorn 1997).  In Canada, the 
lifetime use of LSD has gradually increased from 4.1% in 1989 to 13.2% in 2004 (Adalf 
et al. 2004).  Initially, LSD was being used licitly in mental hospitals during the 1960s, 
and then it got out into the streets and was being used recreationally for so-called 
“spiritual purposes” (O’Shea and Fagan 2001).  LSD is clear, odourless, and tasteless 
(Klein and Kramer 2004) and is self-administered through either inhalation, topical 
application, or more commonly by oral ingestion in the form of pills, blotter paper, or 
liquid (Blaho K et al. 1997; Klein and Kramer 2004; O’Shea and Fagan 2001).  LSD, or 
“acid”, is sold on the street illicitly as hits, with one hit typically consisting of 40 to 120 
μg of LSD at $3 to $5 a hit (Clarkson et al. 1998). 
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In Canada LSD first became illegal to possess in 1962, and is now prohibited 
under Schedule III of Canada’s Controlled Drugs and Substance Act (CDSA).  A survey 
on 210 rave attendees in Montreal, Quebec conducted in 2002, found that LSD was 
ranked number 4 out of 11 as the drug used for first drug experience at an average age of 
16.3, and 56.2% of the respondents had used LSD (Gross et al. 2002).  The Canadian 
Centre on Substance Abuse conducted a telephone survey of 13909 Canadians aged 15 
years or older between December 2003 and April 2004 and found that 11.4% of the 
participants had used hallucinogens, making hallucinogens the second most commonly 
used illicit drug during one’s lifetime (Adalf et al. 2004).  So, even today LSD is being 
used in Canada illicitly, making it a concern for forensic toxicologists. 
 
1.2 Clinical Effects of LSD 
The hallucinogenic effects of LSD are commonly referred to as “trips”.  LSD 
causes panic, anxiety, negative effects, and feelings of insanity, with the effects being 
unpredictable, varying with the amount ingested and the user’s personality, mood, 
expectations, and surroundings (Nichols 2004).  There has not been any proof that LSD 
is addictive, as most people do not continue to use LSD and other hallucinogens on a 
long-term basis after initial experimentation.  However, chronic users can develop a 
tolerance known as tachyphylaxis (Nichols 2004).  The tolerance to LSD’s psychosocial 
effects can occur after just a few doses, probably due to the desensitization of 5-HT 
receptors (O’Shea and Fagan 2001).  Since the 1960s four chronic reactions to LSD have 
been recognized: (1) prolonged psychotic reactions, (2) depression sufficiently severe so 
as to be life threatening, (3) flashbacks, and (4) exacerbations of a pre-existing 
psychiatric illness (Ellenhorn 1997).  Chronic flashbacks are now recognized as 
hallucinogen persisting perceptual disorder (HPPD) (Ellenhorn 1997; Halpern and 
Jarrison 2003).  The American Psychiatric Association require three criteria to be 
fulfilled to be diagnosed with HPPD; “(1) re-experiencing, following cessation of use of 
hallucinogen, of one or more of the perceptual symptoms that were experienced while 
intoxicated with the hallucinogen, (2) symptoms cause clinically significant distress or 
impairment, and (3) symptoms are not due to other mental or medical conditions” 
(Halpern and Jarrison 2003). 
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1.3 Mechanism of Action 
The interaction between LSD and serotonin has been known since 1961 
(Ellenhorn 1997).  LSD is a potent agonist at 5-HT1A receptors, and also has an affinity 
for postsynaptic 5-HT2 receptors in the locus ceruleus and the cerebral cortex (Ellenhorn 
1997).  LSD has been shown in rat studies to activate the 5-HT2A receptor causing an 
increase in the extracellular glutamate concentrations in the prefrontal cortex 
(Muschamp et al. 2004).  The increased glutamate may play a significant role in the 
behavioural effects of LSD.  The signalling of LSD at 5-HT2C receptor has also been 
shown to differ from that of serotonin (Backstrom et al. 1999).  More recently, LSD has 
been shown to cause an increase in the expression of a small set of genes in the 
mammalian brain that are involved in a wide array of cellular functions, such as synaptic 
plasticity, glutamatergic signalling, and cytoskeleton architecture (Nichols and Sanders-
bush 2002).  Despite all the research done on the mechanism of action of LSD, the exact 
signalling pathway to explain LSD’s potency is still not fully known.  Two possible 
explanations are that the interaction of LSD is synergistic with its 5-HT2A receptor 
activation, and/or that there may be an undiscovered signalling pathway coupled to the 
5-HT2A receptor (Nichols 2004). 
 
1.4 Pharmacokinetics 
Lysergic acid is a constituent of the ergot alkaloids, and LSD is its semi-
synthetic hydrolytic derivative (O’Shea and Fagan 2001).  Lysergic acid is obtained by 
treating ergot alkaloids with strong alkali and then neutralizing the basic mixture with an 
acid.  After purification of the lysergic acid it is coupled with diethylamine (Figure 1.2), 
resulting in the formation of LSD (Nichols 2001).  During the production of illicit LSD 
an impurity diastereoisomer (iso-LSD – Figure 1.3) is formed during the synthesis from 
lysergic acid (Johansen and Jensen 2005).  In theory, 4 optical isomers are possible from 
the 2 asymmetric carbon atoms in the LSD molecule (Clarkson et al. 1998).  However, 
many of the ergot alkaloid derivatives have only been found to be isomeric at the C-8 
carbon, but not at the C-5.  In LSD, the C-5 hydrogen atom and the C-8 carboxylic 
amide are in cis configuration, and in iso-LSD they are in trans configuration.  Iso-LSD 
can also form from LSD when exposed to basic aqueous solutions and increased 
4 
temperatures (Reuschel et al. 1999a; Li et al. 1998), ultimately reaching a LSD/iso-LSD 
ratio of 9:1 (Reuschel et al. 1999a; Salamone et al. 1997).   
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Figure 1.2:  Synthesis of LSD. 
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Figure 1.3:  LSD isomerization to iso-LSD at the C-8 carbon. 
 
 
LSD is the most potent known hallucinogen, with doses as small as 50 to 200 μg 
causing hallucinogenic effects lasting 6 to 12 hours (Nichols 2004).  A dose of 0.2 
mg/kg is considered to be a fatal dose (Ellenhorn 1997), with a lethal dose (LD50) of 14 
mg (Clarkson et al. 1998).  There was one documented case of a 25 year old male who 
died 16 hours after being admitted to the hospital, whose cause of death was poisoning 
by LSD (Fysh et al. 1985).  In this case antemortem plasma and stomach contents 
analyzed by high performance liquid chromatography (HPLC) contained 8 and 60 
ng/mL LSD, respectively.  However, there is no evidence that LSD causes damage to 
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any human body organs (Nichols 2004).  Instead deaths associated with LSD use are 
usually due to injuries received under the influence of the drug (Fysh et al. 1985).  LSD 
acute effects last from 0.7 to 8 hours, whereas the psychotropic effects may last for days 
(Ellenhorn 1997).  The urinary elimination half-life and plasma half-life of LSD is 3.6 
hours (Lim et al. 1988) and 5.1 hours (Papac and Foltz 1990), respectively, with an 
elimination rate (Ke) of 0.2/hour (Lim et al. 1988).  After a 50 μg dose of LSD, the 
urinary LSD concentration normally drops to < 200 pg/mL within 12 to 24 hours 
(Reuschel et al. 1999a).  The maximum rate of LSD excretion occurs 4 to 6 hours after 
an oral dose (Lim et al. 1988).  The peak plasma concentration of LSD occurs 
approximately 3 hours after administration (Papac and Foltz 1990).  In general the half-
lives of the metabolites of LSD are longer and the rate of elimination is slower, for 
example the urinary elimination half-life of N-demethyl-LSD (nor-LSD) is 10 hours and 
Ke is 0.1/hour (Lim et al. 1988). 
 
1.5 Metabolism of LSD 
LSD is extensively and rapidly metabolized (Figure 1.4), with only 0.9% of the 
LSD dose being excreted in the urine (Lim et al. 1988).  The metabolites of LSD do not 
have any psychoactive properties, but their presence is indicative of LSD use.  Nor-LSD 
was the first metabolite of LSD confirmed in vivo in humans.  LSD undergoes metabolic 
N-demethylation to produce nor-LSD in humans (Lim et al. 1988).  By using neutral 
loss tandem mass spectrometry experiments, nor-LSD was detected and subsequently 
confirmed using authentic nor-LSD standards (Canezin et al. 2001).  LSD also 
undergoes aromatic hydroxylation to form 13- or 14-hydroxy-LSD glucuronide (Lim et 
al. 1988; Canezin et al. 2001).  Both 13- and 14-hydroxy-LSD have been tentatively 
identified in human urine.  It was also determined that 13- and 14-hydroxy-LSD appear 
in the urine as glucuronide conjugates (Lim et al. 1988).  Lysergic acid ethylamide 
(LAE) was determined to be another metabolite in human liver in vitro and also in vivo 
(Cai and Henion 1996).  LAE is formed by the removal of one of the two N-ethyl groups 
on LSD.  Lysergic acid ethyl-2-hydroxyethylamide (LEO) is formed by adding a 
hydroxyl group on the branched side chain of LSD.  However, in vitro metabolism of 
LSD in human liver found that LEO was not a metabolite (Cai and Henion 1996).  
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Another possible metabolite of LSD in vitro is 2-oxo-LSD (Cai and Henion 1996).  
However, 2-oxo-LSD was not found in positive LSD urine samples (Cai and Henion 
1996). 
 
 
 
 
 
 
Figure 1.4:  Metabolism of lysergic acid diethylamide (LSD) (LAE = lysergic acid 
ethylamide, LEO = lysergic acid ethyl-2-hydroxyethylamide, nor-LSD = N-demethyl-
LSD) (Canezin et al. 2001, figure reproduced with permission from A. Cailleux). 
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More recently 2-oxo-3-hydroxy-LSD (O-H-LSD) was determined to be another 
major metabolite of LSD (Klette et al. 2000).  The formation of O-H-LSD is still under 
investigation, but it is proposed that LSD is oxidized to 2-oxo-LSD which then 
undergoes hydroxylation to O-H-LSD.  Also, when cytochrome P450 in human liver 
microsomes were inhibited, no O-H-LSD was formed (Klette et al. 2000).  Therefore, O-
H-LSD may also be produced via an epoxide intermediate or a dihydroxy-LSD 
intermediate. 
Due to the ethical and legal restrictions of carrying out research on humans with 
hallucinogens, research on the metabolism of LSD may never be fully complete.  
However, it is known that the concentrations of the majority of the metabolites are 
greater than that of LSD.  More recently, it has been found that the concentration of O-
H-LSD is 16 (Poch et al. 2000) to 25 (Horn et al. 2003) times higher than that of LSD.  
However, this is only true in urine because O-H-LSD has not been detected in human 
plasma in vivo (Canezin et al. 2001; Sklerov et al. 2000).  Also, O-H-LSD is not 
generated due to the extraction, analytical processes, or degradation of the sample 
(Klette et al. 2000; Klette et al. 2002).  Therefore, within the last few years methods 
developed for detecting LSD have been directed at identifying O-H-LSD. 
Recent method development and validation for LSD and its metabolites have 
only been done with 2 of the metabolites of LSD, because the research to date is 
incomplete for most of the other metabolites of LSD.  For example, no reference 
compounds of 13- or 14-hydroxy-LSD are available (Clarkson et al. 1998) and their 
concentrations in vivo are too low (Lim et al. 1988), so they cannot be conclusively 
identified or quantified.  LAE also has no available reference compounds.  LEO has only 
been described in human urine by using specific tandem mass spectrometry (MS/MS) 
transitions (Canezin et al. 2001).  And finally, 2-oxo-LSD was not found in positive 
LSD urine samples (Cai and Henion 1996).  Either it is because 2-oxo-LSD 
concentrations decrease rapidly during storage (Cai and Henion 1996), or 2-oxo-LSD is 
really an intermediate compound in the formation of O-H-LSD (Klette et al. 2000). 
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1.6 Literature Review for the Laboratory Analysis of LSD 
An extensive literature search was conducted to examine existing methods for 
the analysis of LSD and its metabolites from human biological specimens.  Suitable 
methods were chosen, adapted, and further developed so that they could be used for the 
analysis of forensic samples using LC/MS/MS.  The method was validated using 
accepted method validation procedures where linearity, sensitivity, accuracy, precision, 
stability, selectivity, recovery, and matrix effects were evaluated (Standards Council of 
Canada 2003; FDA 2001; ICH 1996; SOFT/AAFS 2006).  The validated method was 
then used to analyze forensic samples suspected of containing LSD. 
The analysis of LSD in biological fluids has been a challenge analytically.  The 
challenges are due to the small doses taken (Clarkson et al. 1998), the rapid metabolism 
(Ellenhorn 1997), short half-life (Schneider et al. 1998), and the instability of LSD (Li et 
al. 1998).  In the United States a urine sample must contain >200 pg/mL to be 
considered positive, however after one dose the LSD urine concentration drops to <200 
pg/mL within 12 to 24 hours (Reuschel et al. 1999a).  In order to increase the detection 
time window of LSD a highly sensitive method that detects LSD and its metabolites is 
necessary. 
 
1.6.1 Sample Matrix 
 The analysis of LSD and its metabolites has been carried out on urine, blood and 
hair.  Because LSD is rapidly metabolized, has such a short half life, and is not usually 
associated with death, the analysis of organs postmortem is not common.  LSD and all 
its known metabolites have been detected in urine.  In the blood, O-H-LSD, which is the 
most recent metabolite identified, has not been detected.  The analysis of hair has been 
attempted using rat experiments (Nakahara et al. 1996).  The rats were given LSD and it 
was found that LSD was detectable in hair even with low doses of LSD, but nor-LSD 
was present only with higher doses.  However, when examining hair of humans known 
to be positive for LSD only 2 out of 17 had measurable LSD levels in the hair.  The 
same results were observed when an immunoaffinity extraction (IAE) method using 
commercially available columns for LSD was performed (Röhrich et al. 2000).  Using 
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this method only 1 out of 9 human hair samples tested positive.  Overall, the specimens 
of choice are urine and blood for detecting LSD. 
 
1.6.2 Stability 
The instability of LSD has proven to be a problem in its analysis.  LSD rapidly 
decomposes in urine samples exposed to increased temperatures, sunlight, or ultraviolet 
light (Li et al. 1998; Skopp et al. 2002; de Kanel et al. 1998; Webb et al. 1996).  The 
optimum temperature where LSD is relatively stable is 4°C and 22°C when protected 
from light (Skopp et al. 2002).  In one day LSD was shown to decrease to 3% of its 
initial concentration when exposed to sunlight, and after 3 days no LSD was detectable 
(Skopp et al. 2002).  On the other hand, both nor-LSD and O-H-LSD are less susceptible 
to photodegradation (Klette et al. 2002; Skopp et al. 2002).  Changes in pH resulted in 
significant loss of O-H-LSD.  O-H-LSD is stable at pH 4.6 to 6.5 when maintained at 
temperatures of -20°C to 24°C (Klette et al. 2002).  Trace amounts of metal ions in 
buffer or urine could also catalyze the decomposition of LSD (Li et al. 1998). 
 
1.6.3 Extraction Procedures  
Liquid-liquid extractions (LLE), solid phase extractions (SPE), a combination of 
both, and IAE have been utilized when preparing samples for analyzing LSD.  Since 
forensic analysis is done on various matrices, an extraction procedure to obtain a clean 
extract is very important.  More specifically for LSD, problems with co-eluting 
impurities are a major concern.  Since LSD is in such small concentrations, even minor 
impurities can cause analytical problems as they can mask the LSD.  The most common 
LLE involves basifying the sample with NH4OH and then extracting with a methylene 
chloride/isopropanol mixture.  LLE alone failed to provide the cleanest sample possible, 
as a result SPE was performed after LLE in some analysis.  Since this involves two 
extractions, the percent recovery decreased to as low as 31%.  The overall precision had 
a coefficient of variation (%CV) of 10.8% which is much higher than for LLE or SPE 
alone (Libong et al. 2003a) (Table 1.1). 
Extractions using SPE have been shown to give better results than those obtained 
by LLE.  In one study SPE was shown to have a 45% increase in extraction efficiency, 
10 
38% decrease of limit of detection (LOD) and lowest limit of quantitation (LLOQ), and 
33% reduction of injection volume for O-H-LSD (Horn et al. 2003).  This study used an 
automated SPE procedure, and gave a fast, simple extraction with a recovery as high as 
92%. 
Microgenic Corporation has developed an affinity resin for IAE that is specific 
for LSD (Röhrich et al. 2000).  The LSD in the sample is bound to a monoclonal 
antibody that is immobilized on the surface of a solid support.  After incubation the resin 
is washed to remove matrix components. Finally, a solvent like methanol is added to 
denature the antibodies which cause the release of LSD from the antibody (Röhrich et al. 
2000; Kerrigan and Brooks 1999).  However, IAE has been shown to have less 
recoveries which limits its use for quantitative analysis (Webb et al. 1996).  Other 
disadvantages include its limited LSD binding capacity and the high cost of reagents 
(Kerrigan and Brooks 1999).   
 
 
Table 1.1:  Comparison of methods for analyzing LSD and O-H-LSD 
% Recovery % CV Extraction Chromatography LSD O-H-LSD LSD O-H-LSD 
 
GC/MS(/MS)  
(Lim et al. 1988; Burnley and 
George 2003) 
 
65-86 
 
72 
 
2.8-13 
 
4.0-17.3 
 
LLE 
LC/MS(/MS)  
(Sklerov et al. 2000; Canezin et 
al. 2001) 
67 69-74 2-8.8 6-14.3 
SPE LC/MS(/MS)  
(Skopp et al. 2002; Horn et al. 
2003) 
68-76 48-54 
(92*) 
1.6-5.3 2.9-6.1 
(2.0*) 
GC/MS(/MS)  
(Libong et al. 2003a) 
60 - 10.8 - LLE/SPE 
LC/MS(/MS)  
(Sklerov et al. 2000) 
31-61 32-42 2-8.8 6-14.3 
*with automated SPE 
     
 
 
11 
1.6.4 Immunoassays 
Immunoassays can be used as an initial screen for LSD.  An immunoassay is 
simply a reaction between an antibody and an antigen.  The most commonly used 
immunoassays include enzyme-multiplied immunoassay technique (EMIT), 
radioimmunoassay (RIA), enzyme-linked immunosorbant assay (ELISA), and cloned 
enzyme donor immunoassay (CEDIA) (see Table 1.2).  Immunoassays are relatively 
sensitive, with the cutoff limit for a positive LSD being 500 pg/mL (Schneider et al. 
1998; Acosta-Armas 2003).  However, immunoassays lack selectivity resulting in high 
incidence of false positives (Acosta-Armas 2003).  A few studies have shown that other 
prescription drugs were possibly cross reacting causing this false positive (Acosta-
Armas 2003; Ritter et al. 1997).  A high number of samples, positive for LSD by 
immunoassay methods, are not positive using confirmatory methods.  EMIT has more 
cross reactivity and poorer precision than CEDIA and RIA (Ritter et al. 1997; Wiegand 
et al. 2002).  RIA is not a popular method due to the increase cost and the handling and 
disposal of radioactive material.  Despite the lack of selectivity immunoassays are still 
used due to the simplicity, short turnaround times, and low cost. 
 
Table 1.2:  Comparison of immunoassay methods for the detection of LSD (Wiegand et 
al. 2002; Moore et al. 1999; Immunalysis 2001) 
 EMIT CEDIA RIA ELISA 
Positive cutoff (ng/mL) LSD 0.5 0.5 0.5 0.5 
nor-LSD 100 100 10 50 
iso-LSD 50 50 100 na 
Cross reactivity concentration (ng/mL) 
O-H-LSD 100 100 100 na 
False positive incidence high low low low 
% CV at positive cutoff concentration 9.0 3.5 3.6 8.4 
na = no data available 
     
 
1.6.5 Capillary Electrophoresis (CE) 
The use of CE with laser-induced fluorescence (LIF) detector has been proposed 
as a possible routine forensic method for detecting LSD (Frost and Kohler 1998).  Using 
special sample preparation, electrokinetic injection, and bubble cell capillary, a LOD of 
100 to 200 pg/mL was obtained.  CE/LIF has an advantage over immunoassays, because 
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it does not have cross-reactivity problems.  However, this method has not been shown to 
work using urine samples. 
 
1.6.6 Gas Chromatography-Mass Spectrometry (GC/MS) 
Most laboratories today use GC/MS as their confirmatory method for LSD 
because the instrumentation is available.  A sensitive method for detecting LSD using 
GC/MS has been developed with a LLOQ of 20 pg/mL (Libong et al. 2003a).  However, 
the analysis of LSD using GC/MS has its challenges.  LSD undergoes irreversible 
adsorption during the chromatographic process, it is relatively non-volatile, and finally it 
is not stable at the GC temperatures (Libong et al. 2003a).  Furthermore, sample 
preparation is laborious because the samples require derivatization via silylation of the 
indole nitrogen (Klette et al. 2002; Libong et al. 2003a). 
Peak tailing is the consequence of an adsorption-desorption phenomenon which 
depends on the polarity of the analyte, the nature of the MS system components, and the 
temperature of analysis (Libong et al. 2003b).  To reduce the irreversible adsorption of 
LSD to both the capillary column and the electrodes of the MS, the column requires 
regular conditioning and the MS requires regular cleaning.  Conditioning the column 
with silylating agents N,O-bis(trimethylsilyl) trifluoroacetamide (BSTFA) and 
hexamethyl-disilazane (HMDS) resulted in increased background interferences, and 
conditioning with blank extracted matrix gave satisfactory results (Sklerov et al. 1999).  
Temperature programmed on-column injections have also been used to reduce the 
irreversible adsorption (Libong et al. 2003b; Sklerov et al. 1999). 
Another problem with analyzing LSD is its short detection window.  As a result, 
the development of GC/MS methods for analyzing iso-LSD and the metabolites of LSD 
has been attempted.  Iso-LSD determination using GC/MS has been attempted by first 
isomerizing iso-LSD to LSD, because the instability of iso-LSD does not make it ideal 
for quantification.  The LLOQ of iso-LSD was determined to be 50 pg/mL (Clarkson et 
al. 1998).  However, this method is time consuming requiring two procedures to 
calculate iso-LSD concentrations. 
More recently with the discovery of O-H-LSD, the use of GC/MS to detect it has 
been attempted (Reuschel et al. 1999b; Burnley and George 2003).  Derivatization of 
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LSD attaches a trimethylsilyl (TMS) group to the indole nitrogen, however when O-H-
LSD is derivatized a TMS group can also attach to the hydroxyl group which results in a 
mixture of mono-TMS and bis-TMS derivatives (Reuschel et al. 1999b).  In order to 
accurately quantitate O-H-LSD, when using a GC/MS method requiring derivatization, 
an internal standard with similar properties, such as 2-oxo-3-hydroxy-lyergic acid 
methylpropylamide (O-H-LAMPA-Figure 1.5), must also be used.  GC/MS has also 
been shown to have low sensitivity and irreproducible chromatography for O-H-LSD 
(Poch et al. 1999).   
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Figure 1.5:  Internal standards for LSD analysis, (A)LSD-D3 = deuterated LSD, (B) 
LAMPA = lysergic acid methylpropylamide, and (C) O-H-LAMPA = 2-oxo-3-hydroxy-
LAMPA. 
 
 
1.6.7 Liquid Chromatography-Mass Spectrometry (LC/MS or LC/MS/MS) 
The development and validation of LC/MS methods for analyzing LSD and its 
metabolites is an ongoing area of research.  Due to the difficulties of analyzing LSD by 
GC/MS and the increase popularity of HPLC, recent methods developed for LSD 
analysis have used LC/MS (Table 1.3, page 15) or LC/MS/MS (Table 1.4, page 16).  
The sensitivity of the methods developed have a wide LOD range of 10 (Skopp et al. 
2002) to 500 pg/mL (Webb et al. 1996; White et al. 1999) for LSD, 50 (Skopp et al. 
2002) to 400 pg/mL (Poch et al. 2000; Sklerov et al. 2000) for O-H-LSD, and 25 (de 
Kanel et al. 1998) to 60 pg/mL (Skopp et al. 2002) for nor-LSD.  Methods using tandem 
MS provided the most sensitive methods compared to single MS methods. 
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To the Author’s knowledge, there are no known published validated methods for 
the simultaneous confirmatory and quantitative analysis of LSD, iso-LSD, nor-LSD, and 
O-H-LSD in both urine and blood.  The most recent published method is a LC/MS/MS 
method determination of LSD, iso-LSD and O-H-LSD (Johansen and Jensen 2005).  
However, sample preparation and MS detection were not optimized for O-H-LSD and 
therefore not validated for quantitative analysis.  Also a LLOQ of 10 pg/mL is reported 
for both LSD and iso-LSD in urine and blood, however the accuracy and precision at 
this level are not reported. 
LC/MS/MS is not only sensitive, but is also highly specific.  As a result, 
common over-the-counter products, prescription drugs and their metabolites, other illicit 
compounds, and compounds related to LSD, were found not to cause significant 
interference (Horn et al. 2003; Klette et al. 2002). 
 
1.7 Hypothesis and Study Objectives 
Currently a confirmatory method to analyze LSD and its metabolites in forensic 
laboratories in Canada is lacking in terms of a reliable validated method.  The Royal 
Canadian Mounted Police (RCMP) Forensic Laboratory Services (FLS) in Winnipeg has 
acquired a new tandem mass spectrometer (MS/MS) with a liquid chromatography (LC) 
interface that makes it possible to explore the development and validation of a highly 
sensitive and selective method for the analysis of LSD and its metabolites.  LC has been 
shown to be more sensitive and simpler to perform than GC/MS, especially when using 
MS/MS.  It is hypothesized that LC/MS/MS will make it possible to analyze extracts of 
blood and urine for LSD and its metabolites with enhanced sensitivity and greater ease 
of analysis.  More importantly, the method should be acceptable as a reliable method for 
analyzing forensic samples suspected of containing LSD because it will be fully 
validated.  Furthermore, the project will impact the RCMP FLS in the general use of 
LC/MS/MS as a confirmatory technique.  Consequently the knowledge gained in this 
project can be directly applied to other analyses where it is necessary to confirm the 
presence of other drugs in forensic samples. 
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Chapter 2 
Introduction to the use of Liquid Chromatography Coupled to Tandem Mass 
Spectrometry (LC/MS/MS) in Forensic Toxicology 
2.1 Introduction 
Toxicology is “the study of the adverse effects of chemicals on living organisms” 
(Klaassen 2001), and forensic toxicology is “the study and practice of the application of 
toxicology to the purposes of the law” (Cravey and Baselt 1981).  The main objectives 
of a forensic toxicologist are to detect the presence of drugs or poisons, followed by the 
subsequent confirmation and quantitation of any toxicologically relevant drugs or 
poisons, and finally the interpretation of the results.  Since forensic toxicology pertains 
to the law, the most important objective of a forensic toxicologist after detecting the 
drug is its confirmation.  To obtain a reliable analytical result, the confirmatory test 
should be more specific than the initial screening test, and mass spectrometry should be 
used where possible and practical (SOFT/AAFS 2006).   
 Mass spectrometry should be considered a separate and distinct instrumental 
technique, due to its complexity, expense, and capability, and also since it can be used 
either alone with direct injections or with either gas or liquid chromatography as a 
means of sample separation and injection (Cravey and Baselt 1981).  Since forensic 
toxicology exhibits are normally complex biological matrices, methods such as 
chromatography are needed to separate the compound of interest from matrix 
interferences or from other drugs.  Chromatography requires a flowing mobile phase that 
passes through a stationary phase.  When the mobile phase is liquid it is referred to as 
LC, where separation is based on the relative solubility of the solutes in the mobile and 
stationary phase (Burtis and Ashwood 1996).  At the RCMP FLS Winnipeg, LC is being 
used specifically for acidic and neutral drug screening using a photodiode array (PDA) 
detector (Lyttle, personal communication).  LC with the PDA detector is not used as a 
confirmatory method due to the lack of specificity and selectivity of the PDA detector 
compared to MS.  As a result, GC/MS has been the method of choice for confirmatory 
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analysis.  The RCMP FLS Winnipeg has acquired a new MS/MS with a LC interface 
that now makes it possible to explore the development and validation of confirmatory 
methods for analytes more suited to LC analysis. 
 
2.2 LC/MS versus GC/MS 
In forensic and clinical laboratories GC/MS is the “gold standard” for 
toxicological screening and confirmation (Maurer 1998).  Laboratories may rely on 
GC/MS for a few reasons; (1) laboratories already have extensive experience using 
GC/MS, (2) instrumentation is already available, (3) GC/MS electron ionization (EI) 
provides structural information, (4) a searchable spectral library exists, (5) technology to 
couple LC to MS is relatively new compared to GC/MS, and (6) few laboratories can 
actually afford a LC/MS.  However, GC/MS is somewhat limited for the analysis of 
polar, thermolabile, and volatile analytes.  Before the advancement of LC, laborious 
techniques such as derivatization were employed with GC to increase sample volatility.  
On the other hand, LC/MS has a number of advantages over GC; (1) no derivatization is 
necessary, allowing for simpler sample preparation, (2) extracts may be frozen and re-
examined, and (3) the spectrum of analytes can now include polar active metabolites of 
numerous drugs, which are not suitable for GC/MS (Bogusz 2000).  By assessing the 
polarity and molecular mass of an analyte, LC is capable of analyzing a significantly 
higher number of analytes compared to GC (Figure 2.1).    
 Not only is LC able to analyze many compounds that cannot be analyzed by GC, 
but very difficult separations can be achieved by LC versus GC (Cravey and Baselt 
1981).  This is due to the fact that the efficiency or the number of theoretical plates of 
LC (≥5000 plates/m) is better than GC (≥2000 plates/m).  In chromatography the column 
efficiency is measured using the theoretical plate number (N), which is calculated from 
the retention volume of a solute (VR) and the volume occupied by the solute or the peak 
width (wB) (Equation 2.1), where N gets larger as the column becomes more efficient 
(Lindsay 1987).   
 N = 16 (VR/wB)2 Equation 2.1
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Also along with the ability to vary the stationary phase, flow rate, and temperature, LC 
can also vary its mobile phase.  And finally LC has a wide variety of column packings 
versus GC.   
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Figure 2.1:  Determining optimal analysis based on molecular mass and analyte polarity 
(adapted from Mauer 1998). 
 
 
2.3 MS with GC versus LC 
In forensic toxicological analysis MS is recommended as the confirmatory 
technique when possible (SOFT/AAFS 2006).  This is because MS is capable of 
determining both molecular weight and structural information (McLafferty and Tureček 
1993).  The basic principles of MS are the formation of ions via ionization, separation of 
these ions according to their mass to charge ratio (m/z), and final detection of these ions 
(Cravey and Baselt 1981).  There are generally two types of ionization methods in MS, 
“hard” and “soft” ionization (McLafferty and Tureček 1993).  “Hard” ionization creates 
ionized molecules that tend to undergo fragmentation, whereas “soft” ionization reduces 
the propensity for fragmentation.  EI, a “hard” ionization method, is commonly used 
with GC/MS.  The fragment ions produced in EI provide structural information because 
the masses of these fragment ions are characteristic of the original molecule.  Chemical 
ionization (CI), a “soft” ionization method, is more useful for determining the molecular 
weight of a molecule.  With CI, amines and ethers usually give abundant [M+H]+ ions 
and saturated hydrocarbons normally yield [M-H]+ ions.  Both species are useful for 
determining the molecular weight (McLafferty and Tureček 1993).  EI provides more 
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fragment ions with relative high abundances, but lacks the sensitivity, whereas CI 
provides a spectrum in which the base peak ([M+H]+ or [M-H]+) is more prominent 
making it ideal for highly sensitive quantitative analysis (Libong et al. 2003a). 
Coupling MS to LC presents many challenges.  A suitable interface for LC/MS 
must be able to; (1) eliminate a large volume of gases and vapours produced from the 
LC mobile phase, and (2) transform the molecules in solution in the mobile phase into 
ions in the gas phase without thermal degradation (Marquet and Lachâtre 1999).  The 
most commonly used interfaces for LC/MS with the largest polarity range are 
Atmospheric Pressure chemical Ionization (APcI) and electrospray ionization (ESI), 
which are considered “soft” ionization methods.  Combining both APcI and ESI on one 
instrument would theoretically be complementary to EI (Marquet and Lachâtre 1999).  
In ESI, liquid is sprayed out of a capillary tube to which a high voltage is applied to 
form a spray of charged droplets (Whitehouse et al. 1985).  In APcI, liquid is passed 
through a heated tube and evaporated to produce gas phase molecules.  The gas phase 
molecules are ionized by electrons produced from a corona discharge (Niessen 1998).  
When deciding on what form of ionization to use, both molecular weight and polarity 
should be considered (Figure 2.1, page 19).  ESI is suitable for small to larger polar 
molecules up to several hundred thousand Daltons, whereas APcI is better suited to 
ionization of small, less polar molecules.  Ionization can also be achieved in either 
polarity, producing either positively or negatively charged ions. 
Since LC/MS utilizes “soft” ionization, the mass spectrum typically consists of 
only the protonated molecular ion [M+H]+, which could provide a sensitive method but 
lacks specificity.  It is possible to induce in-source fragmentation by varying the 
potential across the ion transfer lens between the ESI source and the quadrupole analyzer 
(Webb et al. 1996).  Excessive fragmentation could reduce sensitivity through reduction 
of the [M+H]+.  It has also been found that with a given voltage the degree of 
fragmentation varied with different batches of mobile phase.  As a result, fragmentation 
voltage must be monitored when changing batches of mobile phase (White et al. 1997). 
Alternatively, fragmentation can be induced during tandem MS (MS/MS) 
experiments, for which triple quadrupole instruments are ideally suited.  Ions in a 
quadrupole travel between four co-linear rods, and mass separation is achieved by 
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combining radio frequency (RF) and direct current (DC) fields applied to these rods 
(McLafferty and Tureček 1993).  Depending on the exact potential applied to the 
quadrupoles, only ions with a specific mass to charge ratio (m/z) will pass through.  
When conducting MS/MS experiments with a triple quadrupole mass spectrometer the 
first quadrupole is used in a narrow band pass (Q) mode, allowing ions of a particular 
m/z to pass through.  The second quadrupole is used in wide band pass (q) mode as a 
collision cell, in which ions collide with argon atoms and fragment into product ions.  
And finally the third quadrupole is used to resolve and transmit product ions of a 
particular m/z to the detector.   
 Triple quadrupole MS has the capability of acquiring data in a variety of modes, 
such as (1) product (daughter) ion scan, (2) precursor (parent) ion scan, (3) constant 
neutral loss, and (4) multiple reaction monitoring (MRM).  In product ion scan the first 
quadrupole is fixed to allow only ions of a specific m/z (precursor ion) to pass through, 
and ions then undergo collision induced dissociation (CID) with argon atoms in the 
second quadrupole, and finally the third quadrupole is in full scanning mode to allow 
detection of all fragment product ions.  Product ion scan is useful for determining the 
fragmentation pattern of a compound.  In precursor ion scan the first quadrupole is in 
full scanning mode and the third quadrupole is fixed.  Precursor ion scanning is 
beneficial for detecting compounds with similar structures that produce the same 
charged fragment.  For constant neutral loss mode both first and third quadrupole are in 
full scanning mode.  Constant neutral loss mode is used for compounds with similar 
structures that produce the same neutral fragment.   
For MRM mode both the first and third quadrupole are fixed to allow only ions 
of a specific m/z to pass through.  With complex matrices, MRM has the capability to 
eliminate the interference from the matrix (Figure 2.2).  As a result, with MRM, the 
development of a highly sensitive method is possible.  MRM is also useful for 
compounds that are difficult to resolve chromatographically, but have unique precursor 
to product ion transitions (Figure 2.3). 
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Figure 2.2:  (a) Total ion chromatogram (TIC) of blank urine showed a peak close to the 
retention time of LSD ((c) MRM channel of LSD (RT = 9.34) standard), (b) but when 
monitoring the MRM 324>223 channel specific for LSD it showed the absence of this 
peak, suggesting that the peak was an impurity present in the matrix.   
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Figure 2.3:  (a) TIC and MRM acquisition of (b) LSD, (c) LSD-D3, and (d) nor-LSD.  
Chromatographically LSD, LSD-D3, and nor-LSD are not totally resolved, but MRM 
provides unique channels for monitoring all three compounds. 
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2.4 HPLC versus Ultra Performance Liquid Chromatography (UPLC™) 
Waters Corporation has taken the principles of HPLC and further adapted them 
to create Ultra Performance Liquid Chromatography (UPLC™), a new separation 
technique with increased speed, sensitivity and resolution (Swartz. 2005).  The 
performance of a column can be measured in terms of the height equivalent to the 
theoretical plates (HETP or H) which is calculated from the column length (L) and the 
column efficiency, or number of theoretical plates (N).  N is calculated from an analyte’s 
retention time (tR) and the standard deviation of the peak (σ).   
 H = L/N Equation 2.2
 N=(tR/σ)2 Equation 2.3
The van Deemter equation (Equation 2.4) is the empirical formula that describes the 
relationship between linear flow velocity (μ) and column efficiency, where A, B, and C 
are constants related to the mechanistic components of dispersion.   
 H = L/N = A + B/μ + Cμ Equation 2.4
According to the van Deemter plot (Figure 2.4), column efficiency is inversely 
proportional to the particle size (dp) (Equation 2.5), so by decreasing the particle size 
there is an increase in efficiency.  Since resolution is proportional to the square root of N 
(Equation 2.6), decreasing particle size increases resolution.  Also, by using smaller 
particles, analysis time can be decreased without sacrificing resolution, because as 
particle size decreases, column length can also be reduced proportionally to keep column 
efficiency constant.  By using the same HPLC mobile phase and flow rate, UPLC™ 
reduces peak width and produced taller peaks which increased the S/N 1.8 to 8 fold, 
improving both sensitivity and resolution (Churchwell et al. 2005). 
 N α 1/dp Equation 2.5
 R = √N/4(α-1/α)(k/k+1) Equation 2.6
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Figure 2.4:  van Deemter plot (adapted from Waters 2004c). 
 
 
Also according to the van Deemter plot, use of particles smaller than 2 μm 
produces no loss in column efficiency with increasing flow rates.  However, by 
increasing flow rates to decrease analysis time, there is a corresponding increase in 
system pressure.  As a result, a system capable of withstanding the proper pressures 
while still maintaining efficiency is required.  As well, a mechanically stable column is 
needed.  Waters Corporation has designed the ACQUITY system which can withstand 
pressures as high as 15000 psi and a column with enhanced mechanical stability utilizing 
a second generation bridged ethyl hybrid (BEH).  The empirical formula of the BEH 
particle is SiO2(O1.5SiCH2CH2SiO1.5)0.25 which is synthesized by the co-condensation of 
1,2-bis(triethoxysilyl)ethane with tetraethoxysilane (Wyndham et al. 2003).  Not only do 
BEH columns have enhanced mechanical and chemical stability, but also reduce peak 
tailing significantly for basic analytes compared to silica columns, due to the reduced 
acidity of the unreacted surface silanol groups (Wyndham et al. 2003).   
 
2.5 Waters Quattro Premier 
The ion source configuration, collision cell technology, and data acquisition 
speed of the Waters Quattro Premier instrument have all been designed to optimize the 
use of UPLC™.  The Quattro Premier has a Z-Spray™ dual orthogonal ion source 
(Figure 2.5), which protects the source against contamination by non-ionic components 
in complex sample matrices (Waters 2004b).  As well, an exhaust trap positioned 
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opposite the ionization probe allows for rapid removal of non-ionized materials.  Since 
the orthogonal position protects the source from matrix contamination, the cone orifice 
can be increased in size, allowing more ions to be transferred to the MS (Waters LC/MS 
booklet). As a result, there is a decrease in noise which corresponds to an increase in 
sensitivity.  Furthermore, an isolation valve allows for easy removal and cleaning of 
source elements without breaking vacuum (Waters 2004b).  Compared to previous 
Waters models, the Z-Spray™ is more robust and provides better sensitivity (Niessen 
1998).  
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Figure 2.5:  Z-Spray™ (adapted from Waters LC/MS booklet). 
 
 
Previous Waters quadrupole MS utilized a hexapole assembly in the collision 
cell.  However, the Quattro Premier utilizes T-Wave™ (Travelling Wave™) ion optics 
in the collision cell.  The T-Wave™ collision cell is a stacked-ring with only RF (Figure 
2.6) which propels ions by superimposing a voltage pulse on the RF of an electrode and 
moving the pulse to an adjacent electrode to provide a travelling voltage wave on which 
the ions are carried (Figure 2.7), reducing their residence time in the cell (Giles et al. 
2004).  With MRM the duty cycle depends upon two parameters; (1) dwell time, during 
which the ions are monitored, and (2) inter-channel delay between successive MRM 
transitions, during which ions are cleared from the collision cell.  When operating in 
MRM mode with very short dwell times it is important that the time the ions reside in 
the collision cell is minimal to avoid cross-talk between successive transitions (Giles et 
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al. 2003).  T-Wave™ reduces cross-talk to 0.01% without losing sensitivity (Giles et al. 
2003). 
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Figure 2.6:  RF-only stacked ring ion guide (adapted from Giles et al. 2004). 
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Figure 2.7:  T-Wave™ on which the ions surf (adapted from Giles et al. 2004). 
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For reproducible peak area quantification, a chromatographic peak should have 
no less than 10 data points.  As a result, in order to accurately quantify the narrow peaks 
produced with UPLC™, the MS needs to acquire data at a fast rate.   The Quattro 
Premier has the capability of acquisition speeds of 100 data points per second (Waters 
2004a).  The fast acquisition speed is made possible with T-Wave™ as described earlier.   
 
2.6 The Potential of LC/MS(/MS) in Forensic Toxicology 
LC/MS(/MS) at the RCMP FLS Toxicology Services (TS) is a fairly new 
technology, and is currently in the developmental process being used only for 
confirmation of a small number of compounds more suited to LC/MS(/MS) versus 
GC/MS.  Other forensic toxicology laboratories, such as the Institute of Forensic 
Medicine in Aachen, Germany, are using a LC with a single quadrupole MS routinely 
(Bogusz 2000).  Attempts have also been made to create a spectral library using 
LC/MS/MS (Gergov et al. 2004).  But to what extent can LC/MS/MS be used for 
systematic toxicological analysis?  The existing searchable spectral library for GC/MS 
makes it ideal for toxicological screening.  In order for a spectral library to be useful it 
should be reproducible long term and between different laboratories.  By standardizing 
collision energy and gas pressure with a tuning compound, it was found that LC/MS/MS 
spectra using two different instruments from different manufacturers were similar 
(Gergov et al. 2004).  Once standardization of fragmentation intensities and patterns 
between different laboratories is achieved, LC/MS(/MS) may one day even replace 
GC/MS as the “gold standard”. 
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Chapter 3 
Validation Parameters in the Development of Qualitative and Quantitative 
LC/MS/MS Methods in Forensic Toxicology 
3.1 Introduction 
The investigation of drugs or chemicals can be divided into three steps: (1) 
obtaining the case history and suitable specimens, (2) the toxicological analyses, and (3) 
the interpretation of the analytical findings (Klaassen 2001).  In most cases the suspected 
drug or poison is unknown.  As a result, screening tests capable of detecting a wide 
variety of drugs are usually the first step in forensic toxicological analysis.  If the 
screening methods detect the presence of a drug or chemical, it must be confirmed using 
a more specific method.  While the sole presence of a poison may suffice for some cases 
in forensic toxicology, an actual quantity of the drug or poison may also be needed.   
Methods used in forensic toxicology must be validated to ensure reliable results.  
Validation is a permanent process that starts from the beginning of the life of the method 
until its retirement, with the objective of achieving high-quality results by means of an 
analytical method (Boulanger et al. 2003).  Validating a method provides an assurance 
of reliability during normal use, and can also provide documented evidence that the 
method works (Shabir 2003).  There are many guidelines that have been written on how 
to validate a method; however, one must consider the intended purpose of an analytical 
procedure when deciding on what parameters to validate.  For example, the significance 
of certain parameters when validating a qualitative versus quantitative analytical 
procedures, or a pharmaceutical versus forensic analytical procedure, will be different. 
There are many different regulatory agencies, such as the US Food and Drug 
Administration (FDA), the United States Pharmacopeia (USP), and the International 
Conference on Harmonization (ICH), that have put forth validation requirements for 
analytical methods.  However, the guidelines put forth by these three sources are specific 
for pharmaceutical analysis.  The Society of Forensic Toxicologists (SOFT) and the 
American Academy of Forensic Sciences (AAFS) have written guidelines specifically 
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for forensic laboratories (SOFT/AAFS 2006).  As well, the Standards Council of Canada 
has written guidelines for the accreditation of forensic testing laboratories, where it is 
stated that confirmation and quantitative analysis should use methods that have been 
documented and validated by the laboratory, where linearity, selectivity, LOD, accuracy, 
and precision should be assessed (Standards Council of Canada 2003).  The FDA also 
requires the assessment of recovery, stability, and when using LC/MS/MS, matrix 
effects. 
 
3.2 Linearity and Range 
A calibration curve should be constructed from biological matrix standards 
which are spiked with a known amount of analyte.  A calibration curve describes the 
relationship between the instrument response and known concentrations of analyte, with 
a linear relationship being the simplest.  Assuming that a relationship is linear when 
developing a method must be avoided.  Instead, linearity should be evaluated by visual 
inspection of a plot of signal (instrument response) as a function of analyte 
concentration, and by appropriate statistical methods (ICH 1996).  The correlation 
coefficient (r), y-intercept, slope of the regression line, and residual sum of squares 
should also be submitted (ICH 1996).   
Although it has been common practice to define linearity using r, it is not really a 
measurement of linearity.  Linear regression finds the best fit line, whereas correlation 
quantifies how consistently two variables vary together (Motulsky and Christopoulos 
2005).  Another term related to r is the coefficient of determination (r2), which quantifies 
the goodness of fit.  When r2 is 1, all points lie exactly on the curve with no scatter.   
However, using r or r2 as the main criterion for determining the goodness of fit and 
linearity should be avoided. 
Residuals and a runs test can further support the linearity of data.  By visually 
inspecting the residuals, the assumption of linear regression may be verified if the 
residuals are randomly scattered above and below.  Also, a runs test can determine if the 
straight line deviates from the data.  A run is a series of consecutive points that are either 
all above or all below the regression line (Motulsky and Christopoulos 2005).  A low P 
value from the runs test means that data deviates from a straight line.   
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The goal of linear regression is to find the best fit straight line through the points 
of the calibration standards (Miller 1991).  Normally linear regression with unweighted 
least squares makes two assumptions: (1) the y-direction errors are normally distributed 
(Gaussian distribution), and (2) that the standard deviation of y-direction errors is the 
same for all x values (homoscedastic data) (Motulsky and Christopoulos 2005; Miller 
1991).  Therefore, when using unweighted least squares regression all points on the 
graph are of equal weight or importance in the calculation of the best fit line.  In most 
cases of linear regression the first assumption is true, but the second assumption is 
usually not true.  Instead the standard deviation of y-direction errors often increases as x 
increases (heteroscedastic data) (Miller 1991).  As a result, for heteroscedastic data a 
weighted regression should be used instead.   
Linearity should be established using at least three calibrators (calibration 
standards), which should bracket the anticipated concentration of the specimen 
(SOFT/AAFS 2006).  However, according to the FDA a calibration curve should consist 
of six to eight non-zero samples covering the expected range (FDA 2001).  For the 
purposes of this project, all qualitative analysis followed the SOFT/AAFS guideline 
using three calibrators, and all quantitative analysis used the FDA guideline of six to 
eight calibrators.  Although r is not necessarily a good measurement of linearity, 
SOFT/AAFS suggests that r should be 0.99 for accepting a multi-point calibration.  
Back-calculating the value of each calibrator against the curve and then using a percent 
deviation of ±20% acceptance limit is also recommended by SOFT/AAFS.   
 
3.3 Accuracy 
Accuracy is the degree of closeness of the determined value to the nominal or 
known true value (FDA 2001).  To assess accuracy the FDA suggest using a minimum 
of five determinations per concentration, with a minimum of three concentrations within 
the expected range.  In order to determine if a method is accurate the measured values 
should be within 15% of the nominal values, and within 20% for the LLOQ.  
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3.4 Precision 
Precision is the closeness of agreement between a series of measurements 
obtained from multiple sampling of the same homogenous sample under the prescribed 
condition (FDA 2001). The SOFT/AAFS mentions % CV, but not in the context of 
method validation.  Instead it states that it is good practice to monitor the performance of 
assays by periodically calculating the % CV, and that a % CV greater than 15% 
indicates poor precision.  The FDA provides a detailed method for determining 
precision.  A minimum of five determinations per concentration using a minimum of 
three concentrations within the expected range should be measured.  The % CV should 
be 15% (20% for LLOQ) for acceptable precision (FDA 2001).  The FDA also further 
subdivides precision into three more categories; (1) within-run, (2) intra-batch, (3) and 
between-run.   
 
3.5 Sensitivity (LOD and LLOQ) 
The LOD is the lowest concentration of an analyte that the bioanalytical 
procedure can reliably differentiate from background noise, and the LLOQ is the lowest 
concentration that can be quantitatively determined with suitable precision and accuracy 
(FDA 2001).  For simplification, the SOFT/AAFS states that for chromatographic 
assays, the LOD and LLOQ may be defined as the concentration of the lowest calibrator.  
If results need to be reported below the value of the lowest calibrator, the LOD and 
LLOQ would then need to be determined experimentally. 
The FDA suggests that the LLOQ should be at least five times the response of 
the blank and that the analyte peak be identifiable, discrete, and reproducible with a 
precision of 20% CV and accuracy of 80 to 120% (FDA 2001).  Another method of 
determining LOD and LLOQ is based on signal to noise ratio (S/N).  S/N of 3:1 and 
10:1 is considered acceptable for estimating the LOD and LLOQ, respectively (ICH 
1996).  A method utilizing a calculation based on standard deviation (σ) of the response 
and the slope (S) is also available (Equation 3.1 & 3.2, ICH 1996). 
 LOD = 3.3σ/S Equation 3.1
 LLOQ = 10σ/S Equation 3.2
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The σ can be determined by using the residual standard deviation of the regression line 
of a calibration curve in the LOD range.  And S may be determined from the calibration 
curve in the LOD range.  ICH guidelines do not favour one method of determining LOD 
and LLOQ over another.  Instead they state that the S/N method only be used for 
analytical procedures that exhibit baseline noise.  Regardless of which method is used, 
the only requirement is that the method chosen for determining LOD and LLOQ be 
presented and supported with an appropriate number of samples analyzed at the limit 
(ICH 1996; Shabir 2003). 
 
3.6 Selectivity 
Selectivity is defined as the ability of a method to differentiate an analyte in the 
presence of other components in the sample (FDA 2001).  According to the FDA 
selectivity should be assessed by analyzing at least six sources of blank samples of 
appropriate matrix.  Each blank should then be tested for interference and selectivity 
should be established at the LLOQ.   
 
3.7 Recovery 
Recovery is the extraction efficiency of an analytical process (FDA 2001).  A 
high recovery is not essential unless the sensitivity of the method is poor.  However, 
recovery experiments must be assessed at different concentration levels and recovery 
must be consistent, precise, and reproducible. 
 
3.8 Matrix Effect (ME) (Ion Suppression and Ion Enhancement) 
LC/MS/MS has been perceived as a highly selective technique.  As a result, 
simple extraction procedures and chromatographic conditions that result in limited 
retention and separation of analytes from endogenous compounds are often employed.  
Consequently, matrix effects (ME) become more of a concern with LC/MS/MS 
procedure (Matuszewski et al. 2003).  ME in LC/MS/MS is somewhat different from 
other detection techniques.  Interferences from the sample matrix with detection 
techniques such as UV are visible as peaks, whereas in LC/MS/MS interferences are 
generally unseen, causing a suppression or enhancement of the signal (Larger et al. 
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2005).  ME in LC/MS/MS occurs when co-eluting, undetected matrix components 
reduce or enhance the ion intensity of the analytes, and affect the reproducibility and 
accuracy of the assay (Matuszewski et al. 2003).  Specifically with ESI, ME arise from 
the competition between matrix constituents (non-volatile solutes) and analyte molecules 
for access to the droplet surface and subsequent gas phase emission (King et al. 2000).  
Non-volatile matrix constituents can also change eluent properties such as boiling point, 
surface tension, and viscosity (King et al. 2000).   
The FDA suggests that ME be investigated for LC/MS/MS procedures, but no 
specific method on how to accomplish this is given (FDA 2001).  However, a number of 
methods for investigating ME have been proposed.  The first is by using a post-column 
infusion system in which an infusion pump delivers a constant flow of an analyte post 
column, and then blank sample extracts are injected on-column (Bonfiglio et al. 1999).  
Any interference that elutes from the column and causes a variation in ESI response of 
the infused analyte is considered as ionization suppression.  Although this method 
provides information on the chromatographic profile of the interference, it does not 
provide quantitative information (Larger et al. 2005). 
Another proposed method involved injection of sets of samples (Matuszewski et 
al. 2003).  Samples in set 1 are neat solutions made up in the mobile phase, and samples 
in set 2 are extracts of blank matrices spiked with analyte after the extraction.  The 
absolute ME can then be determined by comparing the peak areas of the neat analyte 
standards (A) to the standards spiked after extraction (B) (Equation 3.3). 
 ME % = B/A × 100 Equation 3.3
A ME % greater than 100% suggests an ion enhancement and a ME % less than 100% 
suggest an ion suppression.  Matuszewski et al. suggests using five different sources of 
matrices to provide more accurate bioanalytical data.  A relative ME can be assessed as 
well by comparing the B values of different sources of matrices expressed as the % CV.  
Large differences between B values indicate that the MS/MS response of an analyte is 
different in different sources of matrix. 
When analyzing multiple analytes in one method, the absence of ME for all 
individual analytes needs to be demonstrated.  The presence of either an absolute or 
relative ME does not necessarily suggest that a method is not valid.  As long as the 
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analyte and the internal standard (ISTD) exhibits the same relative ME, the drug to ISTD 
ratio used to calculate drug concentration should not be affected (Matusewski et al. 
2003).  However, if the presence of ME invalidates a method, the ME may be eliminated 
by: (1) changing sample extraction procedures, (2) changing chromatographic conditions 
to separate analytes of interest from undetected endogenous compounds, and (3) 
evaluating and changing the LC/MS interface and the mechanism of ionization 
(Matusewski et al. 2003).  
 
3.9 Stability 
Drug stability in biological fluids is a function of the storage conditions, the 
chemical properties of the drug, the matrix, and the container system (FDA 2001).  The 
FDA suggests evaluating freeze and thaw, short term, long term, stock solution, and post 
preparative stability.  All stability studies should evaluate a low and high concentration 
in at least replicates of three.  All conditions should reflect situations likely to be 
encountered during actual sample handling and analysis. 
For evaluating freeze and thaw stability of an analyte a minimum of three cycles 
should be assessed.  Each cycle involves storing the sample at the intended storage 
temperature, then allowing the sample to thaw at room temperature.  If the analyte is 
unstable at the intended storage temperature the sample should be frozen at -70°C.   
For short term stability a sample should be thawed at room temperature and kept 
at room temperature for the expected duration that samples will be at room temperature 
during actual sample analysis.  Whereas, for long term stability the storage time of the 
sample should exceed the time between the date of first sample collection and the date of 
last sample analysis. 
The stock solutions also need to be shown to be stable in terms of both short term 
and long term stability.  The stability of the stock solutions of drug and ISTD should be 
evaluated at room temperature for at least 6 hours.  Then the storage temperature of the 
stock solutions should be assessed.  And finally the post preparative stability involves 
the assessment of processed samples, such as the time in the autosampler. 
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3.10 Retention Times 
Retention times (RT) should also be included in the acceptance criteria where a 1 
to 2% deviation from the calibrators or controls is acceptable for GC based assays 
(SOFT/AAFS 2006).  For LC based assays, especially when mobile phases are 
programmed via gradient elution, large deviations from the calibrators or controls may 
be acceptable.  SOFT/AAFS does not state a deviation level specific for LC based 
assays.  The International Olympic Committee (IOC) and the World Anti-Doping 
Agency (WADA) have suggested that for GC the RT and relative RT (RRT) of the 
analyte should not differ more than 1% from the calibrators, and 2% for HPLC (Rivier 
2003). 
 
3.11 Ion Ratios 
For MS procedures used in selected ion monitoring modes for confirmation 
and/or quantitation, a qualifying ion in addition to the primary ion, is encouraged 
(SOFT/AAFS 2006).  The acceptance criterion for ion ratios is ±20% relative to that of 
the corresponding control or calibrator.  For LC/MS the acceptance criteria may be 
increased up to ±25 to 30%, because LC/MS assays may be more concentration and time 
dependent.  
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Chapter 4 
Preliminary Development of a HPLC/MS/MS Method for Analyzing LSD, iso-LSD, 
nor-LSD, and O-H-LSD in Urine 
4.1 Introduction 
A preliminary method using an Agilent 1100 HPLC coupled to a Waters Quattro 
Ultima MS was developed for analyzing LSD, iso-LSD, nor-LSD, and O-H-LSD.  The 
purposes of this method were; (1) to determine if HPLC/MS/MS could achieve the 
required sensitivity, and (2) to determine if simultaneous analysis of LSD, iso-LSD, nor-
LSD, and O-H-LSD was possible. 
 
4.2 Materials and Methods 
4.2.1 Reference Standards 
 LSD, iso-LSD, nor-LSD, O-H-LSD, LSD-D3, LAMPA, and O-H-LAMPA were 
obtained from Cerilliant Corporation (Round Rock, TX).  A stock solution of 5 ng/mL 
was prepared in methanol (MeOH).  10, 50, 100, 200, 400, 800, and 2000 pg/mL 
working standards were prepared by spiking blank urine with the 5 ng/mL stock 
solution.  An internal standard test mix (LSD-D3, LAMPA, and O-H-LAMPA) stock 
solution of 200 ng/mL was prepared in MeOH. 
 
4.2.2 Sample Preparation and Extraction 
A simple SPE procedure for basic compounds was done using Waters 
Corporation (Milford, MA) Oasis extraction cartridges.  To the 5 mL working standards, 
20 µL of internal standard test mix (200 ng/mL) was added.  First to condition the SPE 
cartridges, 1 mL of MeOH was added to and drawn through each cartridge.  Next 1 mL 
of water was added to and drawn through each cartridge to equilibrate the column.  After 
conditioning and equilibrating the column, 1 mL of the 5 mL working standard with 
ISTD was added to and drawn through each cartridge.  To wash the cartridges, 1 mL of 
5% MeOH in water (v/v) was added to and drawn through each cartridge.  Finally to 
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elute off the compounds, 1 mL of MeOH was added and the eluate was collected.  Then 
the eluate was evaporated to dryness under nitrogen at 55°C.  The residue was 
reconstituted in 200 µL of 20:80 (v/v) acetonitrile (ACN): 20 mM ammonium acetate in 
0.05% formic acid.  Twenty five microlitres of sample were injected into the HPLC. 
 
4.2.3 HPLC Conditions 
An Agilent Technologies (Palo Alto, CA) HPLC 1100 with an autosampler was 
used.  Chromatographic separation was done using a Zorbax SB C18 (2.1 × 50 mm, 5 
μm particle size, Agilent Technologies, Palo Alto, CA) column with a gradient elution 
using 20 mM ammonium acetate, 0.05% formic acid and ACN at a flow rate of 0.2 
mL/min.  An initial solvent composition of 90:10 ACN:20 mM ammonium acetate in 
0.05% formic acid was held for 1 minute, followed by a step gradient to 15:85 
ACN:aqueous solvent for 7 minutes.  Then another step gradient to 25:75 for 11 minutes 
was used and held for 3 minute. The column was then equilibrated for 6 minutes giving 
a total run of 27 minutes. 
 
4.2.4 HPLC/MS/MS Conditions 
A Waters Corporation (Milford, MA) Quattro Ultima™ tandem quadrupole mass 
spectrometer was used.  API was done via positive ESI.  The electrospray probe tip 
potential was set at 3.00 kV.  The source and desolvation temperature were set at 120 
and 350°C, respectively.  The cone and desolvation gas flow were set at 113 and 748 
L/Hr, respectively.  The collision gas (Argon) pressure was set 3.54 × 10-3 mbar.  The 
mass spectrometer was run in MRM mode.  Four MRM channels in total were 
monitored (Table 4.1). 
 
Table 4.1:  MRM transitions with Water Quattro Ultima 
Standards MRM transition Collision Energy Cone Voltage 
LSD, iso-LSD, LAMPA 324 > 223 21 37 
nor-LSD, iso-nor-LSD 310 > 209 21 37 
O-H-LSD, O-H-LAMPA 356 > 237 22 37 
LSD-d3 327 > 226 22 37 
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4.2.5 Assessment of Linearity and Accuracy 
Linearity was assessed using standards prepared by spiking blank urine with 
analyte concentrations ranging from 10 to 2000 pg/mL and extracting with the SPE 
method described earlier (section 4.2.2).  The calibration curve was plotted with nominal 
concentration to peak area ratios (PAR = peak area (PA) of standard/PA of ISTD).  Both 
unweighted and weighted linear regression for the calibration curve were evaluated.  
Data collection, peak integration, % bias, and linear regression were performed using 
MassLynx™ version 4.0 software (Waters Corporation, Milford, MA).  A suitable linear 
range was determined by evaluating the accuracy (% bias) of back calculated results.   
 
4.3 Results and Discussion 
4.3.1 Gradient versus Isocratic Elution 
Various ratios of solvent A (20 mM Ammonium acetate, 0.05% formic acid) and 
solvent B (ACN) were investigated initially using isocratic elutions.  However, isocratic 
elution was unable to adequately chromatographically separate all compounds with 
similar MRM transitions, and within an optimal time.  Therefore, gradient elution was 
ultimately chosen.  At the beginning of the run the mobile phase has a low organic 
content so that analytes are retained on the column and salts flow through the column.  
Then the mobile phase is ramped from low organic to high organic content so that 
analytes will begin to elute off the column and enter the MS.  The mobile phase then has 
a high organic content to wash any hydrophobic contents off the column.  Finally the 
column is equilibrated back to initial conditions.  Using a neat standard mix, all 
compounds with similar MRM transitions were chromatographically separated using a 
gradient elution with a total run time of 27 minutes (Figure 4.1). 
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Figure 4.1:  TIC of a 250 ng/mL neat solution of O-H-LSD, O-H-LAMPA, LSD, LSD-
D3, nor-LSD, LAMPA, and iso-LSD. 
 
 
4.3.2 Sample Extraction 
Initially a very simple extraction method was employed in an attempt to extract 
all the compounds.  However, this SPE method did not extract O-H-LSD or O-H-
LAMPA (Figure 4.2).  In order to perform simultaneous analysis of all compounds, the 
extraction method therefore needed to be modified or changed. 
 
 
Figure 4.2:  TIC of 2000 pg/mL O-H-LSD, O-H-LAMPA, LSD, LSD-D3, nor-LSD, 
LAMPA, and iso-LSD in a urine extract. 
 
 
4.3.3 Unweighted versus Weighted Linear Regression 
As previously mentioned in Chapter 3 (section 3.2, page 29), unweighted linear 
least squares assumes that the standard deviation of y-direction errors is the same for all 
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x values (homoscedastic data) (Motulsky and Christopoulos 2005; Miller 1991).  In 
some cases the standard deviation of y-direction errors often increases as x increases 
(heteroscedastic data) (Miller 1991).  As a result, for heteroscedastic data a weighted 
regression should be used instead.  From experience it was assumed that since the range 
in the x-values was large (10 to 2000 pg/mL), that the variance at each point was 
expected to be different.  So for the purposes of this preliminary method, weighted (1/x2) 
linear regression was selected.  During the preliminary development of this HPLC 
method, replicate analysis was not conducted, so the standard deviation of the y-
direction errors could not be evaluated.  As a result, evaluation of the proper weighting 
scheme for the calibration curve was not possible.  The suitability of this weighting 
scheme will be further evaluated with replicate analysis in Chapter 5. 
 
4.3.4 Linearity and Accuracy 
The extracted urine standards were linear from 10 to 2000 pg/mL for LSD 
(Figure 4.3).  The r, r2, intercept, and slope, using weighted (1/x2) linear regression are 
shown in Figure 4.3. 
 
r = 0.995744, r2 = 0.991506, y = 0.000513x + 0.00126 
 
Figure 4.3:  Calibration curve of LSD with 1/x2 weighting. 
 
 
A quantitative method was deemed to have acceptable accuracy if the % bias of 
back calculated results from the nominal concentration did not exceed ±15%.  The back 
calculated results were shown to have acceptable accuracy within the entire linear range 
(Table 4.2).   
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Table 4.2:  Accuracy results of a neat LSD standard 
Sample STD (pg/mL) RT (min) PAR Calculated (pg/mL) % Bias 
Blank + IS - - - - - 
LSD 10 10 19.37 0.0065 10.27 2.68 
LSD 50 50 19.41 0.0248 45.95 -8.10 
LSD 100 100 19.37 0.0457 86.68 -13.32 
LSD 200 200 19.37 0.1033 198.98 -0.51 
LSD 400 400 19.37 0.2171 421.05 5.26 
LSD 800 800 19.41 0.4635 901.86 12.73 
LSD 2000 2000 19.41 1.0393 2025.16 1.26 
 
 
4.4 Conclusion 
By using HPLC/MS/MS, LSD, iso-LSD, nor-LSD, and O-H-LSD were 
simultaneously analyzed.  Compounds that shared similar MRM transitions were 
chromatographically resolved and compounds that could not be chromatographically 
resolved had unique MRM transitions.  The method was capable of achieving a sensitive 
analysis of LSD at the low picogram concentration levels.  However, this preliminary 
method requires further adaptation before it can be applied to UPLC™/MS/MS.  Not 
only is the LC and MS instrumentation different, but the models are different as well 
(i.e. HPLC vs. UPLC™, and Waters Quattro Ultima vs. Waters Quattro Premier MS).  
Furthermore, the extraction method needs to be modified in order to extract O-H-LSD, 
and the weighting scheme for the calibration curve requires further evaluation. 
 
 
 42 
Chapter 5 
Preliminary Development of an UPLC™/MS/MS Method for Analyzing LSD, Iso-
LSD, Nor-LSD, and O-H-LSD in Forensic Samples 
5.1 Introduction 
The method developed on the HPLC/MS/MS system needed to be transferred to 
the UPLC™/MS/MS system.  Even if the systems were similar the method would still 
need to be validated on the specific instrument to be used for forensic analysis by the 
RCMP.  Certain parameters were changed and optimized for the UPLC™/MS/MS 
system to further enhance the method sensitivity and robustness prior to beginning full 
method validation. 
 
5.2 Column Change 
The 1.7 μm particle size in the Acquity UPLC™ BEH column versus the 5 μm 
particle size in the Agilent Zorbax column decreased the total analysis time by half 
(Table 5.1).  Resolution was not lost by decreasing total analysis time.  The Acquity 
UPLC™ BEH column maintained the total peak area by producing narrower peak 
widths (~0.45 minute versus ~1 minute peak width at 5% height) and taller peak heights 
(e.g. 4.59 × 106 versus 5.37 × 105) (Figure 5.1).   
It is important to note that accurate quantitation was still possible with the 
narrow peaks.  Although it is generally accepted that a chromatographic peak should be 
made up of 15 to 20 points to accurately define it (Waters 2004a; Dyson 1999), other 
studies have conducted successful quantitative analysis using 6 to 8 points per peak 
(Dallüge et al. 2002; King et al. 2003).   For the narrow (~27 second) peak widths 
obtained when monitoring 12 MRM channels, with a dwell time of 0.2 second and a 
0.01 second inter-channel delay, the 2.52 second duty cycle corresponded to 0.4 data 
points/second, or 11 data points per ~27 second peak.   
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(a) 
(b) 
 
 
 
Figure 5.1:  Comparison of TIC of LSD and congeners using (a) HPLC versus (b) 
UPLC™. 
 
 
5.3 Mobile Phase Change 
The mobile phase was changed from 20 mM Ammonium acetate with 0.05% 
formic acid to a 20 mM Ammonium acetate buffer (pH 4.0).  A low concentration of 20 
mM for the buffer was chosen to ensure that there was no potential competition between 
the analyte and the buffer ions for conversion to gas phase ions.  If the buffer ion is in 
large excess it can inhibit charge separation and subsequent ion evaporation during ESI.  
It may also prevent the ionization of analyte molecules present at low concentrations 
Table 5.1:  Parameters for HPLC versus UPLC™ 
 HPLC UPLC™ 
Column Agilent Zorbax SB C18, 2.1 × 50 mm,5 μm particles 
Acquity UPLC BEH C18, 
2.5 × 50 mm,1.7 μm particles 
Flow Rate 0.2 mL/min 0.2 mL/min 
Injection Volume 25 μL 25 μL 
Total Run Time 30 min 15 min 
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(Waters LC/MS booklet).  Acetate buffer was chosen because it is volatile and therefore 
compatible with MS, and also because its pKa of 4.8 allows accurate pH control at pH 4 
to 5.  LSD has a pKa of 7.8 (Baselt 2000); consequently, a pH of 4.0 for the buffer was 
chosen because, according to the Henderson-Hasselback equation (Equation 5.1), LSD 
should be completely protonated if the mobile phase pH is 2 units below the pKa.  For 
an analyte which is ionized under reversed phase conditions, optimal peak shape, 
detection limits, and consistent retention times will be obtained when using a properly 
buffered mobile phase (Heyrman and Henry 1999).   
 pH = pKa + log([base conjugate]/[acid conjugate]) Equation 5.1
The ACQUITY columns offer greater efficiency and speed, but the minimum peak 
width attainable under isocratic conditions will be limited by extra column broadening.  
When using gradient elution this is less of a problem, because sample components will 
be concentrated onto the head of the column by the weak mobile phase starting 
conditions (Jerkovich et al. 2005).  As a result, like the HPLC/MS/MS method the 
UPLC™/MS/MS method also utilized a gradient elution.  The ACQUITY column also 
reduced the re-equilibration time by taking advantage of the low system dwell volume, 
which is 15% of that of the HPLC (Yang and Hodges 2005).   
 
5.4 Optimizing MS/MS Conditions 
Optimization of the MS conditions was done by direct infusion of reference 
standards (2 μg/mL) in mobile phase (20 mM Ammonium acetate buffer (pH 4.0):ACN 
(80:20)) at 20 μL/min by the syringe pump installed on the MS.  MS parameters were 
adjusted to maximize sensitivity of product ions produced by CID of protonated ions.  
The full scan and product ion mass spectra of LSD, iso-LSD, nor-LSD, O-H-LSD, and 
LSD-D3 are shown in Figure 5.2.  The product ion mass spectrum of LSD and iso-LSD 
were nearly the same as reported by Canezin et al. 2001 using another triple quadrupole 
instrument (API 300 Perkin-Elmer SCIEX, Thornhill, Canada).  Similarly, the product 
ions of LSD, iso-LSD, nor-LSD, O-H-LSD, and LSD-D3 monitored with triple 
quadrupole MS were the same as reported by others (Canezin et al. 2001; de Kanel et al. 
1998; Skopp et al. 2002).  LSD and iso-LSD share common precursor and product ions, 
but were easily separated chromatographically. 
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The proposed fragmentation of LSD, iso-LSD, nor-LSD, O-H-LSD, and LSD-D3 
are shown in Figure 5.3.  The proposed mechanism for the fragmentation of the 
precursor ion to the most abundant fragment ion (LSD and iso-LSD m/z 223, nor-LSD 
m/z 209, LSD-D3 m/z 226) includes cleavage at the carbon-carbon bond alpha to the 
carbonyl group with elimination of the side chain at position eight (Cai and Henion 
1996).  The same is true for the m/z 237 product ion of O-H-LSD, but also includes the 
cleavage of the hydroxyl group (Canezin et al. 2001; Poch et al. 2000).  The m/z 281 
(LSD, iso-LSD, and LSD-D3) and m/z 313 (O-H-LSD) product ions are formed by the 
retro-Diels-Alder reaction induced by the 9-10 double bond (Cai and Henion 1996).  The 
m/z 208 (LSD, iso-LSD, and LSD-D3) and m/z 222 (O-H-LSD) product ions are also 
formed by the retro-Diels-Alder reaction, but also includes a loss of the diethylamine 
group and an additional loss of the hydroxyl group on O-H-LSD (Canezin et al. 2001).  
The m/z 237 product ion of nor-LSD corresponds to a loss of the diethylamine group 
(Canezin et al. 2001), with the m/z 74 product ion being the protonated diethylamine 
group. 
LSD and iso-LSD shared common precursor and product ions, but the 
fragmentation pattern ion intensities of LSD and iso-LSD were different.  The 
equilibrium between LSD and iso-LSD has been shown to be six times slower when iso-
LSD was used versus LSD, showing that the epimerizable proton on LSD is more easily 
removed than the same proton of iso-LSD (Salamone et al. 1997).  The most abundant 
product ion of LSD (m/z 223) is due to cleavage at the epimerizable proton; however, 
since the same proton is more difficult to remove on iso-LSD, the m/z 281 product ion, 
whose fragmentation does not involve the C-8 chiral center, is the most abundant 
product ion for iso-LSD instead. 
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(b) iso-LSD full scan 
 
Product ion spectra 
m/z
100 200 300 400
%
0
100 324
15814160 214
325
m/z
100 200 300 400
%
0
100 281
208
180
100 168
223
251
324
 
(c) nor-LSD full scan 
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(d) O-H-LSD full scan 
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(e) LSD-D3 full scan 
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Figure 5.2:  Infusion full scan and product ion spectras for (a) LSD, (b) iso-LSD, (c) nor-
LSD, (d) O-H-LSD, and (e) LSD-D3. 
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Figure 5.3:  Proposed fragmentation of (a) LSD, iso-LSD, (b) nor-LSD, (c) O-H-LSD, 
and (d) LSD-D3 (Cai and Henion 1996; Canezin et al. 2001). 
 
 
5.5 Effect of Increasing Flow Rates 
In order to take full advantage of the UPLC™ technology, flow rate can be 
increased to further decrease analysis time.  The difficulty with increasing flow rate was 
the increased back pressure, which caused leaking in connecting tubing.  In order to 
decrease the back pressure larger diameter peek tubing could possibly help.  Larger 
diameter PEEK tubing stopped the leaking; however, the larger diameter in the tubing 
caused band broadening in the peaks.  By ensuring a tight seal, smaller diameter PEEK 
tubing could be used without leaking problems.  By increasing the flow rate to 0.4 
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mL/min from 0.2 mL/min the pressure reading was ~7900 psi and the analysis time 
decreased from 15 to 8 minutes (Figure 5.4).   
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Figure 5.4:  TIC of a neat 500 pg/mL LSD test mix showed a decrease in total run time 
from 15 minutes to 8 minutes by increasing flow rate from (a) 0.2 mL/min to (b) 0.4 
mL/min. 
 
 
Although analysis time was reduced, the peak response height was slightly lower 
(3.92 × 105 versus 4.62 × 105) when the flow rate was increased to 0.4 mL/min.  Also 
the peak width at 5% height did not change (~0.45 minutes at both 0.2 mL/min and 0.4 
mL/min).  As a result, increasing flow rate from 0.2 mL/min to 0.4 mL/min did not 
enhance sensitivity.  Although sensitivity was not enhanced, total analysis time was 
decreased without sacrificing resolution.  Despite the decreased analysis time achieved 
for a neat LSD test mix standard, however, extracted samples run at 0.4 mL/min showed 
a decrease in both sensitivity and resolution.  The peak shape was poor and there was a 
decrease in peak purity % (Figure 5.5).  By decreasing total analysis time there seemed 
to be poor separation of the compounds of interest from endogenous materials present in 
the sample matrix.  Therefore, for method validation, a 0.2 mL/min flow rate was chosen 
because resolution and sensitivity were more important than analysis time. 
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(a) 0.4 mL/min flow rate (b) 0.2 mL/min flow rate 
Time
5.00 6.00
%
0
100
LSD_Aug11_27 F1
324 > 223
3.09e3
97%
82%
 
Time
9.00 10.00
%
0
100
LSD_July28_03 F1
324 > 223
9.24e3
100%
100%
 
Time
5.00 6.00
%
0
100
LSD_Aug11_27 F1
310 > 209
847
-1%
 
Time
10.00 11.00
%
0
100
LSD_July28_03 F1
310 > 209
3.16e3
91%
58%
27% 100%
 
Time
1.50 2.00 2.50
%
0
100
LSD_Aug11_27 F1
356 > 237
887
73%
52% 89%
37%
 
Time
3.50 4.00 4.50
%
0
100
LSD_July28_03 F1
356 > 237
2.75e3
93%
22%
66%
 
 
Figure 5.5:  MRM channels for a spiked blood extract (50 pg/mL LSD, iso-LSD, nor-
LSD, and O-H-LSD) run at (a) 0.4 mL/min flow rate showed poor peak shape and a 
decrease in peak purity % versus (b) 0.2 mL/min flow rate. 
 
 
5.6 Effect of Changing Sample Injection Volumes 
The ACQUITY system has the ability to use both partial and full loop-fill 
injections.  Partial loop-filled injections are preferred to full loop-filled injections, with 
partial loop-filled precision being good at volumes up to 80% of the loop total volume 
(Yang and Hodges 2005).  The UPLC™ uses air-gap sandwiching of the sample, 
thereby allowing for better utilization of the sample loop and higher injection precision 
(Yang and Hodges 2005).  The ACQUITY system also incorporates a portion of a weak 
solvent wash to be co-injected with partial loop-filled samples.  The weak solvent wash 
helps to enhance sample focusing onto the column.  Partial loop-filled injections with 
needle overfill draws an excess of sample into the needle and through the valve while 
the loop remains in line with the pump.  The valve is switched to bring the loop off-line 
and the syringe then draws the appropriate volume of sample into the loop.  The valve is 
then switched back again to complete the injection (Jerkovich et al. 2005).   
In order to realize the increased sensitivity benefits, low volume injections with 
minimal carryover are required (Swartz 2005).  A 50 pg/mL neat standard was injected 
using different volumes.  When 15 μL of a 50 pg/mL neat standard was injected the 
LSD S/N was 11.90.  The LSD S/N increased two fold to 23.62 when the injection 
volume was increased to 25 μL (Figure 5.6).  To see if injecting volumes smaller than 
 50 
the loop volume would further enhance precision of repeated injections, one sample was 
injected 6 times using 15 and 25 μL volume injections.  The precision (% CV) of the 
repeated injections using 15 and 25 μL were comparable (Table 5.2).  In order to achieve 
a highly sensitive method for LSD, 20 μL injection volume (sample loop size) was 
chosen for method validation. 
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Figure 5.6:  The effect of two different injection volumes, (a) 15 μL and (b) 25 μL on 
the S/N of LSD.  
 
 
 
Table 5.2:  Precision of repeated injections of a 500 pg/mL neat standard (n=6) using 15 
and 25 μL volume injections 
 15 μL injection 25 μL injection 
 %CV %CV 
LSD 3.6 2.3 
Iso-LSD 3.5 1.0 
Nor-LSD 5.9 2.9 
O-H-LSD 1.9 2.2 
 
5.7 Selection of Reference Standards 
Certified reference standards were obtained from Cerilliant Corporation (Round 
Rock, TX).  All standards came prepared in 1 mL ACN.  All stock standard solutions 
were prepared by diluting volumes of standards to 5 mL.  All stock standards prepared 
for the HPLC/MS/MS (Chapter 4) were prepared in MeOH, and for UPLC™/MS/MS all 
stock standards were prepared in ACN.  It has been shown that iso-LSD rapidly 
isomerizes to LSD when dissolved in MeOH and stored at 2-6°C (Clarkson et al. 1998).  
To prevent isomerization of LSD, standards should not, therefore, be made up in MeOH. 
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5.8 Selection of Internal Standard 
According to the SOFT/AAFS 2006 guidelines for forensic laboratories, the 
ISTD should have similar chemical and physical properties as the analyte.  Stable 
isotope standards are recommended for LC/MS methods, as these normalize the 
responses of target drugs, thus compensating for variations in injections, sample 
preparation, instrumental parameter, and matrix effect (Liang et al. 2003).  Although a 
non-deuterated ISTD may give equivalent or better performance, the use of an isotope 
standard may be the only way to compensate for ion suppression.   
By comparing the slope of the lines, a greater slope value may indicate that better 
accuracy at higher concentrations may be expected.  Methods for analyzing LSD have 
used LAMPA, LSD-D3, and O-H-LAMPA as the ISTD (See Chapter 1, Tables 1.3 and 
1.4).  A calibration curve using each ISTD was constructed (Figure 5.7).  The slopes 
differed and O-H-LAMPA had the largest slope.  The ion chromatogram of each ISTD 
(1000 pg/mL) showed that the PA of LSD-D3 and LAMPA were more than 7 times 
greater compared to O-H-LAMPA (Figure 5.8).  The larger slope could be explained by 
the smaller PA of O-H-LAMPA.  Since the PAR is the PA of the standard divided by 
PA of the ISTD, the PAR was larger for O-H-LAMPA compared to LSD-D3 and 
LAMPA.  The slope will be larger if the ΔPAR is larger since the slope is essentially 
determined from the ΔPAR divided by Δnominal concentration.  With a greater slope O-
H-LAMPA may provide better accuracy compared to LSD-D3 and LAMPA.  The % 
bias and % CV of LSD using each ISTD at 20, 50, 500, and 1500 pg/mL were all within 
acceptable range (Table 5.3).   
 
Table 5.3:  Accuracy and precision of LSD using 3 different internal standards. 
Nominal LSD-D3 LAMPA O-H-LAMPA 
(pg/mL) % bias (n=6) 
% CV 
(n=6) % bias % CV % bias % CV 
20 3.82 10.91 3.97 (n=6) 6.83 (n=6) -2.33 (n=5) 9.54 (n=5) 
50 3.17 3.02 -2.54 (n=6) 6.79 (n=6) -8.77 (n=5) 3.19 (n=5) 
500 2.30 4.76 -2.84 (n=3) 3.11 (n=3) 3.59 (n=4) 4.86 (n=4) 
1500 6.48 3.96 1.41 (n=3) 0.31 (n=3) 6.00 (n=4) 2.19 (n=4) 
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(a)  ISTD = LSD-D3, R = 0.998921, R2 = 0.997843, y = 0.000981812x + 0.00430119 
pg/mL
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(b)  ISTD = LAMPA, R = 0.998399, R2 = 0.996801, y = 0.00207504x + 0.00739736 
pg/mL
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(c)  ISTD = O-H-LAMPA, R = 0.998527, R2 = 0.997057, y = 0.0044249x + 0.0210852 
pg/mL
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Figure 5.7:  Calibration curves for LSD using (a) LSD-D3, (b) LAMPA, and (c) O-H-
LAMPA as the ISTD. 
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Figure 5.8:  TIC of 1000 pg/mL neat standard mix of O-H-LAMPA (RT = 4.16 
minutes), LSD-D3 (RT = 9.21 minutes), and LAMPA (RT = 9.80 minutes). 
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One-way ANOVA (analysis of variance) showed no significant difference 
(p>0.05) between the mean values of LSD at 20, 500, and 1500 pg/mL calculated using 
each ISTD.  However, there was a significant difference (p = 0.003) in the mean value of 
LSD at 50 pg/mL.  When performing a Bonferroni's multiple comparison test there was 
a significant difference (p<0.01) between the calculated mean value of LSD using LSD-
D3 versus O-H-LAMPA as the ISTD.  A one-sample t-test showed a significant 
difference (p = 0.0025) of the calculated mean value of LSD using O-H-LAMPA as the 
ISTD from the hypothetical value of 50 pg/mL.  The same results were observed when 
comparing the accuracy and precision of calculated mean values of iso-LSD, nor-LSD, 
and O-H-LSD using the 3 different ISTD’s.  The slope of LSD-D3 and LAMPA could 
be increased by using a smaller concentration to decrease its PA, but since O-H-LAMPA 
did not enhance either the accuracy or precision of the assay, this was not necessary.  As 
mentioned earlier in Chapter 1 (section 1.6.6) quantitating O-H-LSD via GC/MS 
requires an ISTD with similar properties because a mixture of mono-TMS and bis-TMS 
derivatives occurs when O-H-LSD is derivatized (Reuschel et al. 1999b).  This was not 
as critical with LC/MS/MS since no derivatization was performed, so O-H-LAMPA was 
excluded as an ISTD, leaving LSD-D3 or LAMPA. 
LAMPA is an isomeric compound of LSD, and is itself a controlled drug (White 
et al. 1999).  As a result, using LAMPA as an ISTD may cause problems if LAMPA was 
also present in the sample to be analyzed.  Previous LC/MS methods using single ion 
monitoring (SIM) were limited to using a structurally similar non-deuterated compound 
(i.e. LAMPA) versus an isotope as an ISTD, due to the fact that LSD and LSD-D3 were 
not chromatographically separated and also shared a common major product ion.  With 
MS/MS this was not a problem because MRM could determine which precursor ion 
gave rise to a particular product ion.  As a result, LSD-D3 was chosen as the ISTD for 
method validation.   
 
5.9 Selection of Sample Matrix 
A significant risk in bioanalytical method validation is that spiked matrix 
samples are a poor model for real samples (James et al. 2004).   Despite this risk, it has 
been common practice to used spiked matrix samples for validating bioanalytical 
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methods.  It is recognized that it is quite difficult to make spiked matrix samples exactly 
the same as real case samples.  This is even more difficult with forensic analysis due to 
the variety of samples submitted.  Forensic samples can either be ante- or postmortem, 
with the potential of also receiving decomposing samples.  As well there are many 
different types of blood collection vials with or without preservatives.  As a result, the 
only thing that can be done is to select a sample matrix that is as close as possible to real 
case samples. 
The RCMP FLS Winnipeg uses synthetic drug free urine from Immunalysis 
Corporation (Pomona, CA) and porcine blood diluted 25% with water, containing 0.25% 
sodium fluoride and 0.20% potassium oxalate, as model matrices.  The suitability of 
using porcine blood as the matrix for constructing calibration curves for quantitation was 
determined by comparing calibration curves constructed from the porcine versus blank 
human whole blood collected in grey top Vacutainers™ (sodium fluoride, potassium 
oxalate preservative) using GraphPad Prism version 4.03 for windows (GraphPad 
Software, San Diego, CA) (Table 5.4).  The slope and intercept of the calibration curves 
were compared and the F-test was used to test whether one curve suffices for all data or 
if individual curves were statistically distinguishable.  There was no significant 
difference (p>0.05) between the calibration curves of human versus porcine whole blood 
for LSD, iso-LSD, nor-LSD and O-H-LSD, which showed that porcine whole blood was 
an acceptable substitute for human whole blood. 
 Since urine analysis by the RCMP FLS is only qualitative, full calibration curves 
for quantitation are not done for urine analysis.  As a result, the suitability of synthetic 
urine for constructing calibration curves was not tested.  Instead, the suitability of the 
use of synthetic urine for qualitative analysis was tested for by assessing the selectivity 
and matrix effect compared to human urine.  Blank synthetic urine and porcine blood 
were extracted as outlined in Section 6.2.5 and were determined to be suitable if no 
drugs were present and no interfering peaks were seen (Section 6.3.4).  Selecting the 
appropriate sample matrix is even more critical when using LC/MS/MS due to the 
potential for ion suppression/enhancement (James et al. 2004).  If the sample matrix 
chosen for method validation exhibits ion suppression/enhancement but the real case 
samples did not, the method would be invalid.  As a result, it is essential to demonstrate 
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the absence of ME using different sources of matrix.  ME is described in detail in 
Chapter 3 (section 3.9), with results of the ME study in Chapter 6 (section 6.3.5). 
 
Table 5.4:  Comparison of the slope and intercept (± 95% CI) of calibration curves 
constructed from human (H) versus porcine (P) whole blood. 
  Separate curves One curve Comparison of intercepts 
  Slope (× 10-4) 
Intercept 
(× 10-3) 
Slope 
(× 10-4) 
Intercept 
(× 10-3) 
F ratio 
(DFn, 
DFd) 
p 
value
LSD H 8.12 ± 0.37 8.61 ± 1.68
 P 8.63 ± 0.38 7.00 ± 1.71 8.37 ± 0.26 7.81 ± 1.19 
2.413 
(2,20) 0.115
Iso-LSD H 6.01 ± 0.30 -2.20 ± 1.35
 P 6.54 ± 0.75 -3.12 ± 3.41 6.19 ± 0.28 2.50 ± 1.28 
2.140 
(2,14) 0.155
Nor-LSD H 2.15 ± 0.08 2.26 ± 0.88
 P 2.40 ± 0.20 0.98 ± 2.21 2.28 ± 0.11 1.62 ± 1.23 
3.610 
(2,16) 0.051
O-H-LSD H 2.31 ± 0.15 -0.09 ± 1.66
 P 0.17 ± 0.07 -0.66 ± 0.96 2.25 ± 0.10 -0.20 ± 1.13 
2.844 
(2,13) 0.095
 
5.10 Selection of Extraction Method 
Forensic toxicology specimens are normally complex matrices which require 
some sort of preparation prior to analysis.  In a method that analyzes multiple types of 
matrices, it would be ideal to have a single sample preparation method applicable to all 
types of matrices.  A thorough literature search was conducted to find extraction 
methods used for LSD.  However, the majority of the methods in the literature are 
specific for and therefore optimized for only extracting LSD. 
 An automated SPE method was used to extract LSD and nor-LSD from blood, 
serum, plasma, and urine (de Kanel et al. 1998).  In this method, Varian Bond Elut 
Certify SPE cartridges (Varian Sample Preparation Products, Harbor City, CA) were 
used.  Since the sample batch volume at the RCMP FLS is not expected to be large, an 
automated method is not practical, so the same procedure was conducted manually 
(Figure 5.9a).  This extraction method used a lot of solvents, so another SPE method was 
considered (Reuschel et al. 1999b) (Figure 5.9b).  Overall, SPE was time consuming, 
utilized lots of solvents, yielded dirty extracts, and did a poor job at extracting O-H-LSD 
(Figure 5.10). 
Due to the poor results with SPE, LLE was considered as an alternative.  A LLE 
method adapted from Canezin et al. 2001 and Sklerov et al. 2000 was used (see Chapter 
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6).  The only change was the volume and concentration of ISTD and the volume of 
dichloromethane:isopropyl alcohol used.  The LLE was simple to perform and was able 
to extract all compounds with similar % recoveries, causing no significant ion 
suppression or enhancement (see Chapter 6). 
 
 
 
 
A. SPE method # 1 
1. Condition column 
a) 1.5 mL mix [dichloromethane: isopropanol:NH4OH (78:20:2)] 
b) 3.0 mL MeOH 
c) 1.0 mL water 
d) 3.0 mL 0.1M Phosphate buffer  
2. Add sample (1 mL sample + LSD-D3 + 1 mL water + 2 mL phosphate buffer) 
3. Wash column 
a) 3.0 mL 0.1M Phosphate buffer 
b) 2.0 mL 1M Acetic acid 
c) 3.0 mL MeOH 
d) 0.5 mL mix 
4. Collect eluate 
a) 2.0 mL mix 
5. Dry eluate to dryness under N2 
6. Reconstitute  
 
 
B. SPE method # 2 
1. Condition column 
a) 2.0 mL MeOH 
b) 2.0 mL 0.1 M Phosphate buffer  
2. Add sample (4 mL sample + LAMPA + O-H-LAMPA + 2 mL phosphate buffer) 
3. Wash column 
a) 1.0 mL 1 M Acetic acid 
b) 5.0 mL MeOH 
4. Collect eluate 
a) 2 mL mix [dichloromethane: isopropanol:NH4OH (78:20:2)] 
5. Dry eluate to dryness under N2 
6. Reconstitute 
 
 
Figure 5.9:  (A) SPE method for extracting LSD and nor-LSD from whole blood, serum, 
plasma, and urine (de Kanel et al. 1998). (B) SPE method extracting LSD and O-H-LSD 
in urine (Reuschel et al. 1999b). 
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A.  Urine extract of O-H-LSD (2 ng/mL) using SPE method #1 
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B.  Urine extract of O-H-LSD (2 ng/mL) using SPE method #2 
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C.  Neat O-H-LSD standard (1.5 ng/mL) 
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Figure 5.10:  Comparison of two SPE methods for O-H-LSD in urine.  Same results were 
seen in whole blood. 
 
 
5.11 Selection of Weighting Scheme 
Prior to performing linear regression, the data should be tested for 
homoscedasticity versus heteroscedasticity by plotting residuals versus concentration 
(Mulholland and Hibbert 1997) then applying an F-test to compare the variances.  The 
experimental F-value (Fexp) was expressed as the ratio between the variances obtained at 
the lowest (s12) and at the highest (s22) concentration level of the working range 
(Equation 5.2), and the tabled F-value (Ftab) was then obtained from the F-table 
(Almeida et al. 2002).  For homoscedasticity the variance will be constant and the 
residuals will be scattered randomly around the x-axis and the Fexp < Ftab.   
 Fexp = (s2)2/(s1)2 Equation 5.2
The residual plots and the F-test showed that the data was heteroscedastic.  The 
residuals were increasing as concentration increased (Figure 5.11).  As well, when tested 
with the F-test at the confidence level of 95% for f1 = f2 = (n-1) degrees of freedom, 
there was a significant difference (p<0.05 and Fexp > Ftab) between the variances 
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obtained at the lowest and at the highest concentration level (Table 5.5).  As a result, the 
calibration curve was constructed using weighted linear regression. 
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(b) Unweighted Linear Regression Residuals of iso-LSD
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(c) Unweighted Linear Regression Residuals of nor-LSD
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(d) Unweighted Linear Regression Residuals of O-H-LSD
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Figure 5.11:  Residual plots of (a) LSD, (b) iso-LSD, (c) nor-LSD, and (d) O-H-LSD 
using unweighted linear regression. 
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Table 5.5:  F-test to compare homogeneity of variances  
 pg/mL Mean PAR s2 Fexp p value of variances 
LSD 20 0.024 1.82 × 10-6 142 0.0135 
 2000 2.035 2.68 × 10-4   
Iso-LSD 20 0.027 5.85 × 10-8 11820 0.0002 
 2000 2.075 6.91 × 10-4   
Nor-LSD 50 0.031 1.10 × 10-6 228 0.0087 
 2000 1.279 2.51 × 10-4   
O-H-LSD 50 0.021 2.06 × 10-6 211 0.0094 
 2000 0.991 4.34 × 10-4   
Ftab (f1, f2; 0.95) = Ftab (2, 2, 0.95) = 19.0 
 
Since the evidence showed that the data was not homoscedastic, the next step 
was to determine the appropriate weighting factor.  The best weighting factor was 
chosen according to the % bias (Equation 5.3).   
 
Equation 5.3
The best weighting factor will give rise to a narrow horizontal band of randomly 
distributed % bias around the concentration axis and presents the least sum of the 
absolute % bias values across the whole range (Almeida et al. 2002).  The sums of the 
absolute % bias values across the whole concentration range are shown in Table 5.6.  
The % bias plots of unweighted and different weighted (1/y, 1/y2, 1/x, and 1/x2) linear 
regressions of LSD, iso-LSD, nor-LSD and O-H-LSD are shown in Figures 5.12, 5.13, 
5.14, and 5.15.  The % bias plots showed that unweighted linear regression 
overestimated the concentrations at the LLOQ.  The % bias plots of 1/y2 and 1/x2 
showed the best distribution around the concentration axis, and 1/x2 had the least sum of 
the absolute % bias values.  Based on both the % bias plots and the sum of the 
absolute % bias values, 1/x2 was chosen as the weighting scheme for the calibration 
curve. 
 
Table 5.6:  Sums of the absolute % bias 
 Unweighted 1/x 1/x2 1/y 1/y2 
LSD (n = 18) 308.9 60.3 58.5 60.8 58.7 
Iso-LSD (n = 18) 377.9 58.1 54.8 63.1 57.8 
Nor-LSD (n = 15) 182.3 58.0 54.6 59.4 55.8 
O-H-LSD (n = 15) 233.3 73.3 66.1 72.4 68.2 
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Figure 5.12:  Percent bias versus concentration obtained for unweighted and different 
weighted linear regression models for LSD. 
 
 
 
 
 61 
 
 
Unweighted
-100.0
-50.0
0.0
50.0
100.0
0 500 1000 1500 2000
pg/mL
%
 b
ia
s
 
1/x weighting
-12.0
-6.0
0.0
6.0
12.0
0 500 1000 1500 2000
pg/mL
%
 b
ia
s
1/x^2 weighting
-12.0
-6.0
0.0
6.0
12.0
0 500 1000 1500 2000
pg/mL
%
 b
ia
s
 
1/y weighting
-12.0
-6.0
0.0
6.0
12.0
0 500 1000 1500 2000
pg/mL
%
 b
ia
s
1/y^2 weighting
-12
-6
0
6
12
0 500 1000 1500 2000
pg/mL
%
 b
ia
s
 
 
Figure 5.13:  Percent bias versus concentration obtained for unweighted and different 
weighted linear regression models for iso-LSD. 
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Figure 5.14:  Percent bias versus concentration obtained for unweighted and different 
weighted linear regression models for nor-LSD. 
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Figure 5.15:  Percent bias versus concentration obtained for unweighted and different 
weighted linear regression models for O-H-LSD. 
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5.12 Conclusion 
Before beginning the process of validating a method, a prevalidation should be 
completed to assess the suitability of the system (Shabir 2003).  One of the main 
objectives was to develop a highly sensitive method for LSD.  As a result, prior to 
beginning the full validation study it was important to show that the proposed method 
had the ability to achieve the required sensitivity.  Once it was shown that the method 
would be suitable, other factors such as the mobile phase, injection volumes, flow rates, 
internal standards, and extraction methods, were changed or optimized to further 
increase the sensitivity of the method.  In conclusion, careful planning prior to beginning 
a full validation study is essential in order to save time and ensure a successful 
validation.   
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Chapter 6 
Validation of an UPLC™/MS/MS Method for Analyzing LSD, Iso-LSD, Nor-LSD, 
and O-H-LSD in Whole Blood and Urine 
 
6.1 Introduction 
The RCMP FLS has been involved in the analysis of LSD since about 1991 
(Daplé-Scott et al. 1997).  In 1992 the Abuscreen® RIA procedure was used by the 
RCMP FLS as the screening method but was discontinued in 1997 by the suppliers, 
Roche Diagnostic Systems.  The Coat-A-Count® RIA and ELISA methods were tested 
and found to be suitable replacements (Daplé-Scott et al. 1997).  Today the Immunalysis 
direct ELISA is used by the RCMP FLS as the LSD screening method (Towse and 
Easton 2004).  In 1997 a confirmatory GC/MS/MS method using the Zymark Rapid 
Trace solid phase extractor was developed for the trimethylsilyl derivative of LSD and 
LAMPA, with a LLOQ of 100 pg/mL (Perrigo 2003; Garbutt 2001).  The method was 
shown to work in real case samples (Daplé-Scott et al. 1997), but had its disadvantages.  
Firstly, no metabolites of LSD were included in the analysis.  Secondly, high volumes of 
sample (2 mL blood and 5 mL urine) were required.  Thirdly, samples required 
derivatization for analysis.  Lastly, the GC required pre-conditioning with a minimum of 
six injections of unextracted derivatized LSD followed by several blank injections of the 
derivatizing agent to prevent adsorption. 
This study was done to provide a sensitive, simple, and non-laborious method for 
analyzing LSD, iso-LSD, nor-LSD, and O-H-LSD.  This study describes a 
UPLC™/MS/MS method for analyzing LSD, iso-LSD, nor-LSD, and O-H-LSD in 
whole blood and urine.  Validation parameters including sensitivity, accuracy, precision, 
stability, selectivity, recovery, and matrix effects were evaluated. 
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6.2 Materials and Methods 
6.2.1 Chemicals and Reagents 
 LSD, iso-LSD, nor-LSD, O-H-LSD and LSD-D3 were obtained from Cerilliant 
Corporation (Round Rock, TX).  All reagents were HPLC or reagent grade.  ACN, 
ammonium acetate, ammonium hydroxide, and methylene chloride were obtained from 
Fisher Scientific (Fairlawn, NJ).  Isopropyl alcohol and glacial acetic acid were obtained 
from Caledon Laboratories Ltd (Georgetown, ON).  All water was purified with the 
NANOpure II water purification system (Barnstead, a division of Apogent Technologies 
Inc, Dubuque, IA).  Synthetic drug-free urine was obtained from Immunalysis 
Corporation (Pomona, CA).  Porcine blood obtained from Maple Leaf Meats (Winnipeg, 
MB) was diluted 25% with water containing 0.25% sodium fluoride and 0.20% 
potassium oxalate.  The mobile phase buffer, 20 mM ammonium acetate buffer (pH 4.0), 
was prepared by dissolving 1.54 g of ammonium acetate in ~800 mL of water.  The pH 
was then adjusted to 4.0 (±0.1) with glacial acetic acid and then made up to 1 L with 
water.  The mobile phase buffer was then filtered and sonicated before use.  Ammonium 
acetate buffer (1 M, pH 9.0) was prepared by dissolving 19.27 g of ammonium acetate in 
~150 mL of water.  The pH was then adjusted to 9.0 (±0.1) with concentrated 
ammonium hydroxide and then made up to 250 mL with water. 
 
6.2.2 Standard Solutions 
 A stock solution of each component at 500 ng/mL was prepared in ACN.  A 1 
and a 20 ng/mL calibrator mix containing LSD, iso-LSD, nor-LSD, and O-H-LSD were 
prepared from the stock solutions in ACN.  An ISTD (LSD-D3) stock solution of 500 
ng/mL was prepared in ACN and diluted to give a 20 ng/mL working ISTD.  The 
calibrator mixes were used to prepare calibrators and quality control samples in either 
blank whole blood or urine (Appendix A, page 148). 
 
6.2.3 LC 
 A Waters Corporation (Milford, MA) ACQUITY UPLC™ with an autosampler 
and an ACQUITY UPLC™ BEH C18 (2.5×50 mm, 1.7 µm, Waters Corporation, 
Milford, MA) column was used for chromatographic separation at 30°C.  A gradient 
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elution was conducted using 20 mM ammonium acetate buffer (pH 4.0) and ACN at a 
flow rate of 0.2 mL/min.  Buffer:ACN (90:10) was initially held for 1 minute, followed 
by a step gradient to 75:25 for 10 minutes and held for 1 minute. The column was then 
equilibrated for 2 minutes giving a total run time of 15 minutes. 
 
6.2.4 LC/MS/MS 
A Waters Corporation (Milford, MA) Quattro Premier™ tandem quadrupole 
mass spectrometer equipped with a Z-spray™ ion source was coupled to the UPLC™ 
system.  API was done via positive ESI.  The electrospray probe tip potential was set at 
3.00 kV.  The source and desolvation temperature were set at 120 and 350°C, 
respectively.  The cone and desolvation gas flow were set at 110 and 747 L/Hr, 
respectively.  The collision gas (argon) flow and pressure were set at 0.28 mL/min and 
4.21 × 10-3 mbar, respectively.  The mass spectrometer was run in MRM mode with a 
dwell time of 0.20 seconds (inter-channel delay of 0.01 seconds) (Table 6.1). 
 
Table 6.1:  UPLC™/MS/MS MRM parameters 
Standards Precursor ion [M+H]+ Product ion Collision Cone Voltage 
LSD 324 223*  
208  
281 
24 
31 
19 
35 
35 
35 
iso-LSD 324 281*, 208, 223 24 35 
nor-LSD 310 209*, 237, 74 24 37 
O-H-LSD 356 237*, 222, 313 25 35 
LSD-d3 327 226*, 208, 281 24 35 
*Product ions to be used for quantitation; other ions are qualifier ions. 
 
 
6.2.5 Sample Preparation 
Sample preparation was adapted from Canezin et al. 2001 and Sklerov et al. 
2000.  Blank drug free synthetic urine was spiked with either calibrator mix A (1 ng/mL) 
or B (20 ng/mL).  To 1 mL of sample, 50 µL of LSD-D3 internal standard (20 ng/mL) 
was added.  After vortexing, 500 µL of 1 M ammonium acetate buffer (pH 9.0) was 
added and vortexed again.  Samples were then extracted with 5 mL of 
dichloromethane:isopropyl alcohol (85:15).  The tubes were capped and manually 
shaken briefly, then placed on a shaker bed (Eberbach Corporation, Ann Arbor, MI) at 
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low speed for 20 minutes.  The tubes were then centrifuged at 3500 rpm for 15 minutes.  
The aqueous (top) layer was pipetted off and discarded.  The organic (bottom) layer was 
transferred to a clean tube and evaporated to dryness under nitrogen at room 
temperature.  The residue was reconstituted in 100 µL 20 mM ammonium acetate buffer 
(pH 4.0):ACN (80:20), and 20 μL of sample was injected into the UPLC™ system. 
Blank drug-free porcine whole blood was prepared the same as the urine matrix, 
except after centrifugation the aqueous (top) layer was decanted.  Then the organic 
(bottom) layer was transferred to a clean test tube by passing a pipette through the solid 
layer of blood.  Then the organic layer was repipetted into another clean test tube to 
obtain a clean layer free of blood particulates.  Reconstituted blood sample extracts were 
also either centrifuged or filtered with a 0.2 µm PTFE 13mm syringe filter 
(Chromatographic Specialties Inc, Brockville, ON) to remove particulates before being 
injected.   
 
6.2.6 Assessment for Linearity and Range 
Calibrators (5, 10, 20, 50, 100, 400, 800, 1600, 2000 pg/mL) were prepared by 
spiking blank drug free whole blood or urine in triplicate.  Samples were processed and 
extracted as described earlier (section 6.2.5).  Nominal concentration versus PAR were 
plotted to define the calibration curve.  Weighted (1/x2) linear regression was used.  Data 
collection, peak integration, and weighted linear regression were performed using 
MassLynx™ version 4.0 software (Waters Corporation, Milford, MA).  Weighted linear 
regression was also performed using GraphPad Prism version 4.03 for windows 
(GraphPad Software, San Diego, CA) to further evaluate the linearity.  A suitable linear 
range was determined by evaluating the accuracy (% bias) of calculated results 
(Equation 6.1).   
 
Equation 6.1 
 
6.2.7 Assessment for Accuracy and Precision 
After determining the linear range, a 3 point calibration curve using spiked urine 
(50, 500, 1500 pg/mL) in duplicate, and a 5 to 6 point calibration curve using spiked 
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blood (20, 50, 400, 800, 1600, 2000 pg/mL) in duplicate was used, plus one blank and 
one blank with ISTD.  Three quality control concentrations (50, 500, 1500 pg/mL) using 
both spiked urine and blood were prepared in replicates of six over three days to assess 
inter- and intra-day accuracy and precision.  The back calculated results were 
determined from the equation, as defined by the weighted linear regression of the 
calibration curve.  The accuracy of the method was determined by % bias.  The precision 
of the method was determined by the % CV (Equation 6.2). 
 % CV = (standard deviation/mean)×100% Equation 6.2
 
6.2.8 Assessment of LOD and LLOQ 
Two methods for the determination of LOD and LLOQ were evaluated.  Firstly, 
the calculated method (Equation 6.3 and 6.4) was evaluated.  Weighted (1/x2) linear 
regression was performed on the lower end of the calibration curve using GraphPad 
Prism version 4.03 for windows (GraphPad Software, San Diego, CA) in order to 
calculate the standard deviation of the residuals (Sy.x).  Secondly, S/N ratios were 
evaluated.  LOD and LLOQ were determined where S/N > 3:1 and 10:1, respectively.  
LLOQ must also demonstrate acceptable accuracy and precision. 
 LOD = 3.3 × (Sy.x/slope) Equation 6.3
 LLOQ = 10 × (Sy.x/slope) Equation 6.4
 
6.2.9 Assessment of Selectivity 
To assess the selectivity, 6 different sources of both whole blood and urine blank 
matrices were extracted and analyzed.  Each blank was then tested for interference at the 
LLOQ.   
 
6.2.10 Assessment of Recovery 
Blood and urine at 50 and 1500 pg/mL were prepared for recovery assessment by 
preparing 6 replicates of extracted and unextracted samples at each concentration.  The 
extracted samples were processed as described earlier (section 6.2.5), whereas the 
appropriate volume of calibrator mix A or B was added after extraction for the 
unextracted samples.  The average PARs were used to assess recovery (Equation 6.5). 
 % Recovery =  [PAR extracted/PAR unextracted] × 100% Equation 6.5
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6.2.11 Assessment of Matrix Effect (ME) 
Six different sources of matrix were assessed for both blood and urine.  For 
urine, 5 different lot numbers of synthetic drug-free urine, and one human urine sample 
were evaluated.  For blood, porcine blood and 5 human volunteer blood samples 
collected in grey top Vacutainers™ (XF947, 20 mg potassium oxalate, 100 mg sodium 
fluoride) were evaluated.  Blank blood or urine was extracted and, after extraction, 
appropriate volumes of calibrator A or B and ISTD were added.  Samples were then 
allowed to evaporate under N2 to dryness and reconstituted with 100 µL 20 mM 
ammonium acetate buffer (pH 4.0):ACN (80:20).  The PA of standard and ISTD in 
matrix was compared to PA of neat standard and neat ISTD in 20 mM ammonium 
acetate buffer (pH 4.0):ACN (80:20) (Equation 6.6). 
 % ME =  [PA standard in matrix/PA neat standard] × 100% Equation 6.6
 
6.2.12 Assessment of Stability 
At RCMP FLS TS after a sample exhibit is received, it is placed in a freezer until 
the start of analysis (Treacy, personal communication).  Whole blood and urine are the 
most commonly encountered specimens.  Whole blood is commonly collected in a 
Vacutainer™ with or without preservatives.  The most common preservative used is a 
mixture of potassium oxalate and sodium fluoride at varying concentrations.  Urine may 
also be received with or without preservatives.  Urine may either be received in plastic 
screw top containers, or aliquoted into a Vacutainer™.  Stability studies were assessed 
in whole blood and urine stored in Vacutainers™ with and without preservatives.   
Whole blood and urine for the stability studies were collected from human 
volunteers.  The whole blood samples collected in the Vacutainers™ with preservative 
(XF947, 20 mg potassium oxalate, 100 mg sodium fluoride) were pooled into a glass 
beaker and mixed with a magnetic stir bar.  The volume of pooled whole blood was then 
measured using a graduated cylinder.  The pooled whole blood was divided into 2 equal 
parts to make a 50 and 1500 pg/mL whole blood working stock.  The whole blood 
working stock was then aliquoted into new Vacutainers™ with the preservative removed.  
Before the whole blood samples that were collected in the Vacutainers™ without 
preservative were pooled, mixed, spiked and redistributed to new Vacutainer™, they 
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were first mixed with a blender to break up the clots.  Urine samples were handled the 
same way as the whole blood samples.  Stability studies were conducted to avoid 
exposure to light by storing samples in the dark and by using amber vials for sample 
preparation, unless otherwise noted. 
The stability of the drugs was assessed by comparing concentrations to the 
concentrations determined on day 0.  A calibration curve constructed each day with 
freshly prepared standards was used to determine concentrations. 
 
6.2.12.1 Short Term Stability 
To assess short term stability three aliquots of each of the low (50 pg/mL) and 
high (1500 pg/mL) concentrations were kept at room temperature and analyzed at 0 and 
24 hours.  To assess the effects of light exposure in the RCMP FLS Winnipeg 
laboratory, the short term stability study also included one set exposed to normal 
laboratory light.   
 
6.2.12.2 Long Term Stability 
To assess long term stability three aliquots at low (50 pg/mL) and high (1500 
pg/mL) concentrations were stored in the dark at room temperature (also one set exposed 
to normal laboratory light for 7 days), refrigerated (2 to 3°C) and frozen (-15 to -12°C) 
and analyzed at 0, 7, and 14 days.  To further assess the typical storage temperatures and 
duration of case exhibits, the aliquots stored in the fridge and freezer were also analyzed 
at day 30, 60, and 90. 
 
6.2.12.3 Freeze-Thaw Stability 
Since exhibit samples are commonly received and then frozen, freeze-thaw 
stability was assessed where three aliquots at each of the low (50 pg/mL) and high (1500 
pg/mL) concentrations were stored at -15 to -12°C for 24 hours and thawed unassisted at 
room temperature.  When completely thawed, the samples were refrozen for 24 hours 
under the same conditions.  The freeze-thaw cycle was repeated two more times and 
then analyzed on the third cycle. 
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6.2.12.4 Stock Solution Stability 
To assess the short and long term stability of the stock solutions, stock solutions 
containing individual drug standards at 500 pg/mL were prepared in ACN, MeOH, 
water, pH 4.0 buffer, and pH 9.0 buffer.  Stock solutions were stored at room 
temperature, refrigerated (2 to 3°C), and frozen (-15 to -12°C) and analyzed on day 0, 1, 
and 30.  Stock solutions stored in the fridge and freezer were stored for another 30 days 
and analyzed on day 60.  
 
6.2.12.5 Post Preparative Stability 
To assess the short term post preparative stability, extracted samples at both low 
(50 pg/mL) and high (1500 pg/mL) concentrations in triplicate were stored at 10°C 
(autosampler temperature) and analyzed at 0, 4, and 24 hours. 
 
6.2.13 Other Qualitative Parameters 
For further confirmation, the RT and the ion ratios (Equation 6.7) were included.  
Since an ISTD was used, the RRT was also used (Equation 6.8).  The RT, RRT, and ion 
ratio of calibration standards were compared to the quality control and test samples.  
 Ion Ratio = PA of base peak/PA of another product ion Equation 6.7
 RRT = RT standard/RT ISTD Equation 6.8
 
6.2.14 Assessment of Existing Extraction Methods at the RCMP FLS for Basic Drugs 
 At the RCMP FLS Winnipeg an n-butylchloride (nBuCl) and Toxi-Lab A 
method are used to extract basic drugs.  Whole blood samples are extracted using the 
nBuCl extraction method, where 1 mL blood with ISTD and 75 μl concentrated NH4OH 
is extracted with 4 mL nBuCl.  The nBuCl layer is then transferred to a new test tube 
and evaporated to dryness under N2, then reconstituted in appropriate mobile phase 
(Mason-Daniel 2005).  Urine samples are extracted using Toxi-Lab A tubes from Varian 
Inc (Lake Forest, CA), where 1 mL urine with ISTD is added to the tube and the tubes 
are capped and shaken.  The upper organic layer is transferred to a new test tube and 
evaporated to dryness under N2, then reconstituted in appropriate mobile phase (Pan and 
Yawney 2005).  To assess the suitability of both the nBuCl and Toxi-Lab A extraction 
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method, ME and recovery were assessed.  ME was assessed by analyzing each analyte at 
both a low (50 pg/mL) and high (1500 pg/mL) concentration in triplicate (section 
6.2.11).  Recovery was assessed by analyzing a low (50 pg/mL) and high (1500 pg/mL) 
concentration in replicates of six (section 6.2.10). 
 
6.3 Results and Discussion 
The MRM ion chromatograms of LSD, iso-LSD, nor-LSD, O-H-LSD, LSD-D3, 
and the corresponding blank in urine and whole blood are shown in Figures 6.1 and 6.2.  
The same MRM transitions were monitored by others using triple quadrupole MS 
(Canezin et al. 2001; de Kanel et al. 1998; Skopp et al. 2002).  LSD and iso-LSD have 
the same MRM transitions and are baseline separated, but different product ions were 
used for quantitation for LSD versus iso-LSD due to each having a different base peak in 
the product ion spectrum.  The m/z 281 product ion was the most abundant for iso-LSD, 
whereas m/z 223 was the most abundant product ion for LSD.   
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Figure 6.1:  (a) MRM ion chromatograms of blank urine + ISTD, and (b-e) blank urine, 
and urine spiked with (f) 20 pg/mL LSD (RT = 9.38 min), (g) 20 pg/mL iso-LSD (RT = 
10.48 min), (h) 50 pg/mL nor-LSD (RT = 9.55 min), and (i) 50 pg/mL O-H-LSD (RT = 
4.16 min). 
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Figure 6.2:  (a) MRM ion chromatograms of blank blood + LSD-D3 ISTD, (b-e) blank 
blood,  and blood spiked with (f) 20 pg/mL LSD (RT = 9.21 min), (g) 20 pg/mL iso-
LSD (RT = 10.27 min), (h) 50 pg/mL nor-LSD (RT = 9.34 min), and (i) 50 pg/mL O-H-
LSD (RT = 4.03 min). 
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6.3.1 Linearity and Range 
The linear range of extracted urine standards was 20 to 2000 pg/mL for LSD 
(Figure 6.3a) and iso-LSD (Figures 6.4a), and 50 to 2000 pg/mL for nor-LSD (Figure 
6.5a) and O-H-LSD (Figures 6.6a).  For extracted blood standards the linear range was 
10 to 2000 pg/mL for LSD (Figure 6.3b), iso-LSD (Figures 6.4b), and nor-LSD (Figure 
6.5b), and 20 to 2000 pg/mL for O-H-LSD (Figures 6.6b).  The coefficient of 
determination (r2) of all analytes, both in extracted urine and blood was greater than 
0.99.  The intercept, slope, and correlation coefficient (r) ± standard error (SE), 
standards deviation of the residuals (Sy.x) and the runs test p value using weighted (1/x2) 
linear regression are shown in Table 6.2.  
 
 
Table 6.2:  Linearity parameters in both urine and whole blood 
  Intercept ± SE Slope ± SE r ± SE Sy.x runs 
p 
LSD Urine 0.0049 ± 0.0009 0.00101 ± 0.00002 0.997 ± 0.005 0.068 0.30 
 Blood 0.0035 ± 0.0006 0.00107 ± 0.00002 0.999 ± 0.001 0.048 0.16 
iso-LSD Urine 0.0082 ± 0.0010 0.00110 ± 0.00002 0.998 ± 0.004 0.063 0.60 
 Blood -0.0016 ± 0.0007 0.00089 ± 0.00001 0.999 ± 0.001 0.045 0.34 
nor-LSD Urine 0.036 ± 0.0008 0.00047 ± 0.00001 0.996 ± 0.008 0.036 0.87 
 Blood 0.00086 ± 0.0003 0.00052 ± 0.00001 0.998 ± 0.003 0.027 0.11 
O-H-LSD Urine 0.0027 ± 0.0007 0.00026 ± 0.00001 0.993 ± 0.014 0.029 0.87 
 Blood -0.0003 ± 0.0003 0.00031 ± 0.00001 0.998 ± 0.003 0.017 0.71 
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(a) LSD spiked in blank urine 
 y = 0.00101x + 0.00485 
 r = 0.997, r2 = 0.994 
(b) LSD spiked in blank whole blood 
 y = 0.00107x + 0.00353 
 r = 0.995, r2 = 0.990 
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Figure 6.3:  Calibration curves for LSD in (a) urine and (b) whole blood.   
 
 
 
 
(a) iso-LSD spiked in blank urine 
 y = 0.00110x + 0.00824 
 r = 0.997, r2 = 0.994 
(b) iso-LSD spiked in blank whole blood 
 y = 0.000886x -0.00164 
 r = 0.998, r2 = 0.996 
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Figure 6.4:  Calibration curves for iso-LSD in (a) urine and (b) whole blood.   
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(a) nor-LSD spiked in blank urine 
 y = 0.000470x + 0.00363 
 r = 0.998, r2 = 0.997 
(b) nor-LSD spiked in blank whole blood 
 y = 0.000514x + 0.00129 
 r = 0.995, r2 = 0.990 
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Figure 6.5:  Calibration curves for nor-LSD in (a) urine and (b) whole blood.   
 
 
 
(a) O-H-LSD spiked in blank urine 
 y = 0.000255x + 0.00267 
 r = 0.996, r2 = 0.992 
(b) O-H-LSD spiked in blank whole blood 
 y = 0.000306x + 0.000264 
 r = 0.996, r2 = 0.993 
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Figure 6.6:  Calibration curves for O-H-LSD in (a) urine and (b) whole blood.   
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6.3.2 Accuracy and Precision 
The accuracy was deemed acceptable if the % bias of the back calculated result 
was ±15%, and ±20% at LLOQ, of the nominal concentration.  The precision was 
deemed acceptable if the % CV of back calculated results were ≤15% and ≤20% at 
LLOQ.  Quantitations are normally only done on blood samples at FLS Winnipeg.  This 
is because levels in blood give more information than levels in urine.  Urine levels are 
difficult to interpret due to levels being influenced by urine pH, volume eliminated, and 
other factors (Cravey and Baselt 1981).  Urine analysis is still conducted because it is 
very useful for detecting drugs of abuse, since metabolites are generally more polar than 
the parent compound.  Drug metabolites will appear in higher concentrations in urine 
versus blood and persist for a much longer time than parent drugs.  As a result, for the 
validation experiment, quantitative analysis for blood was conducted using a full 
calibration curve with 5 to 6 points, whereas semi-quantitative analysis was conducted 
for urine using a 3 point calibration curve.  Both inter- and intra-day accuracy and 
precision for all compounds both in urine and blood were within acceptable limits (Table 
6.3, 6.4, 6.5, and 6.6). 
 
Table 6.3:  Accuracy (% Bias) results over three days of analysis in urine 
Day 1 Day 2 Day 3 Average 
 Nominal (pg/mL) %bias n %bias n %bias n %bias n 
LSD 50 -3.97 6 5.07 6 1.32 5 0.78 17 
 500 -2.45 6 -5.66 6 0.06 6 -2.69 18 
 1500 2.07 6 -0.39 5 1.42 6 1.12 18 
iso-LSD 50 5.17 6 2.83 6 -6.84 5 0.81 17 
 500 -3.07 6 0.59 6 0.78 6 -0.57 18 
 1500 1.09 6 -1.47 5 2.00 6 0.66 18 
nor-LSD 50 1.73 6 3.77 6 -9.52 5 -0.86 17 
 500 -2.21 6 3.06 6 2.74 6 1.20 18 
 1500 2.06 6 8.37 5 3.65 6 4.48 18 
O-H-LSD 50 -0.70 6 -2.60 6 2.48 5 -0.44 17 
 500 -3.77 6 -9.44 5 4.13 6 -2.65 17 
 1500 2.80 6 -11.98 5 -0.58 5 -2.88 16 
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Table 6.4:  Precision (% CV) results over three days of analysis in urine 
Day 1 Day 2 Day 3 Average 
 Nominal (pg/mL) % CV n % CV n % CV n % CV n 
LSD 50 5.76 6 6.48 6 3.97 5 6.55 17 
 500 4.77 6 7.46 6 4.83 6 5.96 18 
 1500 3.51 6 3.15 5 2.56 6 3.08 18 
iso-LSD 50 6.22 6 13.19 6 8.73 5 10.61 17 
 500 4.06 6 10.68 6 5.30 6 7.13 18 
 1500 4.77 6 2.14 5 4.05 6 3.96 18 
nor-LSD 50 5.05 6 11.04 6 10.46 5 10.37 17 
 500 5.28 6 4.09 6 5.92 6 5.42 18 
 1500 5.17 6 6.65 5 4.43 6 5.70 18 
O-H-LSD 50 4.67 6 12.01 6 17.64 5 11.70 17 
 500 3.87 6 13.88 5 12.28 6 11.58 17 
 1500 9.47 6 8.13 5 3.48 5 9.81 16 
 
 
Table 6.5:  Accuracy (% Bias) results over three days of analysis in whole blood 
Day 1 Day 2 Day 3 Average 
 Nominal (pg/mL) %bias n %bias n %bias n %bias n 
LSD 50 -5.42 6 -8.03 6 -8.87 6 -7.44 18 
 500 -3.37 6 -3.03 6 -12.44 6 -6.29 18 
 1500 -2.44 5 -1.35 6 -6.46 6 -3.47 17 
iso-LSD 50 -10.64 6 -7.78 6 -11.96 6 -10.12 18 
 500 -3.09 6 4.34 6 -11.77 6 -3.51 18 
 1500 -2.08 5 4.46 6 -5.06 6 -0.82 17 
nor-LSD 50 -13.85 6 -16.59 6 7.13 6 -7.77 18 
 500 -8.03 6 -13.17 6 -1.66 6 -7.63 18 
 1500 -2.75 5 -8.11 6 1.38 6 -3.19 17 
O-H-LSD 50 -14.49 6 -14.68 6 -10.50 6 -13.22 18 
 500 -10.16 6 -10.96 6 -10.47 6 -10.53 18 
 1500 -10.13 5 -9.43 6 -5.45 6 -8.23 17 
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Table 6.6:  Precision (% CV) results over three days of analysis in whole blood 
Day 1 Day 2 Day 3 Average 
 Nominal (pg/mL) % CV n % CV n % CV n % CV n 
LSD 50 5.00 6 1.54 6 7.22 6 5.09 18 
 500 4.72 6 6.10 6 6.51 6 7.23 18 
 1500 2.37 5 1.89 6 2.02 6 3.09 17 
iso-LSD 50 4.63 6 4.15 6 3.83 6 4.44 18 
 500 5.68 6 7.43 6 4.37 6 9.08 18 
 1500 2.60 5 3.50 6 3.83 6 5.30 17 
nor-LSD 50 7.15 6 7.95 6 7.53 6 13.80 18 
 500 4.51 6 5.75 6 6.27 6 7.43 18 
 1500 2.87 5 5.28 6 2.81 6 5.54 17 
O-H-LSD 50 2.17 6 4.58 6 11.33 6 7.25 18 
 500 5.11 6 5.11 6 6.53 6 5.30 18 
 1500 3.70 5 4.91 6 3.93 6 4.60 17 
 
6.3.3 LOD and LLOQ 
LOD and LLOQ were determined by two different methods, where each method 
gave a slightly different value (Table 6.7).  To calculate the LOD and LLOQ both the 
slope and Sy.x were derived from a calibration curve within the LOD range.  A peak-to-
peak S/N was determined using the MassLynx™ version 4.0 software (Waters 
Corporation, Milford, MA), where the greatest height of the signal range above the mean 
noise value was divided by the variance (Figure 6.7, 6.8, 6.9, & 6.10).  Regardless of the 
LLOQ result obtained using the calculated or S/N method, LLOQ was ultimately 
defined as the lowest concentration that showed acceptable accuracy (±20% bias) and 
precision (≤20% CV) (Table 6.8 and 6.9).   
When comparing the two methods used to determine the LOD and LLOQ, the 
S/N method resulted in lower values for both.  This can be explained by two possible 
reasons; (1) possible overestimation errors using the calculated method, and (2) the 
highly efficient columns used with UPLC™.  The calculated method of determining 
LOD and LLOQ could lead to overestimation of the limits, by using a concentration 
range far away from the LOD and LLOQ when creating the calibration curve to estimate 
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the slope and residual standard deviation (Peters and Maurer 2002).  Also, 
chromatography can affect the LOD and LLOQ, where narrower and taller peaks with 
highly efficient columns will result in a higher S/N resulting in lower LOD and LLOQ 
(Shabir 2003).  As a result, to take advantage of UPLC™, the S/N method was chosen as 
the method for determining both the LOD and LLOQ. 
 
Table 6.7:  LOD and LLOQ determined using two different methods in both urine and 
whole blood 
  (pg/mL) Calculated (pg/mL) S/N 
  LOD  LLOQ LOD LLOQ 
LSD Urine 11 33 10 20 
 Blood 10 32 5 10 
iso-LSD Urine 10 29 10 20 
 Blood 11 36 5 10 
nor-LSD Urine 21 64 10 50 
 Blood 13 45 10 20 
O-H-LSD Urine 23 70 10 50 
 Blood 20 66 10 20 
 
Table 6.8:  LLOQ in urine and whole blood with acceptable accuracy and precision 
 Acceptable accuracy and precision LLOQ (pg/mL) 
LSD 20 
iso-LSD 20 
nor-LSD 50 
O-H-LSD 50 
 
Table 6.9:  Accuracy and precision at LLOQ in urine and whole blood 
  % Bias at LLOQ CV% at LLOQ 
LSD Urine 14.50 10.90 
 Blood 2.08 9.79 
iso-LSD Urine 7.33 14.82 
 Blood 1.92 8.01 
nor-LSD Urine -1.03 17.19 
 Blood 0.17 6.13 
O-H-LSD Urine 11.50 9.47 
 Blood 0.03 4.66 
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Figure 6.7:  S/N at LOD of 10 pg/mL for (a) LSD (S/N = 5.05), (b) iso-LSD (S/N = 
8.70), (c) nor-LSD (S/N = 3.08), and (d) O-H-LSD (S/N = 3.20) in urine. 
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Figure 6.8:  S/N at LOD of 5 pg/mL for (a) LSD (S/N = 5.12) and (b) iso-LSD (S/N = 
8.44), and 10 pg/mL for (c) nor-LSD (S/N = 4.15) and (d) O-H-LSD (S/N = 3.90) in 
whole blood. 
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Figure 6.9:  S/N at LLOQ of 20 pg/mL for (a) LSD (S/N = 13.31), (b) iso-LSD (S/N = 
16.62), and 50 pg/mL for (c) nor-LSD (S/N = 12.12), and (d) O-H-LSD (S/N = 12.13) in 
urine. 
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Figure 6.10:  S/N at LLOQ of 20 pg/mL for (a) LSD (S/N = 22.68) and (b) iso-LSD 
(S/N = 20.97), and 50 pg/mL for (c) nor-LSD (S/N = 29.73) and (d) O-H-LSD (S/N 
17.61) in whole blood. 
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The LLOQ of 20 pg/mL for LSD and iso-LSD in urine and whole blood were the 
same as obtained by others using LC/MS/MS with a different triple quadrupole MS (API 
300 Perkin-Elmer SCIEX, Thornhill, Canada) (Canezin et al. 2001).  Johansen and 
Jensen reported a LLOQ of 10 pg/mL for both LSD and iso-LSD in urine and whole 
blood using LC/MS/MS with a triple quadrupole MS (Quattro Micro, Waters); however, 
the accuracy and precision at this level was not reported.  The LLOQ of 50 pg/mL for 
nor-LSD and O-H-LSD in urine and whole blood was a more sensitive result compared 
to others using LC/MS/MS.  Skopp et al. reported a LLOQ of 240 pg/mL and 190 
pg/mL for nor-LSD and O-H-LSD, respectively using LC/MS/MS (API 365, Applied 
Biosystems, Foster City, CA). 
When GC/MS/MS with an ion trap MS was used with cold-on column injections, 
a detection threshold of 20 pg/mL was reported for LSD in whole blood (Libong et al. 
2003a) and urine (Sklerov et al. 1999).  When urine samples were derivatized and 
analyzed using GC/MS/MS with a MSD a LOD and LLOQ of  500 and 1000 pg/mL, 
respectively were reported for O-H-LSD (Burnley and George 2003).  In contrast, a very 
sensitive GC/MS/MS method using positive CI and selected reaction monitoring has 
been reported for LSD and O-H-LSD in urine samples with a LLOQ of 10 pg/mL 
(Reuschel et al. 1999b).  Compared to GC/MS/MS methods, the UPLC™/MS/MS 
method is simpler to perform with similar or better sensitivity.   
The LSD-D3 standard obtained from Cerilliant Corporation (Round Rock, TX) 
was 99% pure as determined by chromatographic analysis (Cerilliant Certificate of 
Analysis).  When analyzed via UPLC™/MS/MS there was a residual amount of LSD 
present.  The S/N of the residual LSD in the ISTD was not greater than 3 (Figure 6.11), 
and the response at the LLOQ for LSD was five times greater than the response of 
residual LSD in LSD-D3 (Figure 6.12).  It may be argued that the residual amount of 
LSD in the ISTD may cause an overestimation during quantitation.  However, since the 
standards used to make up the calibration curve, the QC standards, and the unknowns all 
have the same amount of ISTD added there should be no effect seen on the quantitated 
value in the unknowns. 
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Figure 6.11:  S/N of the residual LSD in the LSD-D3 ISTD. 
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Figure 6.12:  MRM acquisitions of a (a) blank showed the absence of a LSD peak, (b) 
blank + ISTD (LSD-D3) showed the presence of residual LSD (urine PA = 20, whole 
blood PA = 99), and (c) LSD PA at LLOQ of 20 pg/mL in urine and whole blood was 
214 and 585, respectively. 
 
 
6.3.4 Selectivity 
The blank urine in Figure 6.1c (page 74) showed a response (PA = 37.59) at the 
same retention time as iso-LSD (RT = 10.48 minutes).  However, since the PA response 
at the LLOQ was 194.77 it adhered to the recommendations of the FDA that the LLOQ 
should be at least five times the response compared to the blank (FDA 2001).  
Furthermore, 6 different sources of blank urine were extracted and analyzed with none 
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showing a PA response greater than ~40.  When 5 different sources of blank human 
whole blood, and porcine whole blood were extracted and analyzed, no interfering peaks 
were detected. 
 
6.3.5 Recovery 
The percent recoveries are shown in Table 6.10.  Percent recoveries were slightly 
lower in whole blood than in urine.  This was acceptable since the sensitivity in whole 
blood was not affected.  The percent recoveries are nearly the same as reported in the 
original LLE methods (Canezin et al. 2001; Sklerov et al. 2000).  The percent recoveries 
were reproducible with a %CV range of 3.9 to 11.4% and 2.9 to 8.1% in urine and whole 
blood, respectively.  Both high and low concentrations of each analyte showed similar 
percent recoveries.  As well, percent recoveries were similar among different 
compounds. 
The lower percent recovery of whole blood can be explained due to the whole 
blood samples being filtered prior to being injected.  To prevent the loss of analyte 
through filtration, alternatively samples could be centrifuged at a high speed to separate 
the particulate.  However, since the overall sensitivity was not affected this was not 
essential.   
 
Table 6.10:  Extraction percent recovery 
  50 pg/mL 1500 pg/mL Average 
LSD Urine 78 78 78 
 Blood 62 61 62 
iso-LSD Urine 74 78 76 
 Blood 62 66 64 
nor-LSD Urine 88 85 86 
 Blood 69 67 68 
O-H-LSD Urine 76 74 75 
 Blood 66 72 69 
 
6.3.6 Matrix Effect (ME) 
Both urine and whole blood demonstrated similar absolute ME at both the high 
and low concentrations.  LSD, iso-LSD, O-H-LSD, and LSD-D3 showed slight ion 
suppression, whereas nor-LSD showed slight ion enhancement (Table 6.11).  The 
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difference seen in nor-LSD may be explained by the chemistry of the analyte.  It has 
been found that the chemical nature of the analyte may have more of an effect on the 
amount of suppression than the sample preparation method (Bonfiglio et al. 1999).  
Compared to LSD, iso-LSD, LSD-D3, and O-H-LSD, nor-LSD lacks a methyl group.  
The removal of the methyl group on nor-LSD may somehow cause an enhancement in 
ionization.  On the other hand, the endogenous matrix constituents in the nor-LSD MRM 
transition of 309>210 may also account for the slight ion enhancement.  To fully 
understand the different ME response of nor-LSD further investigation is required.  Ion 
suppression studies have been reported for LSD and iso-LSD by injecting extracted 
spiked blank whole blood samples through a syringe pump into a T piece with mobile 
phase (Johansen and Jensen 2005).  This study showed no ion suppression and states that 
the deuterated ISTD corrected for any possible suppression of samples.  
 
Table 6.11:  Matrix effect 
  50 pg/mL 1500 pg/mL Average 
LSD Urine 89 93 91 
 Blood 99 90 95 
iso-LSD Urine 89 100 95 
 Blood 96 97 96 
nor-LSD Urine 119 126 123 
 Blood 122 114 118 
O-H-LSD Urine 93 101 97 
 Blood 97 99 98 
LSD-D3 Urine 90 95 93 
 Blood 94 91 93 
 
Even though the absolute ME of nor-LSD was different compared to the other 
compounds, this did not necessarily indicate that the bioanalytical method was invalid.  
If the relative ME exhibit the same pattern for the drug and the ISTD in all sources of 
matrix studied, the drug to ISTD ratio should not be affected (Matuszewski et al. 2003).  
The relative ME, which was defined by comparing the ME values between different 
sources of matrix, showed no significant difference (p>0.05) when tested with F test 
between the variances of the PAR of neat standard versus whole blood and urine (Figure 
6.13).  The relative ME of all compounds were not shown to differ significantly, 
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confirming that the ME had no effect on the quantitation of LSD, iso-LSD, nor-LSD, 
and O-H-LSD. 
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Figure 6.13:  Precision (CV%) of the PAR of LSD, iso-LSD, nor-LSD, and O-H-LSD at 
both 50 and 1500 pg/mL in □ neat standard (n=6), and ■ 6 different sources of whole 
blood, and ■ 5 different sources of urine.   
 
 
6.3.7 Stability 
The stability was deemed acceptable if the back calculated result did not deviate 
by more than 20% from day 0 concentration.  Nor-LSD and O-H-LSD stability were 
only assessed at the high concentration (1500 pg/mL) because the low concentration (50 
pg/mL) is the LLOQ.  As a result, any results below LLOQ cannot be accurately 
quantified.  LSD and iso-LSD stability were assessed at both low and high 
concentration. 
 
6.3.7.1 Short Term Stability 
LSD, nor-LSD, and O-H-LSD were stable in both preserved and unpreserved 
urine and whole blood stored at room temperature for 24 hours when exposed or not 
exposed to normal laboratory lighting.  Iso-LSD in preserved and unpreserved whole 
blood was also determined to be stable for 24 hours when exposed and not exposed to 
laboratory lighting.  When iso-LSD in urine was stored for 24 hours only the 
unpreserved urine stored in the dark was stable for 24 hours at room temperature.  Iso-
LSD in unpreserved urine exposed to light and in preserved urine both stored in the dark 
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and exposed to the light decreased in concentration by 21 to 39% after 24 hours at room 
temperature. 
 
6.3.7.2 Long Term Stability 
LSD, iso-LSD, nor-LSD and O-H-LSD were all found to be stable for 7 days 
when exposed to normal laboratory lighting at room temperature.  The same results were 
reported for O-H-LSD in urine samples at pH 4.6 and 6.5 kept at 24°C exposed to 
fluorescent light for 9 days (Klette et al. 2002).  It has also been reported that LSD in 
urine samples can withstand normal room light conditions at 25°C for 1 week without 
noticeable structural change (Li et al. 1998).  Another study found that LSD 
concentrations in urine, plasma, and whole blood decreased in concentration to about 
50% when kept at room temperature exposed to fluorescent light over 14 days (de Kanel 
et al. 1998). 
Results of the 30 day room temperature and the 90 day refrigerated (2 to 3°C) 
and frozen (-15 to 12°C) stability study of samples kept in the dark are shown in Figures 
6.14 and 6.15.  LSD was stable at room temperature in all sample types for 30 days.  
Other studies have also found that LSD in urine was stable at 25°C for 4 weeks in the 
dark (Li et al. 1998; Francom et al. 1988).  LSD was stable both refrigerated and frozen 
in all sample types for 90 days.  Similar results were reported for LSD in urine in 
another study (Francom et al. 1988). 
Iso-LSD was stable at room temperature in both preserved and unpreserved 
whole blood for 30 days.  Iso-LSD in urine was generally found to be unstable (22 to 
30% decrease) at room temperature for the first 14 days, but then within stable 
concentrations by day 30.  Iso-LSD was stable refrigerated and frozen in both preserved 
and unpreserved whole blood for 90 days.  Like iso-LSD at room temperature, iso-LSD 
in urine refrigerated and frozen followed a general trend, where there was an initial 
decrease in concentration on day 7 and 14, followed by a gradual increase to day 0 
concentrations by day 90.  Stability studies for iso-LSD in biological matrices have not 
been previously reported; however, it has been found that iso-LSD rapidly isomerizes to 
LSD when dissolved in organic solvents and stored at 2-6°C (Clarkson et al. 1998). 
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Nor-LSD was only stable for 14 days at room temperature, decreasing by 23% in 
unpreserved urine, 37% in preserved urine, and >50% in both unpreserved and preserved 
blood at day 30.  Nor-LSD was also only stable for 14 days refrigerated and frozen, 
decreasing by 43% in both unpreserved and preserved urine, and 47% in both 
unpreserved and preserved blood at day 30 and remained the same up to day 90.  
Another study evaluated the stability of nor-LSD in urine, plasma, and whole blood and 
found that nor-LSD was stable in all sample types for two weeks stored at 4 and -20°C 
in the dark (de Kanel et al. 1998). 
O-H-LSD in preserved urine was stable for 30 days at room temperature, but in 
unpreserved urine O-H-LSD was unstable decreasing in concentration by 30% after 7 
days.  In both unpreserved and preserved whole blood, O-H-LSD was only stable for 7 
days at room temperature decreasing in concentration by 30 to 45% after 14 days and 
greater than 68% after 30 days.  O-H-LSD was stable both refrigerated and frozen in all 
sample types for 60 days.  At day 90 only O-H-LSD in urine both refrigerated and 
frozen was stable.  O-H-LSD in whole blood was unstable by day 90 deviating more 
than 38% and 22% refrigerated and frozen, respectively.  Another study states that O-H-
LSD is stable in specimens at pH 4.6 to 6.5 when maintained at -20 to 24°C for 60 days 
(Klette et al. 2002).  Stability studies for O-H-LSD in whole blood have never been 
previously reported.   
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(d) O-H-LSD stability in urine
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Figure 6.14:  Long term stability of (a) LSD, (b) iso-LSD, (c) nor-LSD, and (d) O-H-
LSD in urine.  Samples (unpreserved ♦room temperature, ■ refrigerated, ▲ frozen, and 
preserved × room temperature, ○ refrigerated, and ● frozen) were kept at room 
temperature for 30 days and in the fridge and freezer for 90 days and were analyzed on 
day 0, 1, 7, 14, 30, 60, and 90.   
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(a) LSD stability in whole blood
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(b) iso-LSD stability in whole blood
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(c) nor-LSD stability in whole blood
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Figure 6.15:  Long term stability of (a) LSD, (b) iso-LSD, (c) nor-LSD, and (d) O-H-
LSD in whole blood.  Samples (unpreserved ♦room temperature, ■ refrigerated, ▲ 
frozen, and preserved × room temperature, ○ refrigerated, and ● frozen) were kept at 
room temperature for 30 days and in the fridge and freezer for 90 days and were 
analyzed on day 0, 1, 7, 14, 30, 60, and 90.   
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 With respect to normal sample handling and conditions at the RCMP FLS the 
results presented here showed that urine and whole blood samples suspected of 
containing LSD, nor-LSD, and O-H-LSD would be stable during the normal sample 
preparation in the laboratory.  Iso-LSD in whole blood was also found to be stable; in 
urine, however, accurate quantitation may not be possible.  Based on the results of this 
study, it is recommended that samples be frozen for long term storage.   LSD in urine 
and whole blood was stable when maintained at temperatures from -15 to 3°C for 90 
days in the dark.  Iso-LSD was stable in whole blood when maintained at temperatures 
from -15 to 3°C for 90 days in the dark.  Iso-LSD was unstable in urine samples and 
therefore accurate quantitation is not possible.  Nor-LSD was stable when maintained at 
temperature from -15°C to room temperature for 14 days in the dark.  O-H-LSD was 
stable when maintained at temperatures from -15 to 3°C for 60 days in whole blood and 
90 days in urine in the dark. 
 
6.3.7.3 Freeze-Thaw Stability 
LSD, iso-LSD, nor-LSD, and O-H-LSD were all stable after being frozen and 
thawed over three cycles.  This is the first study to assess the freeze-thaw stability of 
LSD, iso-LSD, nor-LSD, and O-H-LSD.  These results are important because it showed 
that samples submitted for LSD analysis could be shipped on ice and then frozen on 
receipt.  Furthermore, case samples that were stored in the freezer would still be stable if 
the samples were thawed for LSD reanalysis. 
 
6.3.7.4 Stock Solution Stability 
The stability results of the stock solutions prepared in various solvents are shown 
in Figure 6.16.  After 24 hours only LSD stock solution prepared in ACN and MeOH 
stored at all three temperatures were stable.  For long term stability LSD prepared in 
ACN was most stable for 90 days refrigerated and only for 60 days frozen.  After 24 
hours only iso-LSD stock solution prepared in ACN stored at all three temperatures was 
stable.  As seen in the urine and whole blood stability tests, a general trend was observed 
where there was an initial decrease followed by a gradual increase in iso-LSD stock 
solutions stored refrigerated and frozen.  Nor-LSD stock solution prepared in ACN was 
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most unstable decreasing in concentration by more than 50% after only 24 hours stored 
at room temperature and refrigerated.  This instability of nor-LSD in ACN may be due 
to possible evaporation, whereas the standard obtained from Cerilliant are sealed so to 
prevent any evaporation.  O-H-LSD stock solution prepared in ACN, water, and pH 4.0 
was stable after 24 hours stored at all temperatures.  O-H-LSD stock solution prepared in 
MeOH was also stable after 24 hours, except at room temperature.  O-H-LSD was 
unstable at a high pH of 9.0 decreasing by 23% after 24 hours and by as much as 87% 
after 30 days.   
Since the Cerilliant standards come prepared in ACN, it made most sense to 
prepare stock standard solutions in ACN as well.  For preparing stock standard solutions 
of LSD, iso-LSD, nor-LSD, and O-H-LSD in ACN, ideally all stock standard solutions 
should be prepared fresh.  This is especially true for nor-LSD, which was found to be 
unstable in ACN stored refrigerated and at room temperature after 24 hours.  LSD, iso-
LSD, and O-H-LSD stock solutions prepared in ACN may be stored frozen or 
refrigerated for 30 days if required. 
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(b) iso-LSD stability
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(c) nor-LSD stability
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(d) O-H-LSD stability
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Figure 6.16:  Stability of (a) LSD, (b) iso-LSD, (c) nor-LSD, and (d) O-H-LSD stock 
standards in MeOH, H2O, ACN, pH 4.0 buffer, and pH 9.0 buffer at room temperature, 
in the fridge, and freezer analyzed on day ■1, ■ 30, and □ 60. 
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All stock standards were prepared to contain only that one compound to test for 
the production of degradation products.  On day 0 there were no detectable degradation 
products identified in any of the standards. The same results were seen after 24 hours.  
By day 60, there was still no detectable degradation products identified in the nor-LSD 
and O-H-LSD standards.  After 30 days, detectable levels of LSD were identified in the 
iso-LSD standards prepared in MeOH and pH 9.0 buffer stored at room temperature, and 
in pH 9.0 buffer stored in the fridge.  After 60 days, there were still detectable levels of 
LSD identified in the iso-LSD standard prepared in MeOH at room temperature, and pH 
9.0 buffer stored in the fridge.  There were also detectable levels of iso-LSD identified in 
the LSD standard prepared in pH 9.0 buffer stored at both room temperature and 
refrigerated, and in MeOH stored refrigerated.  There were still detectable levels of iso-
LSD in the LSD standard prepared in pH 9.0 buffer stored in the fridge after 60 days.  
These results are in accordance with other studies that show that LSD will isomerize to 
iso-LSD and vice versa when exposed to basic aqueous solutions, increased 
temperatures (Reuschel et al. 1999a; Li et al. 1998), and when dissolved in MeOH 
(Clarkson et al. 1998). 
 
6.3.7.5 Post Preparative Stability 
LSD, iso-LSD, nor-LSD, and O-H-LSD in extracted samples were all stable after 
being stored at 10°C for 4 and 24 hours.  These results showed that the extracted 
samples were stable while waiting to be analyzed in the autosampler. 
 
6.3.8 Other Qualitative Parameters 
6.3.8.1 RT and RRT 
Both the RT and the RRT were precise (% CV ≤ 4.54%) over three days of 
analysis in both urine and whole blood (Table 6.12).  However, over a period of 2 
months of running on the same column the RT and RRT began to shift (Figure 6.17).  
This shift could be attributed to the cleanliness of the extracts.  The RT and RRT 
precision for the urine samples were better compared to the blood samples.  The extracts 
of the blood samples needed to be filtered to remove the particulate matter that was 
present, whereas the urine samples did not.  The injection of “dirty” extracts may have 
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plugged the column over time to affect the RT.  Others have found it difficult to remove 
the cellular components of blood sample using LLE alone, as a result others have used a 
combination of LLE and SPE to obtain “cleaner” blood extracts (Sklerov et al. 2000).   
 
Table 6.12:  RT and RRT over three days of analysis in urine and whole blood 
  RT (minutes) RRT (minutes) 
  Mean ± SD % CV Mean ± SD % CV 
LSD Urine 9.38 ± 0.03 0.34 1.00 ± 0.00 1.00 
 Blood 8.85 ± 0.26 2.97 1.00 ± 0.00 0.00 
Iso-LSD Urine 10.48 ± 0.04 0.37 1.12 ± 0.00 0.20 
 Blood 9.81 ± 0.33 3.33 1.11 ± 0.01 0.50 
Nor-LSD Urine 9.54 ± 0.05 0.56 1.02 ± 0.00 0.20 
 Blood 9.03 ± 0.23 2.51 1.02 ± 0.01 0.56 
O-H-LSD Urine 4.15 ± 0.01 0.35 0.44 ± 0.00 0.30 
 Blood 3.77 ± 0.17 4.54 0.43 ± 0.01 1.70 
 
 
(a) 
Time
7.00 8.00 9.00 10.00 11.00 12.00
%
0
100
LSD_July12_37 Sm (Mn, 2x1) MRM of 12 Channels ES+ 
324 > 223
7.97e3
9.17
10.27
9.85
 
(b) 
Time
7.00 8.00 9.00 10.00 11.00 12.00
%
0
100
LSD_July19_4 Sm (Mn, 2x1) MRM of 12 Channels ES+ 
324 > 223
7.81e3
9.25
9.63
 
(c) 
Time
7.00 8.00 9.00 10.00 11.00 12.00
%
0
100
LSD_Sept22_33 Sm (Mn, 2x1) MRM of 12 Channels ES+ 
324 > 223
7.50e3
9.25
9.51
11.63
 
(d) 
Time
7.00 8.00 9.00 10.00 11.00 12.00
%
0
100
LSD_Sept28_02 Sm (Mn, 2x1) MRM of 12 Channels ES+ 
324 > 223
1.19e5
9.04
10.14
 
 
Figure 6.17:  Over a 3 month time period the chromatographic separation of LSD (first 
one to elute) and iso-LSD run on the (a-c) same column shifted and ultimately affected 
the resolution.  The initial RT of LSD and iso-LSD were restored when changing to a (d) 
new column. 
 
 
Since the sample batch volume at the RCMP FLS is not expected to be large for 
LSD analysis, and the within day RT and RRT of quality control and test samples 
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relative to the calibration standards were accurate (Table 6.13, 6.14, 6.15, and 6.16), the 
need for “cleaner” extracts may not be necessary.  The RT and RRT were deemed 
acceptable if the quality control and test samples did not differ by more than 2% (% 
bias) relative to the calibration standards (Rivier 2003).  As well, the within day RT and 
RRT were precise with % CV less than 3.33% and 1.58% for RT and RRT, respectively.   
 
Table 6.13:  Within day LSD RT and RRT of calibration standards on 10 different days 
and the corresponding average accuracy (%bias) of the quality control and test samples 
RT RRT 
Calibration Standards Calibration Standards 
Mean ± SD % CV 
%bias of QC 
and test samples Mean ± SD % CV 
%bias of QC 
and test samples 
9.24 ± 0.02 0.20 0.65 1.00 ± 0.00 0.20 -0.04
9.29 ± 0.05 0.50 0.05 1.00 ± 0.00 0.18 0.12
8.79 ± 0.00 0.00 0.28 1.01 ± 0.00 0.00 -0.15
8.89 ± 0.16 1.75 0.27 1.00 ± 0.00 0.24 0.10
9.15 ± 0.03 0.29 0.13 1.00 ± 0.00 0.19 -0.08
9.12 ± 0.08 0.87 -0.20 1.00 ± 0.00 0.23 -0.09
9.17 ± 0.00 0.00 0.43 1.00 ± 0.00 0.00 0.39
8.98 ± 0.14 1.51 -0.27 1.00 ± 0.00 0.23 0.04
9.08 ± 0.00 0.00 0.23 1.00 ± 0.00 0.24 0.02
8.98 ± 0.07 0.80 0.19 1.00 ± 0.00 0.20 0.19
 
 
Table 6.14:  Within day iso-LSD RT and RRT of calibration standards on 10 different 
days and the corresponding average accuracy (%bias) of the quality control and test 
samples 
RT RRT 
Calibration Standards Calibration Standards 
Mean ± SD % CV 
%bias of QC 
and test samples Mean ± SD % CV 
%bias of QC 
and test samples 
9.30 ± 0.00 0.00 0.37  1.08 ± 0.00 0.23 -0.32
10.00 ± 0.04 0.41 -0.16  1.08 ± 0.00 0.03 -0.09
9.63 ± 0.00 0.00 0.55  1.10 ± 0.00 0.00 0.12
9.81 ± 0.17 1.73 0.05  1.11 ± 0.00 0.19 -0.12
10.05 ± 0.02 0.21 0.15  1.10 ± 0.00 0.08 -0.07
10.11 ± 0.09 0.89 -0.10  1.11 ± 0.00 0.20 0.00
10.15 ± 0.02 0.23 0.46  1.11 ± 0.00 0.23 0.44
9.96 ± 0.15 1.50 -0.31  1.11 ± 0.00 0.18 0.01
10.04 ± 0.02 0.21 0.04  1.11 ± 0.00 0.02 -0.17
10.00 ± 0.08 0.76 0.06  1.12 ± 0.00 0.16 0.06
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Table 6.15:  Within day nor-LSD RT and RRT of calibration standards on 10 different 
days and the corresponding average accuracy (%bias) of the quality control and test 
samples 
RT RRT 
Calibration Standards Calibration Standards 
Mean ± SD % CV 
%bias of QC 
and test samples Mean ± SD % CV 
%bias of QC 
and test samples 
9.61 ± 0.02 0.23 0.29 1.04 ± 0.00 0.01 -0.35
9.65 ± 0.04 0.39 -0.09 1.04 ± 0.00 0.11 -0.00
9.04 ± 0.00 0.00 0.51 1.03 ± 0.00 0.00 0.11
9.13 ± 0.16 1.74 0.05 1.03 ± 0.00 0.22 -0.00
9.40 ± 0.02 0.23 0.13 1.03 ± 0.00 0.07 -0.12
9.31 ± 0.07 0.79 -0.16 1.02 ± 0.00 0.15 -0.02
9.38 ± 0.00 0.00 0.32 1.02 ± 0.00 0.00 0.32
9.17 ± 0.12 1.35 -0.27 1.02 ± 0.00 0.21 0.12
9.32 ± 0.03 0.29 0.11 1.03 ± 0.00 0.05 -0.09
9.18 ± 0.06 0.67 -0.02 1.02 ± 0.00 0.14 0.07
 
 
Table 6.16:  Within day O-H-LSD RT and RRT of calibration standards on 10 different 
days and the corresponding average accuracy (%bias) of the quality control and test 
samples 
RT RRT 
Calibration Standards Calibration Standards 
Mean ± SD % CV 
%bias of QC 
and test samples Mean ± SD % CV 
%bias of QC 
and test samples 
3.91 ± 0.02 0.52 0.70 0.42 ± 0.00 0.47 0.06
3.98 ± 0.02 0.56 -0.28 0.43 ± 0.00 0.50 -0.20
3.68 ± 0.02 0.44 0.10 0.42 ± 0.00 0.44 -0.29
3.77 ± 0.13 3.33 1.01 0.42 ± 0.01 1.58 0.97
3.90 ± 0.04 0.94 0.46 0.43 ± 0.00 0.60 0.24
3.97 ± 0.04 1.02 -0.18 0.44 ± 0.00 0.63 0.00
3.95 ± 0.00 0.00 1.78 0.43 ± 0.00 0.00 1.77
3.83 ± 0.07 1.93 0.20 0.43 ± 0.00 0.76 0.53
3.89 ± 0.02 0.42 1.97 0.43 ± 0.00 0.38 1.76
4.04 ± 0.03 0.86 0.03 0.42 ± 0.00 0.33 -0.18
 
6.3.8.2 Ion Ratio 
MRM ion ratios in urine were consistent within day, but when ion ratios between 
days were averaged the precision worsened (Table 6.17).  The ion ratios were consistent 
within and between days for all compounds in whole blood (Table 6.18).  Another study 
found that short term intra-laboratory reproducibility of LC/MS mass spectra was 
satisfactory, with small differences in ion abundances occurring sporadically (Bogusz et 
al. 1999).   
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Table 6.17:  Intra- and inter-day ion ratio over three days of analysis in urine 
 Day 1 Day 2 Day 3 Average 
 Mean ± SD % CV 
Mean ± 
SD % CV 
Mean ± 
SD % CV 
Mean ± 
SD % CV 
LSD 2.1±0.1 5.8 3.1±0.2 5.3 2.9±0.1 4.9 2.7±0.5 17.9 
Iso-LSD 0.7±0.1 7.6 1.1±0.1 4.3 1.1±0.1 5.1 0.9±0.2 22.3 
Nor-LSD 5.5±0.2 4.4 4.7±0.2 4.3 4.4±0.4 8.9 4.9±0.5 11.2 
O-H-LSD 3.2±0.2 6.5 4.6±0.6 13.6 4.8±0.5 9.6 4.1±0.8 20.1 
 
 
Table 6.18:  Intra- and inter-day ion ratio over three days of analysis in whole blood 
 Day 1 Day 2 Day 3 Average 
 Mean ± SD % CV 
Mean ± 
SD % CV 
Mean ± 
SD % CV 
Mean ± 
SD % CV 
LSD 3.3±0.2 6.3 3.3±0.2 4.8 3.4±0.2 7.0 3.2±0.2 6.2 
Iso-LSD 1.1±0.1 4.6 1.1±0.1 5.3 1.1±0.1 5.7 1.1±0.1 5.5 
Nor-LSD 4.6±0.4 7.8 4.7±0.3 6.9 4.5±0.6 12.2 4.6±0.4 9.2 
O-H-LSD 4.6±0.4 9.6 4.8±0.4 7.2 4.4±0.6 14.1 4.6±0.5 11.0 
 
The ion ratios were also found to be concentration dependent.  The precision at 
the low concentration (50 pg/mL) was less compared to the higher concentration (1500 
pg/mL) (Table 6.19), even more so for O-H-LSD.  Since it was demonstrated that the 
ion ratios were concentration dependent, a ±30% bias was chosen for the acceptance 
criteria (SOFT/AAFS 2006).  Another study using a ±20% bias acceptance criteria for 
the ion ratios of O-H-LSD in urine found that 45.3% of the samples tested were outside 
the range relative to the calibrators (Poch et al. 2000).   
 
Table 6.19:  Precision of ion ratios at different concentrations in urine and whole blood 
  50 pg/mL 500 pg/mL 1500 pg/mL 
  % CV % CV % CV 
LSD Urine 7.4 5.7 2.4 
 Blood 9.3 3.1 2.2 
Iso-LSD Urine 4.8 5.2 0.0 
 Blood 7.0 3.7 0.0 
Nor-LSD Urine 6.3 2.2 3.5 
 Blood 12.8 3.7 2.4 
O-H-LSD Urine 20.4 6.9 6.0 
 Blood 16.6 3.0 2.7 
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The variation in the between day ion ratios could be explained by the 
instrumentation.  API sources generally consists of five parts; (1) the device where the 
liquid is introduced, (2) atmospheric pressure ion source region, (3) ion sampling 
aperture, (4) atmospheric pressure to vacuum region, and (5) an ion optical system 
(Niessen 1998), and any variability of these five parts could effect the ionization and 
fragmentation of the compound.  If needed, a tuning compound could be used to 
standardize the instrumentation each day.  However, since the within day ion ratios of 
the calibration standards were found to be precise, and the ion ratios of the quality 
control and test samples were found to be accurate (±30 %bias) relative to the mean ion 
ratio of the calibration standards (Table 6.20, 6.21, 6.22, and 6.23), a tuning compound 
was not necessary.  The results presented here showed that ion ratios were a reliable 
parameter for supporting the confirmation of the compounds when using a ±30% bias 
for the ion ratios of quality control and test samples relative to the calibration standards.   
 
 
 
Table 6.20:  Within day LSD ion ratios of calibration standards on 10 different days and 
the corresponding average accuracy (%bias) of the quality control and test samples 
Calibration Standards Ion ratio 
Mean ± SD % CV 
Average %bias of QC 
and test samples 
1.95 ± 0.10 4.98  -3.2 
1.91 ± 0.14 7.09  0.2 
1.93 ± 0.12 6.33  -0.6 
1.93 ± 0.17 8.67  -5.8 
1.95 ± 0.08 4.09  0.6 
1.89 ± 0.16 8.70  1.6 
2.01 ± 0.16 7.79  -2.3 
1.90 ± 0.11 5.63  -4.0 
2.05 ± 0.12 6.06  -2.8 
2.08 ± 0.18 8.83  -1.8 
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Table 6.21:  Within day iso-LSD ion ratios of calibration standards on 10 different days 
and the corresponding average accuracy (%bias) of the quality control and test samples 
Calibration Standards Ion ratio 
Mean ± SD % CV 
Average %bias of QC 
and test samples 
0.79 ± 0.03 3.81  -3.0 
0.74 ± 0.05 7.02  7.5 
0.78 ± 0.07 8.57  -4.7 
0.76 ± 0.05 7.06  0.7 
0.78 ± 0.06 8.02  -4.1 
0.78 ± 0.04 5.21  -1.6 
0.79 ± 0.05 6.50  -1.4 
0.76 ± 0.05 6.79  0.6 
0.81 ± 0.08 9.81  -1.0 
0.83 ± 0.05 5.61  -2.6 
 
 
 
Table 6.22:  Within day nor-LSD ion ratios of calibration standards on 10 different days 
and the corresponding average accuracy (%bias) of the quality control and test samples 
Calibration Standards Ion ratio 
Mean ± SD % CV 
Average %bias of QC 
and test samples 
4.16 ± 0.32 7.70  8.4  
4.58 ± 0.44 9.70  -2.3  
4.60 ± 0.60 13.15  -4.5  
4.57 ± 0.51 11.14  -4.8  
4.59 ± 0.27 5.94  -3.5  
4.45 ± 0.55 12.37  0.9  
4.48 ± 0.39 8.79  -1.1  
4.52 ± 0.15 3.26  -2.6  
4.24 ± 0.54 12.73  -0.3  
3.73 ± 0.45 12.18  10.0  
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Table 6.23:  Within day O-H-LSD ion ratios of calibration standards on 10 different 
days and the corresponding average accuracy (%bias) of the quality control and test 
samples 
Calibration Standards Ion ratio 
Mean ± SD % CV 
Average %bias of QC 
and test samples 
4.74 ± 0.38 8.05  -4.4  
4.35 ± 0.56 12.82  -15.8  
4.76 ± 0.58 12.08  -1.1  
4.35 ± 0.56 12.82  -5.0  
4.59 ± 0.34 7.43  2.8  
4.10 ± 0.60 14.63  -4.4  
4.30 ± 0.47 10.96  6.9  
4.22 ± 0.71 16.93  -12.3  
4.62 ± 0.44 9.62  1.7  
4.82 ± 0.73 15.17  -10.7  
 
6.3.9 Existing Extraction Methods at RCMP FLS (nBuCl and Toxi-Lab A) 
 The nBuCl extraction method for whole blood was not suitable for simultaneous 
extraction of LSD, iso-LSD, nor-LSD, and O-H-LSD, because it was unable to extract 
O-H-LSD (Figure 6.18).   
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Figure 6.18:  MRM channels for 50 pg/mL  (a) LSD (RT = 9.00 minutes), iso-LSD (RT 
= 10.10 minutes), (b) nor-LSD (RT = 9.17 minutes) , (c) O-H-LSD (not present), and (d) 
LSD-D3 in spiked blood extracted using the nBuCl method. 
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 As well, the percent recovery of the remaining compounds were inconsistent 
between the low (50 pg/mL) and high concentration (1500 pg/mL) (Table 6.24). 
Furthermore, nBuCl provided optimal extraction of LSD and iso-LSD with a % recovery 
of 86 and 80%, respectively, over nor-LSD with % recovery of 66%. 
 
Table 6.24: Percent recovery in whole blood for LSD, iso-LSD, nor-LSD, and O-H-LSD 
using the nBuCl extraction method 
 50 pg/mL 1500 pg/mL Average 
LSD 93 79 86 
iso-LSD 84 77 80 
nor-LSD 70 61 66 
O-H-LSD - - - 
 
 When urine was extracted using the Toxi-Lab A method, all compounds were 
extracted with similar % recoveries (Table 6.25 and Figure 6.19).  Like the nBuCl 
extraction method, the Toxi-Lab A resulted in inconsistent % recoveries between the 
low (50 pg/mL) and high concentration (1500 pg/mL).  The precision of the % 
recoveries of nor-LSD and O-H-LSD at 50 pg/mL were 22.9 and 21.8% CV, 
respectively, which was less precise than the dichloromethane/isopropyl alcohol 
extraction method with 8.7 and 11.4% CV for nor-LSD and O-H-LSD, respectively. 
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Figure 6.19:  MRM channels for 50 pg/mL  (a) LSD (RT = 9.00 minutes), iso-LSD (RT 
= 10.14 minutes), (b) nor-LSD (RT = 9.17 minutes) , (c) O-H-LSD (RT = 3.86 minutes), 
and (d) LSD-D3 in spiked urine extracted using the Toxi-Lab A method. 
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Table 6.25: Percent recovery in urine for LSD, iso-LSD, nor-LSD, and O-H-LSD using 
the Toxi-Lab A extraction method 
 50 pg/mL 1500 pg/mL Average 
LSD 86 77 81 
iso-LSD 75 83 79 
nor-LSD 63 80 72 
O-H-LSD 74 74 74 
  
 Both the nBuCl and Toxi-Lab A extraction methods resulted in slightly different 
ME (Table 6.26) compared to each other and to the dichloromethane/isopropyl alcohol 
extraction method.  The nBuCl resulted in different ME at low and high concentrations 
for LSD and iso-LSD with ionization suppression at 50 pg/mL and ion enhancement at 
1500 pg/mL.  The Toxi-Lab A suppressed ionization in LSD 10% more compared to the 
dichloromethane/isopropyl alcohol method (91% versus 81% ME).  Overall, the nBuCl 
method resulted in more ion enhancement, and the Toxi-Lab A resulted in more ion 
suppression compared to the dichloromethane/isopropyl alcohol extraction method. 
 
Table 6.26: nBuCl and Toxi-Lab A matrix effect 
  50 pg/mL 1500 pg/mL Average 
LSD nBuCl 92 102 97 
 Toxi-Lab A 79 83 81 
iso-LSD nBuCl 97 113 105 
 Toxi-Lab A 90 102 96 
nor-LSD nBuCl 110 110 110 
 Toxi-Lab A 107 103 105 
O-H-LSD nBuCl 92 107 99 
 Toxi-Lab A 94 95 94 
LSD-D3 nBuCl 104 105 104 
 Toxi-Lab A 86 84 85 
 
Since LSD is found in such small concentrations compared to other commonly 
encountered drugs of abuse, an extraction method specific for LSD and its metabolites is 
optimal.  Using extraction methods that already exist may be beneficial for efficiency.   
With case samples there is also the possibility of encountering an insufficient volume of 
sample to analyze for LSD after completing screening tests, so to be able to use an 
already extracted sample used on other instruments may also be useful.  During the 8 
months of method validation a few positive LSD ELISA cases were found to be false 
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positives using the UPLC™/MS/MS method.  However, in these cases the nBuCl and 
Toxi-Lab A extraction methods were used.  The effect of these two extraction methods 
on the selectivity and sensitivity were not tested and therefore the extraction methods 
could have affected the results.  However, in most cases of LSD use, the case history 
alone makes the investigators suspect LSD.  In the cases tested to date, the case history 
gave no indication of behaviour related to hallucinogens.  To summarize, use of the 
nBuCl extraction method for accurate quantitation is not recommended.  For 
confirmation, the Toxi-Lab A and nBuCl could be used as alternative extraction 
methods, but they are not ideal and should be avoided if possible.   
 
6.4 Conclusion 
An accurate, precise, selective, and sensitive UPLC™/MS/MS method was 
validated to identify, confirm, and quantitate LSD, iso-LSD, nor-LSD, and O-H-LSD in 
urine and whole blood.  Based on the stability results, accurate quantitation is only 
possible for all compounds in whole blood samples if stored frozen or refrigerated for up 
to 2 weeks.  Accurate quantitation of iso-LSD in urine samples is not possible, but LSD, 
nor-LSD, and O-H-LSD in urine samples may be accurately quantitated if stored frozen 
or refrigerated for 2 weeks.  For samples stored 14 to 60 days frozen or refrigerated only 
LSD and O-H-LSD can be accurately quantitated.  Although quantitative analysis is 
commonly performed on whole blood specimens, for LSD the qualitative analysis may 
be more important.  Instead the stability studies should serve more as a guideline to 
prevent loss of LSD due to improper storage and handling.  The one-step LLE will allow 
simple confirmation of urine and whole blood samples testing positive with ELISA at 
the positive cutoff of 1 ng/mL for urine and 0.5 ng/mL for whole blood.  Furthermore, 
the simultaneous analysis of LSD, iso-LSD, nor-LSD, and O-H-LSD provides a superior 
interpretation versus analyzing LSD alone.   
To the Author’s knowledge, there are no known published validated methods for 
the simultaneous confirmatory and quantitative analysis of LSD, iso-LSD, nor-LSD, and 
O-H-LSD in both urine and blood.  Furthermore, compared to other published methods, 
the LOD and LLOQ obtained in this study for O-H-LSD and nor-LSD in both whole 
blood and urine are among the lowest.   
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Chapter 7 
UPLC™/MS/MS Analysis of LSD, iso-LSD, nor-LSD, and O-H-LSD in Blind 
Samples and a Case Sample 
7.1 Introduction 
As previously mentioned, the purpose of validating a method is to provide an 
assurance of reliability during normal use, and to provide evidence that the method 
works (Shabir 2003).  All the validation parameters tested in Chapter 6 were conducted 
using blanks spiked with known amounts of standard.  To remove the bias associated 
with the spiked samples, eight blind samples prepared by another laboratory (McKay, 
Pharmalytics Inc, Saskatoon, SK), were tested.  Additionally, the blind samples were 
analyzed by two different analysts to demonstrate the reproducibility of the method.  To 
provide further evidence that the method works, a case which screened positive for LSD 
previously with RIA was tested. 
 
7.2 Blind Samples 
Proficiency testing involves analyzing simulated case samples, and evaluating 
the results to determine the quality of the performance of the method (Burtis and 
Ashwood 1997).  Simulated case samples were provided in the form of blind samples, 
which were samples that the analysts had no knowledge of the identity of the 
compounds as well as their concentration levels.  The blind sample results obtained by 
the analysts were then compared to the actual results to test the reliability of the method.  
Eight blind samples (4 urines and 4 whole bloods) prepared by another laboratory were 
supplied.  Samples were shipped on ice and placed in the freezer on receipt.  On the day 
of analysis, samples were thawed at room temperature.  The samples were prepared and 
extracted in duplicate, with calibration standards (Appendix A, B, and C).  The analysis 
was conducted by two different analysts on different days. 
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7.2.1 UPLC™/MS/MS Results 
A 5 (O-H-LSD and nor-LSD) or 6 (LSD and iso-LSD) point calibration curve 
was constructed to quantitate the blood samples.  A 3 (O-H-LSD and nor-LSD) or 4 
(LSD and iso-LSD) point calibration curve was constructed to quantitate the urine 
sample.  The r and r2 of all calibration curves were greater than 0.99.  Quality control 
samples (0.50 ng/mL) were run in duplicate and were within acceptable limits.  The 
MRM ion chromatograms of the blind samples are shown in Figures 7.1 to 7.10.   
RT, RRT, and ion ratios were used for confirmation.  For confirmation of each 
compound, all ions for each compound (LSD = MRM 324>223, 208, 281, iso-LSD = 
MRM 324>223, 208, 281, nor-LSD = MRM 310>209, 237, 74, O-H-LSD = MRM 
356>237, 222, 313) were present in the blinds and quality control sample at the same RT 
(±2%) as the calibration standards.  The ion ratios were also within ±30% of the 
calibration standards (LSD = 223/208, 223/281, iso-LSD = 281/208, 281/223, nor-LSD 
= 209/237, 209/74, O-H-LSD = 237/222, 237/313).  The ISTD was also found and the 
RT, ions (MRM 327>226, 208, 281), and ion ratios (226/208, 226/281) were within 
range.  The measured results obtained with the UPLC™/MS/MS method are 
summarized in Table 7.1.  In order for a compound to be confirmed, all three 
identification criteria (RT, RRT, and ion ratios) must be met.  None detected means that 
the level was below the LOD or one or more of the identification criteria failed. 
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Figure 7.1:  MRM acquisitions of blank urine + ISTD (LSD-D3) for (a) LSD-D3, (b) 
LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  The response of the blank is 
acceptable since at the LLOQ was five times the response compared to the blank.  
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Figure 7.2:  MRM acquisitions of extracted blind urine sample #1 for (a) LSD-D3, (b) 
LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  Refer to Figure 7.1 for blank results. 
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Figure 7.3:  MRM acquisitions of extracted blind urine sample #2 for (a) LSD-D3, (b) 
LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  Refer to Figure 7.1 for blank results. 
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Figure 7.4:  MRM acquisitions of extracted blind urine sample #3 for (a) LSD-D3, (b) 
LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  Refer to Figure 7.1 for blank results. 
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Figure 7.5:  MRM acquisitions of extracted blind urine sample #4 for (a) LSD-D3, (b) 
LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  Refer to Figure 7.1 for blank results. 
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Figure 7.6:  MRM acquisitions of blank whole blood + ISTD (LSD-D3) for (a) LSD-D3, 
(b) LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  The response of the blank is 
acceptable since at the LLOQ was five times the response compared to the blank.  
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Figure 7.7:  MRM acquisitions of extracted blind whole blood sample #1 for (a) LSD-
D3, (b) LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  Refer to Figure 7.6 for blank 
results. 
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Figure 7.8:  MRM acquisitions of extracted blind whole blood sample #2 for (a) LSD-
D3, (b) LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  Refer to Figure 7.6 for blank 
results. 
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Figure 7.9:  MRM acquisitions of extracted blind whole blood sample #3 for (a) LSD-
D3, (b) LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  Refer to Figure 7.6 for blank 
results. 
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Figure 7.10:  MRM acquisitions of extracted blind whole blood sample #4 for (a) LSD-
D3, (b) LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  Refer to Figure 7.6 for blank 
results. 
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Table 7.1:  Blind trial results from two different analysts 
  Measured Values (ng/mL) 
  
Spiked Level 
(ng/mL) Analyst 1 Analyst 2 
LSD 3.00 >1.50 (2.59) >1.50 (2.48) 
iso-LSD 2.40 >1.50 (2.42) >1.50 (2.28) 
nor-LSD 0.00 ND ND 
Urine #1 
O-H-LSD 8.80 >1.50 (9.09) >1.50 (9.62) 
LSD 0.10 0.09 0.09 
iso-LSD 0.60 0.58 0.57 
nor-LSD 0.10 0.09 0.08 
Urine #2 
O-H-LSD 6.50 >1.50 (6.76) >1.50 (6.95) 
LSD 0.00 ND ND 
iso-LSD 0.00 ND ND 
nor-LSD 0.00 ND ND 
Urine #3 
O-H-LSD 8.00 >1.50 (9.01) >1.50 (9.01) 
LSD 0.00 ND ND 
iso-LSD 0.50 0.49 0.48 
nor-LSD 0.00 ND ND 
Urine #4 
O-H-LSD 10.00 >1.50 (10.63) >1.50 (10.53) 
LSD 0.27 0.22 0.15 
iso-LSD 0.44 0.39 0.34 
nor-LSD 0.00 ND ND 
Blood #1 
O-H-LSD 1.50 1.29 1.30 
LSD 1.00 0.77 0.56 
iso-LSD 0.75 0.69 0.62 
nor-LSD 0.20 0.14 0.12 
Blood #2 
O-H-LSD 1.00 0.92 0.89 
LSD 0.00 ND ND 
iso-LSD 0.50 0.48 0.45 
nor-LSD 0.00 ND ND 
Blood #3 
O-H-LSD 1.00 0.92 0.99 
LSD 0.00 ND ND 
iso-LSD 0.00 ND ND 
nor-LSD 0.00 ND ND 
Blood #4 
O-H-LSD 0.50 0.45 0.41 
ND = none detected. 
Bracketed result is from extrapolating the calibration curve above the highest calibrator. 
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To test both the reliability and reproducibility of the method, the results obtained 
from two different analysts were compared one another and to the spiked values.  The 
results obtained from the two different analysts, showed that the method was 
qualitatively reproducible.  Both analysts were able to correctly identify the analytes 
100% of the time.  When comparing the results from the two analysts to the spiked 
value, there was a good correlation of the expected value to the experimental quantitated 
results.  As well, the analysis is reproducible between different analysts, because there 
was also a good correlation of the quantitated results of analyst 1 and 2.  
 
7.2.2 Discussion 
Some of the results were reported as >1.50 ng/mL because the levels were higher 
than the highest calibrator (1.50 ng/mL).  The accuracy of extrapolating the calibration 
curve has not been tested.  However, by extrapolating the calibration curve, the 
calculated concentrations were all ±15% bias from the spiked value, suggesting that the 
method was quite linear and not near saturation for detection at 3.0 ng/mL for LSD, 2.4 
ng/mL for iso-LSD, and 10.0 ng/mL for O-H-LSD. 
The higher % bias of the measured nor-LSD may be explained by the reported 
instability of the nor-LSD stock standard in ACN (Chapter 6, section 6.3.7.4).  All the 
measured values from both analysts that were within the range of the calibration curves 
were lower than the spiked value.  The standards used to prepare the blind samples were 
different than the standards used to prepare the calibration curve.  Since the quality 
control samples were within acceptable limits, and the residuals were randomly scattered 
with no obvious trend, the calibration curves were deemed acceptable.  Since the 
calibration curves were acceptable, the lower measured values may have been caused by 
the fact that different standards were used to prepare the calibration standards versus the 
blinds.  It may also have been possible that during shipment of the blind samples that the 
compounds degraded slightly.   
This was the first time that Analyst 2 performed the method by following the 
written standard operating procedures (SOPs) (Appendix A, B, and C), as a result, 
Analyst 2 lacked the experience of Analyst 1 (author).  Analyst 2 had difficulties in 
obtaining an organic layer free of blood particulates, so resorted to using a syringe filter.  
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LSD may have been lost from using the syringe filter.  From experience, the author had 
found that by practising and using the right technique that it is possible to obtain a 
“clean” organic layer without having to use syringe filters.  The quantitative results 
should be reproducible when performed by experienced analysts. 
The significance of the actual level of LSD, iso-LSD, nor-LSD, and O-H-LSD in 
blood and urine has yet to be discussed in the literature.  Unlike prescription drugs or 
other medications, LSD does not have a therapeutic concentration range and has not 
been found to cause organ damage.  Forensically, because LSD is an illicit drug the mere 
presence of it is significant.  Most importantly, the blind trial results from the 2 analysts 
demonstrated that the incidence of false positives was absent.  By following the 
identification criteria regarding the ion ratios, RT, and RRT the correct identification of 
LSD, iso-LSD, nor-LSD, and O-H-LSD were obtained 100% of the time.  Furthermore, 
by ensuring that the LLOQ samples response for LSD was at least 5 times the blank 
sample containing the ISTD, the residual LSD present in the ISTD did not result in false 
positive results.   
 
7.3 Case Sample 
7.3.1 History 
This case occurred in 1995.  A 19 year old man leapt out of a 16th floor window 
and landed on the 5th floor of a parking garage.  He died shortly after from "multiple 
blunt force injuries".  When his friends were questioned, they said that he may have 
taken LSD.  The man’s father stated that he was not aware of any specific history of 
drug abuse, other than an occasional beer.  There was also no history of depression or 
suicidal thoughts. 
 
7.3.2 Initial 1995 Laboratory Analysis 
Four samples were collected post-mortem; (1) femoral blood collected in grey 
top (potassium oxalate, sodium fluoride) Vacutainer™, (2) subclavian blood collected in 
plastic screw top container, (3) vitreous humor collected in Vacutainer™ with no 
additives, and (4) urine collected in grey top (potassium oxalate, sodium fluoride) 
Vacutainer™.  An alcohol and routine toxicology screen (immunoassay and GC/MS) 
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was conducted.  There was no alcohol or other common drugs in the routine screen 
except for 3 mg/L acetaminophen in the blood.  Based on the history, a LSD RIA kit was 
obtained and run with appropriate controls.  All samples "screened positive".  Final 1995 
report was "presumptive" LSD, a confirmatory method is not available. 
 
7.3.3 UPLC™/MS/MS Confirmation Results 
Since 1995, the samples were initially stored refrigerated for about 2 to 4 
months, then stored at -50°C.  Samples were shipped and received on ice and stored at 
4°C for one day until analyzed.  The samples were extracted in duplicate and analyzed 
(Appendix A, B, and C).  A 5 to 6 point calibration curve was constructed to quantitate 
the blood samples.  A 3 point calibration curve was constructed to quantitate the urine 
sample.  A 3 point calibration curve using reference standards made in acetonitrile was 
constructed to quantitate the vitreous humor sample.  The r and r2 of all calibration 
curves were greater than 0.99.  Quality control samples were run in duplicate and all 
were within acceptable limits.  The MRM ion chromatograms of the case sample are 
shown in Figure 7.11 to 7.16.   
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Figure 7.11:  MRM acquisitions of blank whole blood + ISTD (LSD-D3) for (a) LSD-
D3, (b) LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  The response of the blank is 
acceptable since at the LLOQ was five times the response compared to the blank.  
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Figure 7.12:  MRM acquisitions of extracted femoral blood case sample for (a) LSD-D3, 
(b) LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  Refer to Figure 7.11 for blank 
results. 
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Figure 7.13:  MRM acquisitions of extracted subcalvian blood case sample for (a) LSD-
D3, (b) LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  Refer to Figure 7.11 for 
blank results.  
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Figure 7.14:  MRM acquisitions of extracted vitreous humor case sample for (a) LSD-
D3, (b) LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  Method has not been 
validated for vitreous humor matrix. 
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Figure 7.15:  MRM acquisitions of blank urine + ISTD (LSD-D3) for (a) LSD-D3, (b) 
LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  The response of the blank is 
acceptable since at the LLOQ was five times the response compared to the blank.  
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Figure 7.16:  MRM acquisitions of extracted urine case sample for (a) LSD-D3, (b) 
LSD, (c) iso-LSD, (d) nor-LSD, and (e) O-H-LSD.  Refer to Figure 7.15 for blank 
results. 
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Like the blind samples, RT, RRT, and ion ratios were used for confirmation, 
where all the ions were present for each compounds, the RT and RRT were within ±2% 
of the calibration standards, and the ion ratios were within ±30% of the calibration 
standards (Table 7.2).  The results obtained with the UPLC™/MS/MS method are 
summarized in Table 7.3.  Trace results means that the level was above the LOD, but 
lower than the LLOQ.  None detected means that the level was below the LOD or one or 
all three identification criteria failed. 
 
 
Table 7.2:  The % bias of the confirmatory parameters of the case sample relative to the 
calibration standards 
  RT RRT Ion ratio 1 Ion ratio 2 
LSD 0.8 -0.2 0.00 -9.4 
iso-LSD 0.8 -0.2 11.4 7.2 
nor-LSD 0.9 -0.1 -49.3* 9.4- 
Femoral  
Blood 
O-H-LSD 0.2 -0.8 -1.5 14.1 
LSD 0.8 0.3 -7.3 -10.9 
iso-LSD 0.6 0.1 5.2 3.9 
nor-LSD 0.7 0.1 -9.2 32.1* 
Subclavian 
Blood 
O-H-LSD 0.2 -0.3 4.0 -3.0 
LSD 1.6 -0.3 4.2 -9.1 
iso-LSD 2.0* 0.1 160.8* -96.7* 
nor-LSD -48.1* -50.1* -91.6* -100.0* 
Vitreous 
humor 
O-H-LSD 10.4* 8.2* -62.2* -67.9* 
LSD -0.6 -0.6 -3.6 -11.1 
iso-LSD -0.4 -0.4 9.1 5.1 
nor-LSD -0.4 -0.4 3.1 -6.6 
Urine 
O-H-LSD 0.2 0.2 -4.5 17.2 
* Outside acceptable parameters for confirmation.  Acceptable parameters for RT and RRT is 
±2% bias, and for ion ratios ±30% bias. 
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Table 7.3:  Measured concentrations of LSD, iso-LSD, nor-LSD, and O-H-LSD in 
whole blood, urine, and vitreous humor samples from a 19 year old male 
 LSD 
(ng/mL) 
Iso-LSD 
(ng/mL) 
Nor-LSD 
(ng/mL) 
O-H-LSD 
(ng/mL) 
Femoral Blood 0.56 trace ND 0.17 
Subclavian Blood 0.54 trace ND 0.17 
Urine >1.50* 0.07 0.19 >1.50† 
Vitreous humor§ 0.07 ND ND ND 
ND = none detected. 
Trace is when result is ≥ LOD, < LLOQ. 
Extrapolating the calibration curve gives a result of *2.33 ng/mL, and †9.29 ng/mL. 
§ The method has not been validated for vitreous humor sample matrix. 
 
 
7.3.4 Discussion 
To my knowledge this is the first time that O-H-LSD has been detected and 
confirmed in whole blood case samples.  The majority of the methods published for O-
H-LSD have only attempted analysis in urine (Horn et al. 2003; Poch et al. 2000; Klette 
et al. 2002; Skopp et al. 2002), but methods that have attempted to analyze O-H-LSD in 
blood were unable to detect O-H-LSD in case blood samples positive for LSD (Sklerov 
et al. 2000; Canezin et al. 2001).  It is still not confirmed that O-H-LSD is strictly a 
urinary metabolite since the research on the metabolism of LSD is incomplete.  Despite 
publications stating that O-H-LSD was not detected in blood samples, O-H-LSD was 
still included during method validation in whole blood. 
Previous LC/MS(/MS) methods for analyzing O-H-LSD in blood may have been 
unsuccessful in detecting O-H-LSD in real samples due to the lack in sensitivity 
compared to this UPLC™/MS/MS method.  One method using an Agilent HPLC 
coupled to a MSD was unable to detect O-H-LSD in blood case samples (Sklerov et al. 
2000).  When spiked blood samples were extracted only 32 to 42% was recovered versus 
69 to 73% in spiked urine.  The low recovery is due to the SPE done after the initial LLE 
to obtain “cleaner” extracts.  The LOD and LLOQ of 400 pg/mL was only determined in 
urine, but the low recovery in blood could ultimately affect the sensitivity of the method 
resulting in a higher LOD and LLOQ.  Nonetheless, a LOD and LLOQ of 400 pg/mL for 
O-H-LSD would not have been able to detect O-H-LSD in this case sample. 
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 Like the blind samples, a few results for LSD and O-H-LSD were reported as 
>1.50 ng/mL because levels were higher than the highest calibrator (1.50 ng/mL).  If the 
calibration curve was extrapolated the concentration of LSD was approximately 2.33 
ng/mL and O-H-LSD was approximately 9.29 ng/mL.  The most important result was 
that urine O-H-LSD was in higher concentrations than LSD.  Others have found that the 
concentration of O-H-LSD is 16 (Poch et al. 2000) to 25 (Horn et al. 2003) times higher 
than that of LSD.  This study found that O-H-LSD was 4 times higher than LSD in 
urine.   
The method has not been validated for vitreous humor sample matrix.  Since it 
was shown that vitreous humor samples may also contain LSD, validating for the 
vitreous humor sample matrix could be done for future experiments.  No other published 
methods have analyzed vitreous humor samples for LSD.   
 The most interesting result was that even after 10 years LSD and metabolites 
were still detectable.  Since no quantitation was conducted on the samples 10 years ago, 
the stability cannot be assessed.  These results show that LSD is relatively stable if kept 
frozen.  More importantly, these results showed that 10 year old cases screening positive 
for LSD during a time when no confirmatory analysis was available, could now be 
analyzed for confirmation if required. 
 
7.4 Conclusion 
The results of the blind trial and the case sample further support the reliability of 
this method.  By following the identification criteria regarding the ion ratios, RT, and 
RRT the correct identification of LSD, iso-LSD, nor-LSD, and O-H-LSD should be 
obtained 100% of the time.  The interpretation of the results to confirm the use of LSD 
was further supported by also analyzing metabolites and the isomer of LSD. 
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Chapter 8 
Summary, Future Experiments, and Conclusion 
8.1 Introduction 
Selective and sensitive methods for forensic analysis must be developed to 
withstand the scrutiny of the law.  The detection and confirmation of highly potent drugs 
and their metabolites from complex matrices need techniques that employ mass 
spectrometry as the detector in order to achieve the necessary selectivity and sensitivity.  
One such forensic example is in analyzing biological samples for the presence of LSD.  
In order for a method to be used routinely at the RCMP FLS TS, the method must be 
validated.  Validating a method ensures that the method would work during normal use.  
Full validation as recommended by the FDA, USP, ICH, SOFT, and AAFS suggest the 
evaluation of linearity, selectivity, LOD, accuracy, precision, recovery, stability, and 
ME.  These parameters were evaluated to validate an UPLC™/MS/MS method that will 
be used by the RCMP FLS TS for routine confirmatory analysis of samples screening 
positive for LSD with ELISA. 
 
8.2 Summary 
The intended study objectives and hypothesis (Chapter 1, section 1.7) were 
successfully achieved.  Compared to the GC/MS method previously utilized by the 
RCMP in 1997 (section 6.1), the UPLC™/MS/MS method was able to analyze extracts 
of blood and urine for LSD with better sensitivity and greater ease of analysis (Table 
8.1).  The UPLC™/MS/MS method is more efficient than the previously used GC/MS 
method, decreasing total analysis time and cost.  The preparation of samples using the 
GC/MS method first requires mixing the sample with buffer then adjusting the pH for 
urine samples and sonicating blood samples.  Next an automated SPE is used which 
takes approximately 18 minutes for one sample, followed by evaporation of the eluent 
and 30 minutes for derivatization.  Additionally, 6 injections of blanks and several 
injections of derivatizating agents to prevent adsorption, requires a total of 15 minutes 
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for each injection.  So a full run with an unknown, 6 calibration standards, a quality 
control sample, and a blank each run in duplicate would take about 20 hours.  In contrast, 
the UPLC™/MS/MS method only takes about 10 hours.  The GC/MS method is more 
costly because it requires SPE cartridges and more solvents compared to the LLE 
method.  The interpretation of confirming LSD use is also further enhanced by 
simultaneously analyzing LSD with iso-LSD, nor-LSD, and O-H-LSD.  Furthermore, 
the linearity, accuracy, precision, LOD, LLOQ, selectivity, recovery, ME, stability, RT 
and RRT, and ion ratio were all found to be acceptable, to validate the method. 
 
Table 8.1:  GC/MS/MS method used in 1997 by RCMP versus the UPLC™/MS/MS 
method validated in this study 
 GC/MS/MS UPLC™/MS/MS 
Analytes analyzed  LSD only  LSD 
 iso-LSD 
 nor-LSD 
 O-H-LSD 
LLOQ (pg/mL)  100  20 to 50 
Volume of Sample  2 mL blood  1 mL blood 
  5 mL urine  1 mL urine 
Derivatization  yes  no 
Adsorption onto column  yes*  no 
*pre-conditioning required 
   
 
The validation parameters were all conducted using samples spiked with known 
amounts of standard.  To remove the bias of using spiked standards prepared by the 
analyst, known positive case samples confirmed with another method or another 
laboratory should ideally be analyzed and compared.  Before this method was validated 
no other forensic laboratories in Canada had a method that was being used to analyze 
LSD.  So comparing results between different laboratories was not possible.  To provide 
further proof of the reliability of this method, a case sample screening positive with RIA 
and blind samples prepared by another laboratory were analyzed (Chapter 7).  Validating 
the method, and analyzing both the case sample and blind samples, showed that the 
method was reliable for analyzing forensic samples suspected of containing LSD. 
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Finally the knowledge gained from this project, impacted the RCMP FLS in the 
general use of LC/MS/MS as a confirmatory technique.  By showing that a compound 
that was difficult to analyze via GC/MS/MS, such as LSD, was more amenable to 
LC/MS/MS analysis, demonstrated that other “problem” compounds could also be more 
suitable for LC/MS/MS.  Furthermore, the steps involved in conducting the validation 
study for the detection, confirmation, and quantitation of LSD could be used as a model 
for validating other compounds using LC/MS/MS.   
 
8.3 Future Experiments 
It was previously mentioned that validation is a permanent process that starts 
from the beginning of the life of the method until its retirement, where the objective 
should be to build results of quality by means of an analytical method (Boulanger et al. 
2003).  So although the intended purpose of this study was achieved, if time permitted 
there are a few experiments that may be considered for the future to further increase the 
quality of the method.   
 
8.3.1 Upper Limit of Quantitation (ULOQ) 
In Chapter 7, the case urine sample resulted in LSD and O-H-LSD values above 
the highest calibrator.  Another study found that the average concentration of O-H-LSD 
in human urine samples to be 3.47 ng/mL (Reuschel et al. 1999b).  The ULOQ could be 
increased or the accuracy of diluted standards could be tested.  This may be important to 
show if the method is linear at the higher concentrations with no saturation effect.  
Certain validation parameters may also need to be shown to be valid at the higher 
concentrations, particularly the ion ratios.  Ion ratios are a qualitative confirmatory 
parameter that would be used for urine samples.  Based on the results obtained for the 
ion ratios precision, it would be expected that the precision would increase with 
increasing concentration, because results showed that the precision at the low 
concentration was less compared to the higher concentration (Table 6.19). 
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8.3.2 Specificity 
The specificity of the method can also be evaluated by testing to see if other 
drugs and their metabolites, other illicit compounds, and compounds related to LSD 
cause interference.  According to the recommendations by the FDA, specificity is not 
included in the parameters included for validation.  However, since in forensic analysis 
the identities of compounds in the samples are unknown it may be possible that other 
drugs are present in the samples.   
 
8.3.3 Extraction Method 
The extraction method used was less laborious than the GC/MS/MS method used 
in 1997 by the RCMP, but compared to the nBuCl method used routinely for basic drug 
screens in blood it was more laborious.  This was because the organic layer was at the 
bottom below a layer of solid blood.  As a result, trying to transfer the organic layer 
without transferring blood particulate was difficult.  If possible, other extraction methods 
with the organic layer on top may be considered.  Additional cleanup after the initial 
LLE of the blood extract may be considered as well.  However, this may result in lower 
recoveries and subsequently affect the sensitivity of the method.  To compensate for the 
possible loss of sensitivity from performing additional cleanup, the final extract may be 
reconstituted in a smaller volume (<100 µL) so that the final extract is more 
concentrated.  Yet, reconstituting in a smaller volume could limit the ability to re-inject 
(20 µL injected) a sample if needed. 
 
8.3.4 Other Matrices 
In Chapter 7, the case tested included a vitreous humor sample.  The original 
validation method was conducted for urine and blood samples only.  The case vitreous 
humor sample confirmed the presence of LSD, so validating this method for vitreous 
humor matrix could be done as well.  Furthermore, other sample matrices may also be 
tested for, such as tissue samples.  
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8.3.5 ELISA Cross Reactivity 
Since May 2005, none of the samples screening positive for LSD with ELISA 
were not confirmed to be LSD when tested with LC/MS/MS.  The cross-reactivity of 
iso-LSD, nor-LSD, and O-H-LSD with the LSD ELISA test was tested and found to be 
insignificant (Appendix D).  As a result, a cross-reactivity study of other commonly 
encountered drugs or compounds structurally related to LSD could be conducted to try 
and determine the compounds that are causing the false positives.   
 
8.3.6 Case Samples 
The most important work to do in the future would be to run more cases, because 
there is a need to publish more information on the levels of LSD in blood.  At the RCMP 
FLS actual case samples will only be run by LC/MS/MS for confirmation if the LSD 
ELISA screening method tests positive.  In order to report a positive result with the LSD 
ELISA screening method, the levels must be greater than 0.50 ng/mL in blood and 1.00 
ng/mL in urine.  To take full advantage of the highly sensitive UPLC™/MS/MS method, 
with a LLOQ of 0.02 ng/mL for LSD, the LSD ELISA cutoff level for positive LSD 
may need to be reconsidered.  As an example, the case blood samples analyzed by the 
UPLC™/MS/MS method in Chapter 7 were quantitated to have concentrations of 0.56 
and 0.54 ng/mL in the femoral blood and subclavian blood, respectively.  Concentrations 
of 0.56 and 0.54 ng/mL are close to the 0.50 ng/mL LSD ELISA cutoff level for blood, 
so those samples may or may not have tested positive for LSD via ELISA.  As a result, 
under normal circumstances the blood samples may have been reported as negative by 
ELISA and not of been carried on for confirmatory analysis by LC/MS/MS.  This 
example demonstrates that there is a possibility of reporting a sample that actually 
contains LSD, as being negative with the current ELISA cutoff concentrations.   
 
8.4 Conclusion 
A majority of forensic toxicology laboratories lack a reliable validated method 
for detecting LSD.  Without an available method it is not known if the illicit use of LSD 
actually exists or if it is just simply missed.  Without a method for confirming LSD, the 
diagnosis of suspected overdose situations can only be done by clinical signs.  In 
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conclusion, a validated UPLC™/MS/MS is now available to the RCMP FLS for 
confirming the illicit use of LSD in Canada.  This method will be applied to real cases 
screening positive for LSD with ELISA.  Furthermore, other agencies in Canada can 
also rely on the RCMP FLS for confirmatory analysis of LSD if needed.   
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1.  Associated SOPs - 
1.1 LSD LC_MS_MS... 
1.2 quant... 
1.3 LCMS_confirm… 
 
2.  Definitions -  
2.1  LSD - lysergic acid diethylamide 
2.2 iso-LSD - lysergic acid diethylamide isomer 
2.3 nor-LSD - N-demethyl lysergic acid diethylamide 
2.4 O-H-LSD - 2-oxo-3-hydroxy lysergic acid diethylamide 
2.5 LSD-D3 - deuterated lysergic acid diethylamide 
2.6 ISTD - internal standard 
2.7 LLOQ - lowest limit of quantitation 
2.8 UPLC™/MS/MS - ultra performance liquid chromatography tandem mass 
spectrometry 
2.9 BEH - bridged ethyl hybrid 
 
3. Safety -  
3.1 Routine laboratory safety guidelines for handling biohazardous materials are 
followed. 
 
4. Equipment Used -  
4.1 Waters Corporation (Milford, MA) Acquity UPLC™ with an autosampler.  
4.2 Waters Corporation (Milford, MA) Quattro Premier™ tandem quadrupole mass 
spectrometer. 
4.3 Acquity UPLC™ BEH C18 (2.5×50 mm, 1.7 μm, Waters Corporation, Milford, 
MA)  
4.4 pH meter 
4.5 Mechanical Shaker 
4.6 Centrifuge 
 
5. Reagents Needed -  
5.1 20 mM Ammonium acetate buffer (pH 4.0) 
Dissolve 1.5416 g ammonium acetate and dissolve in 800 mL NANOpure  water, 
then adjust pH to 4.0 (± 0.1) using glacial acetic acid.  Make up to 1 L with 
NANOpure  water.  Thoroughly mix then filter and sonicate. 
 
5.2 1 M Ammonium acetate buffer (pH 9.0) 
 Dissolve 19.270 g ammonium acetate in 150 mL NANOpure water.  Adjust pH 
to 9.0 (± 0.1) with ammonium hydroxide.  Make up to 250 mL with NANOpure 
water. 
 
5.3 methylene chloride:isopropyl alcohol (85:15 (v:v)) 
 
5.4 Acetonitrile (HPLC grade) 
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5.5 Calibrator solutions in acetonitrile are prepared as follows: (Calibrators are 
purchased from Cerilliant)  
 
5.5.1 LSD - prepare a 500 ng/mL stock.  
 
  25 μg/mL Cerilliant standard - 100 μL diluted to 5 mL with acetonitrile 
giving a 500 ng/mL stock 
 
  100 μg/mL Cerilliant standard - 25 μL diluted to 5 mL with acetonitrile  
       giving a 500 ng/mL stock 
 
  1 mg/mL Cerilliant standard - First prepare a 100 μg/mL stock by 
diluting 100 μL of the 1 mg/mL 
standard to 1 mL with acetonitrile.  
Then follow 100 μg/mL standard 
directions. 
 
 5.5.2 iso-LSD - same as for LSD (5.5.1) 
 
5.5.3 nor-LSD - same as for LSD (5.5.1) 
 
 5.5.4 O-H-LSD - same as for LSD (5.5.1) 
 
 5.5.5 Working Spiking mix #1  
 Pipette 10 μL of each 500 ng/mL stock standards in a 5 mL volumetric 
flask and make up to volume with acetonitrile, giving 1 ng/mL of LSD, 
iso-LSD, nor-LSD, and O-H-LSD. 
 
5.5.6 Working Spiking mix #2  
 Pipette 200 μL of each 500 ng/mL stock standards in a 5 mL volumetric 
flask and make up to volume with acetonitrile, giving 20 ng/mL of LSD, 
iso-LSD, nor-LSD, and O-H-LSD.   
 
Working spiking mix’s are prepared fresh before each quantitation. 
 
5.6 Internal Standard in acetonitrile is prepared as follows: (Internal standard 
purchased from Cerilliant) 
 
 5.6.1 LSD-D3 500 ng/mL Stock - 100 μL of the 25 μg/mL Cerilliant 
standard diluted to 5 ml with acetonitrile giving 500 
ng/mL LSD-D3. 
 
 5.6.2 Working ISTD -  
   200 μL of the 500 ng/mL LSD-D3 stock diluted to 5 mL with 
acetonitrile giving 20 ng/mL LSD-D3. 
 
 Working internal standard is prepared fresh before each quantitation. 
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6. Procedure -  
6.1 Carry appropriate calibrators through the analytical procedure in parallel with 
samples to be analyzed.  Set up a calibration curve selecting similar 
concentrations as illustrated in the table below. 
 
Sample 
(1 mL Blood) 
μL of spiking mix 
#1 (1 ng/mL) 
μL of spiking mix 
#1 (20 ng/mL) 
μL of working 
LSD-D3 ISTD 
(20 ng/mL) 
Blank 0 0 0 
Blank + ISTD 0 0 50 
0.02 ng/mL 20 0 50 
0.05 ng/mL 50 0 50 
0.40 ng/mL 0 20 50 
0.80 ng/mL 0 40 50 
1.60 ng/mL 0 80 50 
2.00 ng/mL 0 100 50 
Control 1:  0.05 ng/mL 50 0 50 
Control 2:  0.50 ng/mL 0 25 50 
Control 3:  1.50 ng/mL 0 75 50 
 
6.2 Add 1 mL blood and 50 μL working ISTD to a test tube and mix. 
 
6.3 Basify the samples by adding 500 μL 1 M Ammonium acetate buffer (pH 9.0) to 
each tube and mix thoroughly. 
 
6.4 Extract with 5 mL methylene chloride:isopropyl alcohol (85:15) to each tube and 
cap.  Vortex tube to break up blood clot then shake the tube manually to ensure 
tube is capped tightly.  Then put on a mechanical shaker for 20 minutes. 
 
6.5 Centrifuge at 3500 rpm for 15 minutes. 
 
6.6 Decant off aqueous (top) layer and discard. 
 
6.7 Using a glass pipette, pass through the solid blood layer and pipette the organic 
(bottom) layer to a new test tube.   
 
6.8 Repipette organic layer into another new test tube and ensure no transfer of blood 
particulate and evaporate to dryness under nitrogen with no heat. 
 
6.9 Reconstitute residue in 100 μL 20 mM ammonium acetate buffer (pH 4.0):ACN 
(80:20). 
 
6.10 Centrifuge reconstituted extracts or filter to remove particulates before being 
injected. 
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6.11 Transfer supernatant to a Waters ACQUITY UPLC™ using a Waters 150 μL 
insert. 
 
6.12 Analyze by UPLC™/MS/MS (See LSD LC_MS_MS SOP).  
 
7. QC and Analytical Results-  
7.1 Data collection, peak integration, and weighted (1/x2) linear regression of the 
calibration curve is performed using the MassLynx™ version 4.0 software 
(Waters Corporation, Milford, MA).   
 
7.2 Exclude the 20 pg/mL calibrator from nor-LSD and O-H-LSD calibration curve.  
LLOQ of nor-LSD and O-H-LSD is 50 pg/mL. 
 
7.3 Calculate the concentration and ion ratios of LSD, iso-LSD, nor-LSD, and O-H-
LSD using the MassLynx™ version 4.0 software (Waters Corporation, Milford, 
MA).  The use of internal standards and at least four calibrators bracketing the 
unknown samples, as recommended by SOFT guidelines are adhered to.  A 
calculated correlation coefficient of 0.98 or better is considered acceptable. 
 
7.4 The results of control measurements are considered acceptable if they are within 
±15% of target values.  The 50 pg/mL (LLOQ) quality control sample for nor-
LSD and O-H-LSD is permitted to be within ±20% of the target value. 
 
7.5 The lowest calibrator must be at least 5 times the response of the blank. 
 
7.6 For positive confirmation, the ion ratios of the quality control samples and the 
unknown should be within ±30% for the calibrators. 
  
 Ion ratios: LSD = 223/208, 223/281 
   Iso-LSD = 281/208, 281/223 
   Nor-LSD = 209/237, 209/74 
   O-H-LSD = 237/222, 237/313 
   LSD-D3 = 226/208, 226/281 
 
7.7 Relative retention times of unknowns should be within 2% of the calibrators. 
 
8. Method Validation Including References - 
8.1 [FDA] Food and Drug Administration: Guidance for Industry: Bioanalytical 
Method Validation, 2001. 
 
8.2 [SOFT/AAFS] Society of Forensic Toxicologist and American Academy of 
Forensic Sciences: Forensic toxicology laboratory guidelines, draft 2006 
version. 
 
8.3 Canezin, J., Cailleux, A., Turcant, A., Le Bouil, A., Harry, P., and Allain, P.: 
Determination of LSD and its metabolites in human biological fluids by high-
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performance liquid chromatography with electrospray tandem mass 
spectrometry. J Chromatogr B 765: 15-27, 2001. 
 
8.4 Sklerov, J. H., Magluilo, J., Jr., Shannon, K. K., and Smith, M. L.: Liquid 
chromatography-electrospray ionization mass spectrometry for the detection of 
lysergide and a major metabolite, 2-oxo-3-hydroxy-LSD, in urine and blood. J 
Anal Toxicol 24 (7): 543-9, 2000. 
 
9. Appendices -  
9.1 Extraction worksheet 
9.2 Calibration review 
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LSD, iso-LSD, nor-LSD, and O-H-LSD Extraction & Confirmation 
 
Requisition for Sample Extraction of LSD, iso-LSD, nor-LSD, and O-H-LSD and 
LC/MS/MS confirmation 
 
Case #:____________________________ Date Submitted:________________ 
Exhibit #:__________________________ Submitted by:__________________ 
Case Type:_________________________ Common Locker: YES NO 
 
Exhibit Type: Blood / Urine / Other ___________________ 
 
Special Instructions 
 
 
Extraction: 
Date of sample extraction and submission for LC/MS/MS analysis:_________By:_____ 
 
□ 1mL blood, 50μL ISTD (20ng/mL) LSD-D3 and mix. 
□ Basify sample with 500μL 1M Ammonium acetate buffer (pH 9.0) and mix thourougly. 
□ Extract with 5mL dichloromethane:isopropyl alcohol (85:15).  Shake for 20 minutes.   
Centrifuge at 3500 rpm for 15 minutes.  Remove organic (bottom) layer and evaporate to 
dryness under nitrogen. 
□ Reconstitute residue in 100μL 20mM Ammonium acetate buffer (pH 4.0):Acetonitrile (80:20) 
□ Transfer to LC (Waters Amber screw top) vials using a 150μL insert (Waters).  If delay in  
 analysis, store at  -20ΒC until ready for analysis. 
□ Inject 20μL on LC/MS/MS 
 
Comments & Results: 
□ Positive Case: One or more analytes are present. 
   All ions:  
    LSD = MRM 324>223, 208, 281 
    iso-LSD = MRM 324>223, 208, 281 
    Nor-LSD = MRM 310>209, 237, 74 
    O-H-LSD = MRM 356>237, 222, 313 
are present in the unknown and control at the same retention time (±2%) as the 
calibrator. 
    
   Ion ratios must be within ±30% of the calibrator 
    LSD = 223/208, 223/281 
    Iso-LSD = 281/208, 281/223 
    Nor-LSD = 209/237, 209/74 
    O-H-LSD = 237/222, 237/313  
 
Similarly, the internal standard must be found and the retention time, ions 
(MRM 327>226, 208, 281) and ion ratios (226/208, 226/281) must be within 
range. 
 
□ Negative Case 
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Calibration Review: LC/MS/MS (ESI+)  LSD, iso-LSD, nor-LSD, and O-H-LSD 
 
File Number: _____________    Date:__________________ 
 
 
□ Residual Plot included and doesn’t show any unusual trends 
 
□ Regression line has a minimum of four valid calibrators (within 15% of target).   
 It is permitted for the LLOQ calibrator to be within 20% of target. 
 
□ Controls are within 15% of the target and bracketed by valid calibrators.  It is  
 permitted for the controls at the LLOQ level to be within 20% of target. 
 
□ A valid blank was run (Lowest calibrator is at least 5 times the response of the  
 blank) 
 
□ No significant changes in RRT (<2% deviation from the mid calibrator(s)) 
 
□ Calculations for the slope, intercept, and coefficient of determination (r2>0.98) 
 are correct. 
 
□ Calculations for the unknowns are correct.  The unknowns are within 20% of  
 their mean.  The correct number of significant figures are expressed. 
 
□ Comments: 
 
 
 
 
 
The calibration has been reviewed. 
 
Reviewer:___________________ 
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1. Associated SOPs - 
1.1 LSD LC_MS_MS… 
1.2 LCMS_confirm… 
 
2. Definitions -  
2.1  LSD - lysergic acid diethylamide 
2.2 iso-LSD - lysergic acid diethylamide isomer 
2.3 nor-LSD - N-demethyl lysergic acid diethylamide 
2.4 O-H-LSD - 2-oxo-3-hydroxy lysergic acid diethylamide 
2.5 LSD-D3 - deuterated lysergic acid diethylamide 
2.6 ISTD - internal standard 
2.7 MS - mass spectrometer 
2.8 UPLC™/MS/MS - ultra performance liquid chromatography tandem mass 
spectrometry 
2.9 BEH - bridged ethyl hybrid 
 
3. Safety -  
3.1 Routine laboratory safety guidelines for handling biohazardous materials are 
followed. 
 
4. Equipment Used -  
4.1 Waters Corporation (Milford, MA) Acquity UPLC™ with an autosampler.  
4.2 Waters Corporation (Milford, MA) Quattro Premier™ tandem quadrupole mass 
spectrometer 
4.3 Acquity UPLC™ BEH C18 (2.5×50mm, 1.7μm, Waters Corporation, Milford, 
MA) column 
4.4 pH meter 
4.5 Mechanical Shaker4.6 Centrifuge 
 
5. Reagents Needed -  
5.1 20mM Ammonium acetate buffer (pH 4.0) 
Dissolve 1.5416 g ammonium acetate and dissolve in ~800 mL NANOpure  
water, then adjust pH to 4.0 (± 0.1) using glacial acetic acid.  Make up to 1 L 
with NANOpure  water.  Thoroughly mix then filter and sonicate 
 
5.2 1M Ammonium acetate buffer (pH 9.0) 
 Dissolve 19.270 g ammonium acetate in ~150 mL NANOpure  water.  Adjust pH 
to 9.0 (± 0.1) with ammonium hydroxide.  Make up to 250 mL with NANOpure  
water.   
 
5.3 Methylene chloride:isopropyl alcohol (85:15 (v:v)) 
 
5.4 Acetonitrile (HPLC grade) 
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5.5 Calibrator solutions in acetonitrile are prepared as follows: (Calibrators are 
purchased from Cerilliant)  
 
5.5.1 LSD - Prepare a 500 ng/mL stock (follow instructions based on 
Cerilliant standard concentration). 
 
  25 μg/mL Cerilliant standard - 100 μL diluted to 5 mL with acetonitrile 
giving a 500 ng/mL stock 
 
  100 μg/mL Cerilliant standard - 25 μL diluted to 5 mL with acetonitrile 
       giving a 500 ng/mL stock 
 
  1 mg/mL Cerilliant standard - First prepare a 100 μg/mL stock by 
diluting 100 μL of the 1 mg/mL 
standard to 1 mL with acetonitrile.  
Then follow 100 μg/mL standard 
directions. 
 
 5.5.2 iso-LSD - same as for LSD (5.5.1) 
  
 5.5.3 nor-LSD - same as for LSD (5.5.1) 
 
 5.5.4 O-H-LSD - same as for LSD (5.5.1) 
 
 5.5.5 Working Spiking mix 
 Pipette 200 μL of each 500 ng/mL stock standards in a 5 mL volumetric 
flask and make up to volume with acetonitrile, giving 20 ng/mL of LSD, 
iso-LSD, nor-LSD, and O-H-LSD. 
  
 Working spiking mix is prepared fresh before each analysis. 
 
5.6 Internal Standard in acetonitrile is prepared as follows: (Internal standard 
purchased from Cerilliant) 
 
  5.6.1 LSD-D3     500 ng/mL Stock - 100 μL of the 25 μg/mL 
Cerilliant standard diluted to 5 ml with acetonitrile 
giving 500 ng/mL LSD-D3. 
 
  5.6.2 Working ISTD -  
   200 μL of the 500 ng/mL LSD-D3 stock diluted to 5 mL with 
acetonitrile giving 20 ng/mL LSD-D3. 
 
  Working internal standard is prepared fresh before each quantitation. 
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6. Procedure -  
6.1 Carry a blank and 1.5 ng/mL quality control sample (refer to table below) 
through the analytical procedure in parallel with samples to be analyzed.   
  
Sample (1 mL Urine) μL of spiking mix (20 ng/mL) 
μL of working LSD-D3 
ISTD (20 ng/mL) 
Blank 0 0 
Blank + ISTD 0 50 
Control: 1.5 ng/mL 75 50 
 
6.2 Add 1 mL urine and 50 μL working ISTD to a test tube and mix.  
 
6.3 Basify the samples by adding 500 μL 1 M Ammonium acetate buffer (pH 9.0) to 
each tube and mix thoroughly. 
 
6.4 Extract with 5 mL methylene chloride:isopropyl alcohol (85:15) to each tube and 
cap.  Shake the tube manually to ensure tube is capped tightly.  Then put on a 
mechanical shaker for 20 minutes. 
 
6.5 Centrifuge at 3500 rpm for 15 minutes. 
 
6.6 Pipette off aqueous (top) layer and discard. 
 
6.7 Transfer organic (bottom) layer to a new test tube and evaporate to dryness under 
nitrogen (no heat). 
 
6.8 Reconstitute residue in 100 μL 20 mM Ammonium acetate buffer (pH 4.0):ACN 
(80:20). 
 
6.9 Transfer reconstituted residue to a Waters ACQUITY UPLC™ using a Waters 
150 μL insert. 
 
6.10 Analyze by UPLC™/MS/MS (See LSD LC_MS_MS SOP). 
 
7. QC and Analytical Results-  
7.1 Data collection and peak integration is performed using the MassLynx™ version 
4.0 software (Waters Corporation, Milford, MA). 
 
7.2 Calculate the ion ratios using the MassLynx™ version 4.0 software (Waters 
Corporation, Milford, MA).  
 
7.3 For positive confirmation the ion ratios of the case should be within ±30% for 
the calibrators. 
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 Ion ratios: LSD = 223/208, 223/281 
   Iso-LSD = 281/208, 281/223 
   Nor-LSD = 209/237, 209/74 
   O-H-LSD = 237/222, 237/313 
   LSD-D3 = 226/208, 226/281 
 
7.4 Relative retention times of unknowns should be within 2% of the calibrators. 
 
7.5 The lowest calibrator must be at least 5 times the response of the blank. 
 
7.6 This is a qualitative method only.  Quantitative results are not given for urine. 
 
8. Method Validation Including References - 
8.1 [FDA] Food and Drug Administration: Guidance for Industry: Bioanalytical 
Method Validation, 2001. 
 
8.2 [SOFT/AAFS] Society of Forensic Toxicologist and American Academy of 
Forensic Sciences: Forensic toxicology laboratory guidelines, draft 2006 version. 
 
8.3 Canezin, J., Cailleux, A., Turcant, A., Le Bouil, A., Harry, P., and Allain, P.: 
Determination of LSD and its metabolites in human biological fluids by high-
performance liquid chromatography with electrospray tandem mass 
spectrometry. J Chromatogr B 765: 15-27, 2001. 
 
8.5 Sklerov, J. H., Magluilo, J., Jr., Shannon, K. K., and Smith, M. L.: Liquid 
chromatography-electrospray ionization mass spectrometry for the detection of 
lysergide and a major metabolite, 2-oxo-3-hydroxy-LSD, in urine and blood. J 
Anal Toxicol 24 (7): 543-9, 2000. 
 
9. Appendices - N/A 
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Appendix C 
 
 
 
 
 
Title:   LSD, iso-LSD, nor-LSD, and O-H-LSD UPLC/MS/MS Analysis 
 
 
Identification/Filename of this SOP: LSD LC_MS_MS SOP.wpd  
 
 
 
 
Scope:  This SOP describes conditions used for UPLC/MS/MS analysis of LSD, 
iso-LSD, nor-LSD, and O-H-LSD extracts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Written/Revised by: Authorized by: Bench copies 
Name: A. Chung 
 
Position: 
 
Date 
Name: 
 
Position: 
 
Date: 
How many?____________
 
Located?______________ 
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1. Associated SOPs -  
1.1 LSD Quant Blood… 
1.2 LSD Urine SOP... 
1.3 LCMS_confirm… 
 
2. Definitions -  
2.1  LSD - lysergic acid diethylamide 
2.2 iso-LSD - lysergic acid diethylamide isomer 
2.3 nor-LSD - N-demethyl lysergic acid diethylamide 
2.4 O-H-LSD - 2-oxo-3-hydroxy lysergic acid diethylamide 
2.5 ESI+ - electrospray ionization positive 
2.6 MS - mass spectrometer 
2.7 MRM - multiple reaction monitoring 
2.8 UPLC™/MS/MS - ultra performance liquid chromatography tandem mass 
spectrometry 
2.9 BEH - bridged ethyl hybrid  
 
3. Safety -  
3.1 Routine laboratory safety guidelines for handling biohazardous materials are 
followed. 
 
4. Equipment Used -  
4.1 Waters Corporation (Milford, MA) Acquity UPLC™ with an autosampler.  
4.2 Waters Corporation (Milford, MA) Quattro Premier™ tandem quadrupole mass 
spectrometer.       
4.3 Acquity UPLC™ BEH C18 (2.5×50 mm, 1.7 μm, Waters Corporation, Milford, 
MA) column. 
 
5. Reagents Needed -  
5.1 Mobile Phase: 
Solvent A: 20 mM Ammonium acetate buffer (pH 4.0) 
Dissolve 1.54 g ammonium acetate and dissolve in 800 mL 
NANOpure  water, then adjust pH to 4.0 (± 0.1) using glacial 
acetic acid.  Make up to 1 L with NANOpure  water.  Thoroughly 
mix then filter and sonicate 
 
 Solvent B: Acetonitrile (HPLC grade) 
 
5.2 Seal Wash - Acetonitrile:water (10:90) 
 
5.3 Weak Needle Wash - Acetonitrile:water (10:90) 
 
5.4 Strong Needle Wash - Acetonitrile:water (75:25)  
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6. Procedure –  
6.1 ESI Source Conditions: 
 Ion Mode -  ESI+ 
 Capillary (kV) - 3.0 
 Cone (V) -  MRM Specific 
 Extractor (V) - 6.0 
 RF Lens (V) -  0.2 
 Source Temperature (ΒC) -  120 
 Desolvation Temperature (ΒC) - 350 
 Cone Gas Flow (L/Hr) -  110 
 Desolvation Gas Flow (L/Hr) - 750 
 
6.2 MS Analyzer Conditions: 
 LM Resolution 1 - 11.0 
 HM Resolution 1 - 11.0 
 Ion Energy 1 -  1.0 
 Entrance -  5.0 
 Collision -  MRM Specific 
 LM Resolution 2 - 11.0 
 HM Resolution 2 - 11.0 
 Ion Energy 2 -  2.1 
 Multiplier -  650 
 Collision Gas Flow (mL/min) - 0.28 
 Collision Gas Pressure (mbar) - 4.21 × 10-3 
 Source T-Wave Parameters -  Automated 
 Collision Cell T-Wave Parameters - Automated 
 
6.3 MS Tune Parameters: 
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6.4 Sample Conditions: 
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6.5 Solvent Manager Conditions: 
 
 Injection Volume (μL): 20 
 
7. QC and Analytical Results-  
 
7.1 Before any analytical work is attempted, do a signal to noise check 
(LCMS_confirm SOP) to ensure LC/MS/MS is properly working. 
 
7.2 When switching over solvent systems, perform seal wash, syringe wash, and 
prime all lines with appropriate solvents. 
 
8. Method Validation Including References - 
8.1 N/A 
 
9. Appendices - N/A 
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Appendix D 
 
LSD ELISA Cross Reactivity 
Since it has been found that O-H-LSD, nor-LSD, and iso-LSD are found along 
with LSD in the samples of people taking LSD, their reactivity with the LSD direct 
ELISA kit was tested.  The RCMP FLS uses the Immunalysis LSD direct ELISA kit 
(Pomona, CA) to screen for LSD in both urine and whole blood.  The Immunalysis LSD 
direct ELISA kit is based on the competitive binding to antibody of enzyme labelled 
antigen and unlabeled antigen.  The procedure in outlined in Figure D1.  
 
 
20 µL unknown diluted specimen + 100 µL enzyme (horseradish peroxidase) labelled 
LSD derivative in micro-plate wells (coated with purified polyclonal antibody) 
↓ 
Wash wells 
↓ 
Add chromogenic substrate 
↓ 
Add a dilute acid to stop color production 
↓ 
Read wells at 450 nm 
↓ 
Intensity of Color is inversely proportional to concentration of drug in sample 
 
 
Figure D1:  Immunalysis LSD direct ELISA kit procedure. 
 
 
Varying concentrations of LSD (0.02, 0.05, 0.1, 0.4, 0.8, 1.6 ng/mL), a 2 ng/mL 
LSD test mix (containing LSD, iso-LSD, nor-LSD, and O-H-LSD), and 2 ng/mL of iso-
LSD, nor-LSD, and O-H-LSD each alone in both blood and urine matrix were analyzed 
via ELISA.  Results are summarized in Table D1.  The averaged absorbance must be 
equal to or less than the averaged absorbance of the cutoff level (0.05 ng/mL in whole 
blood, and 1 ng/mL in urine) to be reported as positive for LSD.    
O-H-LSD and iso-LSD in both whole blood and urine at 2 ng/mL did not cross 
react.  The method is reported to be sensitive to 0.05 ng/mL (Immunalysis 2001), and 
the absorbance of O-H-LSD and iso-LSD in both whole blood and urine were above the 
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0.05 ng/mL LSD absorbance.  Nor-LSD at 2 ng/mL in whole blood resulted in a positive 
result with an absorbance close to the 1 ng/mL positive control.  In urine, the absorbance 
of nor-LSD at 2 ng/mL was above the 1 ng/mL cutoff, but below the 0.05 ng/mL LSD 
absorbance.  The LSD test mix tested positive and the presence of iso-LSD, nor-LSD, 
and O-H-LSD did not suppress the reactivity of LSD.  The results showed that LSD 
needed to be present to test positive, with the exception of nor-LSD.  The concentration 
of nor-LSD has been found to be inconsistent, so although nor-LSD cross reacted its 
presence without LSD present is uncommon (Poch et al. 1999).   
 
Table D1:  ELISA results of LSD, iso-LSD, nor-LSD, and O-H-LSD in whole blood and 
urine. 
ng/mL (n = 2) Whole Blood Urine 
 Absorbance Result Absorbance Result 
LSD negative control 2.509  2.231  
LSD cut off level 
(0.05 – whole blood, 1.00 – urine) 0.981  0.822  
LSD positive control 
(1.00 – whole blood, 2.00 – urine) 0.723  0.367  
0.02 LSD 2.089 - 2.039 - 
0.05 LSD 1.922 - 1.665 - 
0.10 LSD 1.761 - 1.513 - 
0.40 LSD 1.086 - 1.375 - 
0.80 LSD 0.690 + 0.837 - 
1.60 LSD 0.543 + 0.612 + 
2.00 LSD test mix 0.382 + 0.489 + 
2.00 iso-LSD 2.166 - 2.086 - 
2.00 nor-LSD 0.745 + 0.932 - 
2.00 O-H-LSD 2.046 - 1.987 - 
(-) negative, (+) positive     
 
